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Abstract 
Small chiral molecules are very important building blocks in the synthesis of biologically active 
compounds. These building blocks include nitrogen and oxygen-containing heterocycles such as 
2-oxazolidinones, 1,3-oxazinan-2-ones, 2-oxazolines, oxazines, morpholine and morpholinones. 
Because of their interesting properties, chiral heterocycles have stirred great interest in the 
synthetic chemist community to develop useful and efficient strategies to these molecules. In this 
dissertation, the design and syntheses of various heterocyclic building blocks are presented, as 
well as the testing of their biological activities as antibacterial. Another very interesting family of 
heterocycle-containing molecules are the Aeruginosins. They are a family of marine natural 
products isolated from a blue-green algae, which display inhibitory activity against serine 
proteases such as thrombin, trypsin, and factor VIIa. Most aeruginosins contain an heterocyclic 
moiety called the 2-carboxy-6-hydroxyoctahydroindole (Choi) ring; this Choi moiety is a rigid 
bicyclic unnatural amino acid and is the core structure in the aeruginosins, indispensable to their 
biological activity. A synthesis of a ring-oxygenated variant of the Choi from D-mannose is 
reported in this dissertation. The ring-oxygenated variant of 2-carboxy-6-
hydroxyoctahydroindole can potentially be used as a surrogate of Choi in the design and 
synthesis of aeruginosin-based thrombin inhibitors. 
 
 
 
 
Keywords: Chiral heterocycles; 2-oxazolidinones; 1,3-oxazinan-2-ones; aeruginosins; 2-
carboxy-6-hydroxyoctahydroindole; serine protease inhibitors. 
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Chapter I. Introduction 
 
I. Chiral nitrogen and oxygen-containing molecules as building blocks for the 
synthesis of biologically active molecules. 
 
Small chiral molecules are very important building blocks in the synthesis of biologically active 
compounds. These building blocks include nitrogen and oxygen-containing heterocycles such as 
oxazolidinones, oxazinanones, oxazolines, oxazines, morpholine and morpholinones. For 
example, the (S)-5-aminomethyl-2-oxazolidinone 1 is the core structure in antibacterial agent 
linezolid 31-2 which is the first member of the synthetic oxazolidinone antibiotics3–7 effective 
against resistant Gram-positive bacterial infection. The six-membered ring 1,3-oxazinan-2-one 2 
derivatives also exhibit biological activities, such as anti-inflammatory,8 anti-thrombotic,9 and 
antibacterial activities.10 The oxazolines heterocycles also display a wide variety of biological 
properties. For instance molecule 4 has antibiotic activity;11 other 2-oxazolines have shown 
neuroprotective12 and cytotoxic activities13. The homologous oxazines have equally useful 
properties, they are important synthetic intermediates,14 but also 1,4-oxazine 5  is a human 5-HT6 
receptor inhibitor15 and can be developed as an anti-depressant. Other oxazines have shown good 
potential as drugs against hereditary obesity by inhibiting cholesteryl ester transfer proteins;16 
additionally, anti-cardiovascular disease activity by inhibition of the thromboxane A2 (TXA2) 
receptor17 has been reported, as well as potential as antibacterial agents18-19. Morpholine and 
morpholinone-containing molecules have also shown very interesting biological activities. The 
antibiotic Linezolid 3 contains a morpholine cycle that is important for its biological properties. 
Other molecules such as 6 have displayed an anti-schizophrenic activity20 via interaction with the 
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N-methyl-D-aspartate (NMDA) receptor in the brain. Reboxetine 7 is a commercially available 
anti-depressant that contains a morpholine cycle essential to its activity21. Morpholinone cycles 
are found in many biologically active molecules and the reported properties include thrombin 
inhibitors22, selective T-type calcium channel blockers23, HIV-protease inhibitors24 and 
important intermediate in vitamin B5 synthesis25 as well as antibacterial compounds’ synthesis.26 
Besides being used as synthetic intermediates and displaying interesting biological properties, 
many small heterocyclic molecules, notably 2-oxazolidinones, 1,3-oxazinan-2-ones and 2-
oxazolines are very useful as chiral auxiliaries in asymmetric synthesis27-29 or as a form of 
protecting groups30 for amino alcohols. 
 
Because of their importance as synthetic intermediates and their good potential as medicinally 
active molecules, many efforts have been made and are ongoing to synthesize these small chiral 
heterocycles efficiently. Many methods have been described for the synthesis of chiral cyclic 
carbamates, such as the Hoffmann rearrangement reaction on a chiral hydroxyl-amide,31 or the 
carbonylation of 1,3-amino alcohols.32 Most of these methods occur with a retention of 
stereochemistry.33-46 Only a few other synthetic routes to cyclic carbamates afford a product with 
opposite stereochemistry from that of the starting material.36, 47-51 An example of the synthesis of 
an N-substituted chiral 1,3-oxazinan-2-one from a 1,3-amino alcohol in scheme 1.1; the synthesis 
occurs with retention of stereochemistry.32, 52  
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Figure 1.1 Representative nitrogen and oxygen-containing heterocycles. 
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Scheme 1.1. Synthesis of N-aryl-1,3-oxazinan-2-one from Aspartic acid. 
 
In scheme 1.1 an epoxide-containing Cbz-protected arylamine 8 was obtained as an intermediate 
from aspartic acid; the epoxide ring was then opened by sodium azide to yield 9 and cyclization 
of the hydroxyl group with the Cbz group gave the desired 1,3-oxazinan-2-one 10. Several 
methods have been reported for the synthesis of chiral oxazoline and oxazine cycles. Some of the 
representative methods are the asymmetric cyclization of olefins using a chiral nitridomanganese 
complex53 (Scheme 1.2), the solid phase cyclization of a β-halogeno-amide in basic conditions54 
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(Scheme 1.3) or the cyclization of a β-halogeno-amide by electrochemical reduction.55 The 
cyclization of a β-hydroxy-amide in which the hydroxyl group has been transformed into a good 
leaving group has also been reported.47 Another recent strategy uses a one-pot synthesis by 
mixing a carboxylic acid and a 1,3-amino alcohol in presence of the fluorinating agent bis-(2-
methoxyethyl) amino-sulfurtrifluoride (Deoxo-fluor) (Scheme 1.4).56-57 This one-pot reaction is 
similar to the technique using the combination of a carboxylic ester with a 1,3-amino alcohol in 
the presence of lanthanide chloride as a catalyst.58 More specific to the synthesis of 1,2-oxazines, 
a tandem “oxime formation-epoxide ring opening” reaction has also been described18 and is 
shown in scheme 1.5.  
45-88%
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CH2Cl2, 0 oC
11 12  
Scheme 1.2. Synthesis of 2-oxazoline by cyclization under nitridomanganese complex catalysis. 
 
R2
FmocHN
O
N
H O
H
N
OH
R1
O
R2
FmocHN
O
N
H O
H
N
I
R1
O
R2
FmocHN
O
N
O
H
N
I
R1
O
H O
H
N
R1
OO
N
R2
FmocHN
TPP, I2, Imid.
CH2Cl2, RT
DMF, RT
16 h
13 14
15
56-72%
 
Scheme 1.3. Solid phase synthesis of 2-oxazolines using a NH-Rink-PEGA800 resin. 
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Scheme 1.4. Synthesis of 2-oxazoline in a one-pot reaction using Deoxo-Fluor reagent. 
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Scheme 1.5. Synthesis of 1,2-oxazine via tandem “oxime formation-epoxide ring opening”. 
 
Similarly to the cyclic carbamates, oxazoline and oxazine heterocycles, several synthetic 
strategies to the morpholinone and morpholine cycles have been reported in the literature. One 
method uses the Ugi five-center-three component reaction,59,60 reacting the glycolaldehyde dimer 
22 with an aminoacid 23 and an isocyanide 24 to afford a 3-substituted morpholin-2-one-5-
carboxamide23 25 (Scheme 1.6). A more common method is the intramolecular cyclization of a 
β-hydroxy-amide by elimination of a leaving group such as a mesylate of a halogen22, 24 (Scheme 
1.7). Other reactions involve the cyclization of an amino alcohol with an oxalyl chloride 
derivative to afford a morpholin-1,3-dione followed successively by a Wittig reaction and a 
reduction on the 1-carbonyl to give a 1-substituted morpholin-2-one25,61 (Scheme 1.8). 
Morpholine cycles, which are found in many medicinally active molecules, are generally derived 
from morpholinones by controlled reduction of the ring’s carbonyl group21 (Scheme 1.9). A less 
common method is the cyclization of diol 38 by dehydration in refluxing acidic conditions to 
yield morpholine 39 (Scheme 1.10).62 
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Scheme 1.7. Synthesis of morpholin-2-one intramolecular cyclization. 
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Scheme 1.8. Synthesis of morpholin-2-one via oxalyl chloride condensation. 
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Scheme 1.9. Synthesis of a morpholine cycle by reduction of a morpholin-2-one.  
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Scheme 1.10. Synthesis of a morpholine cycle by acidic dehydration. 
 
Because of their ubiquitous presence in biologically active molecules many of which are 
commercially available drugs, and because of their importance as building blocks in organic 
synthesis, nitrogen and oxygen-containing heterocycles have drawn great interest from the 
organic synthetic chemists’ community. As well as others, we have developed several synthetic 
strategies to these molecules in our laboratory. The subject of our syntheses of small chiral 
heterocycles as building blocks for the synthesis of bioactive molecules will be the focus of the 
second chapter of this dissertation. 
 
 
 
7 
 
II. Synthesis of rigid bicyclic aminoacids as building blocks for peptidomimetics. 
 
Despite being naturally biologically active, peptides show many disadvantages when used as 
drugs.63-65 The most noticeable drawbacks are a very limited stability towards proteolysis by 
peptidases, in the gastrointestinal tract as well as in the serum. The high molecular weight 
decreases the bioavailability and subsequently the excretion through the liver is rapid and the 
clearance is very high. Finally, the molecules flexibility reduces the selectivity to one biological 
target and would potentially result in a lot of unwanted side effects. The potent activity of 
peptides coupled to their inconveniences as drugs have led to the development of the field of 
peptidomimetics. Peptidomimetics are molecules that bear identifiable structural resemblance to 
a natural peptide, leading to them mimicking or inhibiting the effect of that natural peptide.66-67 
The advantages of the peptidomimetics as drugs are based mostly on the circumvolution of 
peptides shortcomings; firstly and most importantly, the constrained structure will minimize the 
ability to bind to multiple biological receptors and increase the interaction with the desired 
biological target, therefore increasing the desired therapeutic effect, while reducing the potential 
unwanted side effects. Finally, the structural modifications of peptidomimetics compared to its 
corresponding peptide decrease the susceptibility to be degraded by peptidases in vivo, enabling 
the drug to stay in the serum longer and therefore increasing the chances of interaction with the 
biological target. As a result of their properties cited above, peptidomimetics are of high interest 
as bioactive agents and as drugs. Some of the main biological properties observed in 
peptidomimetics include Angiotensine Converting Enzyme (ACE) inhibitors,68 protease 
inhibitors,69-81 somatostatin inhibitors,82 antimicrobial agents,83-96 anti-cancerous,97-106 
analgesics,107-112 thrombin and trypsin inhibitors,113-132 psychotropic;133-134 some peptidomimetics 
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have been used as chemical probes,135 catalysts for asymmetric synthesis,136-139 and even as 
organogelators.140 Within the peptidomimetics compounds, a prominent class of molecules is the 
rigid bicyclic amino acids.  
 
Among the most notable molecules containing a bicyclic amino acid moiety are the aeruginosins, 
a family of natural compounds isolated from a blue-green algae Microcystis aeruginosa.114-115 
Aeruginosins are generally linear oligopeptides, that contain a core structure, the constrained 
bicyclic amino acid 2-carboxy-6-hydroxyloctahydroindole (Choi) moiety 57. Some of the 
representative aeruginosins and related molecules are shown in Figure 1.2. These molecules 
typically display serine protease inhibition activities, some of them are inhibitors of the blood 
coagulation cascade factors, such as thrombin and factor VIIa. These properties give these 
compounds a strong potential to be developed into antithrombotic drugs and have stirred the 
interest of the organic chemists community into designing efficient strategies towards the 
synthesis of the Choi moiety and its variants, this moiety being a key structure of aeruginosins 
and their analogs. Aeruginosins belong to the class of direct thrombin inhibitors, as indicated by 
the X-ray crystal structures of the complex formed between aeruginosins and thrombin during 
the inhibition process.119,121,143 The interaction mode of aeruginosin 298-A with the protein is 
similar to that of other direct thrombin inhibitors as it binds to the active site of thrombin in a 
noncovalent way forming an antiparallel strand with thrombin.119 The five-membered ring of the 
Choi residue occupies the hydrophobic binding site, while its six-membered ring projects out and 
loosely interacts with thrombin. The crystal structures of oscillarin and dysinosin-A complexes 
with thrombin revealed similar binding patterns. The amide NH from the octahydroindole 
carboxamide interacts with thrombin, however no interactions were observed with the 6-
9 
 
hydroxyl group of the Choi moiety. The terminal phenyl group has no interaction with the 
enzyme.143 On the basis of the crystal structures and the binding sites interactions, organic 
chemists can design novel inhibitors with similar core structure motifs but with different 
substituents and functionalization to enhance binding, activity, and pharmacokinetic properties. 
Thrombin generally can tolerate imprecise binding from different molecules, however the rigid 
bicyclic amino acid structure is very important in defining the conformation of the molecule and 
it is essential to their antithrombin activity. Modifications on the core structure in the area of the 
6-hydroxyl group should not impact negatively on binding to the protein while some changes 
will increase contact and enhance binding. Such changes include introducing an oxygen atom at 
the C-4 position and/or adding an additional hydroxyl group to the C-5 or C-7 position.149 
Because pharmacokinetics are very unpredictable, these changes will result in new biological 
properties and might broaden the scope for improving the pharmacokinetic profile of this 
compound class if required. The availability of different stereoisomers is also important in 
elucidating structure-activity relationships. Studies to rationalize electronic and steric influence 
of different inhibitors have not given good correlations so far. Modification from the natural 
analogues can allow us to understand the stereo-electronic factors that determine the activity of 
these inhibitors, as well as provide us with molecules with a good potential as new and better 
antithrombotics. 
10 
 
 O
HN
N
O
HO
OH
O NH
HO
H
N NH2
NHHO
Aeruginosin 298-A
41
N
H
OHO
OH
40
2-carboxy-6-hydroxyotahydroinhole
2
33a
4
5
6
7 7a
OH
HO
O
HN
N
O
HO
O NH
N
NH2
NH
Oscillarin
HO
O
HN
N
O
HO
O NH
N
NH2
NH2
OSO3
Chlorodysinosin A
42 43
Cl
 
Figure 1.2. Structures of aeruginosins and related compounds. 
 
A few syntheses to the octahydroindole structure have been reported in the literature and some of 
the most representative methods are described here. One strategy uses a chiral synthon derived 
from L-glutamic acid, which can yield the desired bicycle after a ring-closing metathesis, 
followed by a stereoselective epoxidation and eventually an epoxide ring-opening122, 141 to give 
the N-protected 2-carboxy-5,6-hydroxyloctahydroindole ester 48 (Scheme 1.11), which 
corresponds to the Choi subunit found in Chlorodysinosin A 43.  
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Scheme 1.11. Synthesis of a protected 2-carboxy-5,6-dihydroxyl-octahydroindole ester 
from L-glutamic acid. 
 
Another approach to the synthesis of the octahydroindole cycle starts with L-tyrosine which is 
methylated to afford O-methyl-L-tyrosine 50.142 Birch reduction of 50, followed by a treatment 
in 3N HCl of the resulting dihydroanisole 51 leads to a mixture of diastereomeric amino acids 
with a cis-fusion of the bicyclic nucleus (only diastereomer 52 is showed here in scheme 1.12). 
Compound 52 was then reacted with benzyl bromide in basic conditions to give benzyl ester 53. 
Transesterification of 53 leads to methyl ester 54; benzyl deprotection and amidation give 55 
which after reduction of its ketone group yields the Choi moiety 56.116a,116b  
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Scheme 1.12. Synthesis of a protected 2-carboxy-6-hydroxyloctahydroindole ester 
from L-tyrosine. 
 
Another method that has been used to synthesize aza-heterocycles and more importantly 
octahydroindole bicycles is the N-acyliminium ion cyclization.128,143-146 The synthesis of 2-
carboxy-6-octahydroindole via the N -acyliminium ion aza-Prins cyclization is detailed in 
scheme 1.13. The sequence starts with N-Boc-L-glutamate 57 which undergoes enolate 
alkylation141 to afford 58. N-deprotection, cyclization and N-Boc protection lead to the 
corresponding pyroglutamate 59. Partial reduction and protection of the lactam carbonyle group 
give the hemiaminal 60. The [4,3,0] bicyclic structure 62 is obtained via the N-acyliminium 
intermediate 61 by treatment with tin tetrabromide at low temperature. Displacement of the 
bromide with tetra-n-butyl ammonium acetate affords the L-Choi subunit 63. 
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Scheme 1.13. Synthesis of a protected 2-carboxy-6-hydroxyloctahydroindole ester 
Via N-Acyliminium aza-Prins Cyclization. 
 
Besides the Choi bicyclic structures in the aeruginosins, many other constrained bicyclic 
moieties have been synthesized as peptidomimetics and have displayed interesting biological 
activities. Some representative molecules are the bicyclic lactams, which are found in many 
biologically relevant peptidomimetics.86,89,101 One method uses a 1,3-dipolar cycloaddition 
between a cyclic nitrone 65 and acrylamide 64 to afford the [1,2-b]isoxazolidine 66 (only major 
diastereomer is shown in scheme 1.14). Compound 70 is then reduced in acidic conditions to 
give peptidomimetic bicyclic lactam 67.89  
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Scheme 1.14. Synthesis of a bicyclic lactam peptidomimetic via 1,3-dipolar addition. 
 
Another method to prepare bicyclic lactams uses a pyroglutamate 68 as starting material. After 
the N-Boc protection gives compound 69, selective reduction of the lactam and reaction of the 
resulting hemiaminal intermediate with methanol in acidic conditions gives the aminal 70. After 
Grignard reaction and oxidative cleavage, the trans aldehyde major isomer 71 is obtained. 
Reductive amination with tert-butyl glycinate and NaBH3CN, followed by Cbz protection affords 
intermediate 72. After simultaneous removal of the Boc group and hydrolysis of the t-butyl ester 
in acidic conditions, cyclization is achieve using a BOP coupling reagent to give the desired 
bicyclic lactam 73.147  
15 
 
HN
O
O
OEt
N
O
O
OEt
Boc
N
MeO
O
OEt
Boc
N
O
OEt
Boc
O
H
N
O
OEt
Boc
N
Cbz
tBuO2C
N
N
O
OEtO
Cbz
Boc2O, Et3N
80%
1) LiEt3BH, -78oC
2) MeOH, PTSA
89%
1) (CH3)2C=CHMgBr
2) O3, Me2S
89%
1) H-Gly-OtBu.HCl/
NaBH3CN
2) CbzCl, THF
1) 4N HCl
2) BOP, DMF
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73  
Scheme 1.15. Synthesis of a bicyclic lactam peptidomimetic by BOP coupling. 
Besides bicyclic lactams and octahydroindole cycles there are a multitude of bicyclic amino acid 
structures widely explored as peptidomimetics. Among these molecules are the “β-turn peptide 
mimetics”. A β-turn is an important secondary structure that involves four consecutive residues. 
It folds the polypeptide chain back onto itself by nearly 180° and makes the protein a compact 
globular structure. It is also an internal component of antiparallel beta-strand so that it plays an 
important role in protein folding and molecular recognition.148  Diketopiperazines are bicyclic 
structures that are synthesized as potential β-turn-peptidomimetics.92 One method to these 
bicycles uses a solid-phase synthesis starting with α-N-Boc-β-N-Fmoc-L-diaminopropionic acid 
74 attached to a Merrifield resin. Fmoc group of 74 is deprotected using 25% piperidine in DMF, 
then Ugi three-component reaction yields intermediate 75. Deprotection of the Boc group 
followed by displacement of the bromide by the free amine in basic conditions gives compound 
76. The second ring system is created via Boc-amino acid coupling, Boc amino deprotection, and 
cyclitive cleavage induced by heating in acidic conditions to give diketopiperazine 77. 
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Scheme 1.16. Solid-phase synthesis of a β-turn petidomimetic diketopiperazine. 
Peptidomimetics are a very good alternative to peptides as drugs. Their constrained conformation 
enables them to interact with biological targets selectively, a property that peptides, with their 
inherent flexibility, do not possess. Also, the chemical and physical properties of 
peptidomimetics as synthetic drugs can be optimized to increase their therapeutic effects. 
Notable peptidomimetics are the rigid bicyclic amino acids, which are widely explored for their 
multiple biological properties. Among these bicyclic amino acids are the aeruginosins, a family 
of marine natural products isolated from a blue-green algae; these molecules have serine protease 
inhibitory activities and present a strong potential as anti-thrombotic drugs. A moiety that has 
been found to be the core structure in the compounds of this family is the 2-carboy-6-
hydroxyloctahydroindole (Choi) cycle. Because of its importance, the Choi subunit and its 
variants has been subject to many total syntheses. In our laboratory, we have developed an 
17 
 
efficient method to the Choi bicyclic structure and its analogs; these works will be reported with 
details in the fifth chapter of this dissertation. 
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Chapter II. Design and Synthesis of New Chiral 1,3-Oxazinan-2-ones from  
Carbohydrate Derivatives. 
 
Abstract 
Small chiral molecules are very important building blocks in the synthesis of biologically active 
compounds. These building blocks include nitrogen and oxygen-containing heterocycles such as 
oxazolidinones, oxazinanones, oxazolines, oxazines, morpholine and morpholinones. Because of 
their interesting properties, chiral heterocycles have stirred great interest in the synthetic chemist 
community to develop useful and efficient strategies to these molecules. Chiral oxazinanones in 
general are useful intermediates in the synthesis of pharmaceutical compounds and amino 
alcohols. The works presented in this chapter introduce a new synthetic method to chiral 6-
hydroxymethyl-1,3-oxazinan-2-ones and their analogs from carbohydrate derivatives. The 
synthesis was accomplished by the reaction of optically pure (S)-3-hydroxy-γ-butyrolactone with 
different primary amines, thus opening the lactone cycle to form butyramides with different N-
substitutions. The amides where reduced to the corresponding amines, which were carbonylated 
and cyclized to give the desired chiral 6-hydroxymethyl-1,3-oxazinan-2-ones. 
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Introduction 
 
Small chiral molecules are very important building blocks in the synthesis of compounds 
presenting a pharmaceutical interest. Chiral 5-substituted-2-oxazolidinones 1 and 2 and the 
homologous 6-substituted 1,3-oxazinan-2-ones 3 and 4 shown in figure 2.1 are important core 
structures in many drug molecules and useful intermediates in the synthesis of chiral 
aminoalcohols. 5-Hydroxymethyl or 5-aminomethyl-2-oxazolidinones (1, 2) are important in the 
preparation of oxazolidinone antibacterial agents.1-10 Representative 2-oxazolidinones antibiotics 
include Linezolid (Zyvox®).1-2 5 and dihydrothiazine analog 6.5 2-Oxazolidinones are also 
important as synthetic intermediates and have been used in the synthesis of chiral aminoalcohols 
such as beta-blocker carvedilol (Eucardic®).11-20 Because of their usefulness as both synthetic 
tools and biologically relevant molecules, there have been great interests in developing efficient 
synthesis towards 2-oxazolidinones. We and others have developed several efficient synthetic 
methods towards the synthesis of chiral 5-substituted-2-oxazolidinones.21-29 Like their 5-
membered ring counterpart, the homologous 6-membered cyclic carbamate 1,3-oxazinan-2-ones 
are found in many biologically active compounds.30-36 Some 6-phenyl-1,3-oxazinan-2-ones like 
compound 7 (Figure 2.2),  possess phosphodiesterase IV inhibitory effects and have shown to be 
potential remedies for inflammatory diseases and asthma.30 These six-membered ring carbamates 
are found in the cytotoxic alkaloid maytansine 8 and its analogs, which are explored as potential 
anti-cancerous drugs (Figure 2.2).37-40 They are also being explored as anti-inflammatory agents, 
for the treatment of ulcers, allergies, asthma, arthritis and diabetes.41 1,3-Oxazinan-2-ones have 
been extensively used as synthetic tools;17, 41-47 they are key intermediates in Woodward’s total 
synthesis of erythromycin A,48 in the synthesis of thrombolytics such as 931 (Figure 2.2) and in 
the synthesis of liquid crystal devices.49 The six-membered 1,3-oxazinan-2-one ring systems 
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have also been used as chiral auxiliaries or other chiral control elements50-51 although in that role, 
they are not used as extensively as the corresponding 2-oxazolidinones; The major reason for this 
is probably the difficulties in synthesizing chiral 1,3-oxazinan-2-ones.  
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Figure 2.1. 2-oxazolidinones and 1,3-oxazinan-2-ones building blocks 
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Figure 2.2. Representative compounds containing a 1,3-oxazinan-2-one ring. 
 
There are not many available syntheses for chiral 1,3-oxazinan-2-ones in the literature.34, 52-56 
One chiral pool approach method utilizes aspartic acid as the starting material (Scheme 2.1), an 
epoxide containing Cbz protected arylamine was obtained as an intermediate 10, then the 
epoxide ring was opened by sodium azide and cyclization of hydroxyl group with the Cbz group 
gave the desired 1,3-oxazinan-2-one 12.57 A short synthesis for 1,3-oxazinan-2-one 14 was 
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accomplished by reductive amination of 2-deoxy-D-ribose followed by cyclization of the 
arylchloroformate derivatized amine.58 Other methods to synthesize 1,3-oxazinan-2-ones include 
halogen mediated cyclization reactions,59-61 a trans-sulfamoylation through sulfamides 
intermediates,62 selenium mediated cyclization of aminoalcohol with carbon monoxide,63 
rearrangement from cyclic sulfates,64 intramolecular Michael additions,65 asymmetric 
dihydroxylation of homoallylic amines,66 and a Hoffmann rearrangement of a primary amide to 
form the carbamate.67 The iodoaminocyclization reaction is highly stereoselective when using a 
homoallyl carbamate with a chiral center at the homoallylic position (Scheme 2.2).59 
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Scheme 2.1. Synthesis of N-aryl-1,3-oxazinan-2-ones from aspartic acid. 
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Scheme 2.2. Synthesis of 1,3-oxazinan-2-one by iodoaminocyclization. 
 
Because of their great potential as biologically active molecules and as part of our interests in 
synthesizing new chiral heterocylic derivatives as therapeutic agents, we developed a novel 
method to synthesize these chiral 6-membered ring carbamates from carbohydrate derivative (S)-
γ-butyrolactone.  
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Results and Discussions 
We designed and carried out the syntheses of these important chiral compounds from 
carbohydrate derivative, (S)-3-hydroxy-γ-butyrolactone 15 as shown in Scheme 2.3. Starting 
from optically pure lactone 15,68 ring opening with amines led to the dihydroxy butyramide 16 
quantitatively.69 The diol was selectively protected with a trityl group to increase the 
hydrophobicity of the compound. This is necessary for the reduction step when the R group is a 
small alkyl group. Without a protecting group, the reduction product is too polar and it is hard to 
recover it from the reaction mixture. Trityl group showed excellent selectivity to primary 
hydroxyl group although some small amount of di-protected byproduct can be obtained under 
prolonged period of stirring. Reduction of the protected amide 17 using LiAlH4 in THF gave the 
corresponding intermediate aminoalcohol 18 in excellent yield. Cyclization of the intermediate 
18 using carbonyl diimidazole gave the protected 1,3-oxazinan-2-ones 19 in 70-93% yield. 
Attempt of using Cbz protected amine and using the carbonyl group of the Cbz group to form the 
carbamate ring resulted in a lower yield. The trityl protecting group was removed using TFA in 
dichloromethane quantitatively. The primary hydroxyl group in 20 can then be converted to an 
amino group by converting it to the mesylate 21 and displacement of the mesylate by 
benzylamine in DMSO at 60-80°C. The benzyl protecting group in 22 can be removed by 
catalytic hydrogenation to give the corresponding 6-aminomethyl-1,3-oxazinan-2-ones. The 
displacement product is mainly the direct SN2 displacement product 22 when using DMSO as 
solvent and 2 to 2.5 equivalent of benzylamine at 60-80°C. However, we found that when the 
temperature is higher than 85°C and in the presence of potassium carbonate, a significant 
quantity of compound 23 was obtained. This is presumably obtained from rearrangement of the 
1,3-oxazinan-2-one 22. 
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Scheme 2.3. Synthesis of chiral 1,3-oxazinan-2-ones from lactone 15. 
 
In order to understand the requirement for the rearrangement, we monitored the compound 22b 
(R = CH2CH3) in D6-DMSO at >85 °C by 1H NMR spectroscopy. The 1,3-oxazinan-2-ones are 
stable under neutral conditions. Heating at over 85 °C for 48 hours resulted in almost no 
decomposition of pure compound 22b in DMSO. Addition of benzylamine to the sample did not 
cause rearrangement of compound 22b either. However, addition of potassium carbonate 
promoted the rearrangement in the presence of benzylamine. In the absence of benzylamine, 
K2CO3 promoted the rearrangement to completion after 18 hours of heating at >85 °C. This 
indicated that participation of a non-bulky base is important to the reaction. We also carried out 
the rearrangement reaction for compound 22a cleanly in DMSO using 2 equivalents of 
potassium carbonate at 100 °C for 24 hours. A possible mechanism of the formation of 23 is 
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shown in Scheme 2.4. A base B− (such as hydroxide) molecule attacks the carbamate and opens 
up the 6-member ring forming a tetrahedral intermediate 24, cyclization with the neighbor 6-
benzylamino group leads to the formation of the 5-member ring carbamate, the oxazolidinone 
23.  
NOH
N
O
NO
N
O BH
N
OH
N
O
N
H
O
N
O B
B
B
B
N
H
O
N
O
22
23
24
 
Scheme 2.4. A possible mechanism of the rearrangement from 6-membered to 5-membered-ring  
carbamates promoted by base. 
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Figure 2.3. Starting material and different potential products of the rearrangement reaction 
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Besides the 5-membered ring oxazolidinone, another possible rearrangement product could be 
the 7-membered urea 25 by cleaving C-O bond instead of C-N bond. However, this possibility is 
ruled out for the above rearrangement reaction based on both 1H and 13C NMR spectra data. The 
five-membered ring is also, according to Baldwin rules of cyclization, more stable than the 
seven-membered ring. The amine 23a has certain solubility (~10mg/mL) in water, and it is easily 
protonated. The protonated form 26 would exhibit changes of chemical shifts for the methyl a 
and methylenes b, c. The 1H NMR spectra of the three compounds are shown in Figure 2.4. If the 
7-member ring urea 25 is the rearrangement product, the 1H NMR chemical shifts for the methyl 
a and methylene b should not change significantly since the chemical environment for a and b 
are essentially the same in 22a and 25. However, if the rearrangement product is the amine 23a, 
then the 1H NMR absorptions of a and b should change significantly. This is what we have 
observed as shown in Figure 2.4. The chemical shift for methyl a moved upfield from 2.94 ppm 
in 22a to 2.38 ppm, the methylene group b also shifted upfield from 2.78 in 22a to 2.68 ppm. 
The methine proton d moved upfield from 4.34ppm in 22a to 4.68 ppm in the rearrangement 
product. This is a strong evidence that the structure 25 is not the rearrangement product, in which 
the methine proton d is expected to have a chemical shift around 4.00 ppm. Furthermore, the 
absorption for a and b in the ammonium salt 26 should move down field comparing to the 
neutral form 23a. For the urea, addition of acid will not affect the chemical shifts of a and b 
significantly. As shown in Figure 1, the chemical shifts of the groups close to the nitrogen have 
significantly moved downfield after addition of acid: methyl a shifted from 2.38 ppm to 2.60 
ppm and methylene b shifted from 2.68 ppm to 3.01 ppm. We have also compared the 1H and 
13C spectra data to existing 2-oxazolidinones6 and the similarities of the 5-member ring 
absorption data confirmed that the structure 23a is the correct product. The above results confirm 
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our hypothesis that the rearrangement product is the 5-member ring 2-oxazolidinone 23 instead 
of the 7-member ring urea 25.  
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Figure 2.4. The 1H NMR spectra of compounds 22a (bottom), neutral amine 23a (middle), and 
the protonated amine 26 (top), all spectra obtained in CDCl3. 
 
The formation of 23 is another method of synthesizing chiral oxazolidinones that have opposite 
stereochemistry as the Hoffmann rearrangement method from 16c.22 The rearrangement product 
23 can be used to synthesize 2-oxazolidinones with an alkene functional group by oxidation of 
the amine (after converting to a tertiary amine and treatment with hydrogen peroxide) and 
followed by Cope elimination (Scheme 2.5). The 2-oxazolidinone 28 after Cope elimination can 
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be used as a general building block in the synthesis of 2-oxazolidinone derivatives.  Substituted 
2-oxazolidinones can be obtained by electrophilic addition to the double bonds. 
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Scheme 2.5. A proposed synthesis of a new oxazolidinone building block 28. 
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Conclusions 
Small chiral molecules, featuring 5-membered ring and six-membered ring carbamates are 
important building blocks in the synthesis of biologically active molecules and are found in 
many drugs that are currently available commercially. They are also useful synthetic tools and 
can be used as chiral auxiliaries and catalysts in asymmetric synthesis. Because of their 
interesting chemical properties, these heterocycles have been the subject of many strategies with 
the common goal of finding simple and efficient ways to synthesize them. We have developed a 
new efficient method to synthesize chiral 6-substituted 1,3-oxazinan-2-ones from (S)-3-hydroxy-
γ-butyrolactone. The reaction scheme is straightforward, efficient and with complete retention of 
stereochemistry. We also discovered that under basic conditions, heat can promote the 
rearrangement of the 6-membered ring 1,3-oxazinan-2-ones to the more stable 5-membered ring 
2-oxazolidinones. The product 2-oxazolidinone has opposite stereochemistry comparing to the 2-
oxazolidinone synthesized by Hoffman rearrangement. This method allows us to synthesize 
chiral core structures with complementary stereocenter since the priority order is switched. The 
efficient syntheses of these chiral carbamates are important in the preparation of biologically 
active pharmaceutical compounds. The synthesis also provides intermediates for synthesizing 
chiral aminoalcohol derivatives.  
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Experimental Section: 
General procedure for the synthesis when R = Me is used as an illustration for the procedure. The 
compounds with R = Et and H are synthesized by a similar method. The characterization data for 
the N-Et analogues and when R = H are given. Melting point was measured using Fisher-Jones 
melting point apparatus. 
 
(S)-3,4-Dihydroxy-N-methylbutyramide 16a. Compounds 16a-c were obtained by similar 
methods in the literature.21 The lactone (20.2 g, 198 mmol) and methyl amine (77.7 g, 1.00 mol, 
40%wt in water) were mixed at room temperature for 6 to 8 h. The excess methyl amine was 
removed by washing with hexane and the last trace of solvent and methyl amine were removed 
on a vacuum pump. The crude product was obtained as a brown viscous liquid (26.3 g, 198 
mmol) and was used directly in the second step without further purification. Yield: 100% [α]D25 
−25.9 (c 1.08, EtOH).  1H NMR (D2O, 400 MHz)  δ ppm 3.94 (m, 1H), 3.48 (dd, 1H, J = 11.7, 
3.9 Hz), 3.38 (dd, 1H, J = 11.7, 6.8 Hz), 2.61 (s, 3H), 2.32 (dd, J = 14.7, 3.9 Hz), 2.22 (dd, J = 
14.7, 8.8 Hz). 13C NMR (CD3OD, D2O, 100 MHz) δ ppm, 175.1, 70.1, 69.2, 40.8, 26.9.  
 
(S)-N-Ethyl-3,4-dihydroxybutyramide 16b Yield: 99%, yellow crystals. m.p. 59.0-61.0°C. 
[α]D25 −26.7 (c 1.07, EtOH). 1H NMR (CDCl3, 400 MHz) δ ppm. 5.69 (bs, 1H), 4.07 (m, 1H), 
2.41 (dd, 1H, J = 15.6, 8.8 Hz), 2.31 (dd, 1H, J = 15.6, 3.9 Hz), 3.67 (m, 1H), 3.51 (m, 1H), 3.29 
(m, 2H), 1.14 (t, 3H, J = 7.3 Hz). 13C NMR (D2O, 5%CD3OD, 100 MHz) δ ppm. 174.2, 70.1, 
66.2, 40.9, 35.6, 14.6.  
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(S)-3-Hydroxy-N-methyl-4-trityloxybutyramide 17a. 3,4-Dihydroxy-N-methylbutyramide 16a 
(19.4 g, 146 mmol) was dissolved in 52 mL of anhydrous DMF under N2. Trityl chloride (49.0 g, 
176 mmol) and pyridine (35.0 mL, 438 mmol) were added to the solution, which was then stirred 
at room temperature for 24 to 36 h. The reaction was quenched by addition of ice water (100 
mL) to the solution. The water was decanted and the solid precipitate was dissolved in EtOAc 
(150 mL). The organic phase was washed 3 to 4 times with 30 mL of water and finally with 30 
mL of brine. After drying with Na2SO4, the ethyl acetate was removed on a rotavap and the 
product was obtained as an off white solid (55.0 g, 146 mmol) without further purification. The 
crude product however can be purified by flash chromatography on silica gel using a gradient of 
solvent system of hexane: ethyl acetate 3:1 to 1:1. Yield: 100%. m.p. 107.0-108.0 °C. [α]D25 
−18.3. (c 1.12, EtOAc). 1H NMR (CDCl3, 400 MHz) δ ppm δ 7.40 (d, 6H, J = 7.8 Hz), 7.19-7.34 
(m, 9H), 5.98 (bs, 1H), 4.14 (m, 1H), 3.55 (s, 1H), 3.15 (dd, 1H, J = 9.8, 5.9 Hz), 3.10 (m, 1H), 
2.72 (d, 3H, J = 4.9 Hz), 2.40 (dd, 1H, J = 15.6, 2.9 Hz), 2.31 (dd, 1H, J = 15.6, 8.8 Hz). 13C 
NMR (CDCl3, 100 MHz) δ ppm 172.3, 143.5, 128.4, 127.6, 126.9, 86.4, 67.8, 66.6, 39.4, 25.9. 
HRMS calcd for C24H25NO3Na+ [M+Na]+ 398.1732, found 398.1746. IR (CHCl3): 3347, 3015, 
1653, 1550, 1491, 1448, 1217, 1074, 758 cm-1. 
 
(S)-N-Ethyl-3-hydroxy-4-trityloxybutyramide 17b Yield: 95% after purification using hexane: 
ethyl acetate 1:1, RF = 0.3. (0.05 mmol scale). Product is obtained as a white solid. m.p. 119.0 
°C.  [α]D25 −19.1 (c 1.11, EtOAc). 1H NMR (CDCl3, 400 MHz) δ ppm, 7.50-7.16 (m, 15H), 5.90 
(bs, 1H), 4.16 (m, 1H), 3.52 (sb, 1H), 3.23 (m, 2H), 3.13 (m, 2H), 2.38 (dd, 1H, J = 15.6, 2.9 
Hz), 2.31 (dd, 1H, J = 15.6, 7.8 Hz,), 1.08 (t, 3H, J = 6.8Hz). 13C NMR (CDCl3, 100 MHz) δ 
ppm, 171.5, 143.7, 128.6, 127.8, 127.1, 86.7, 68.0, 66.6, 39.6, 34.2, 14.7. HRMS calcd for 
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C25H27NO3Na+ [M+Na]+ 412.1889,  found 412.1909. IR (CHCl3): 3444, 3372, 3062, 3017, 2934, 
2878, 1651, 1533, 1448, 1217, 1074, 758 cm-1. 
 
(S)-3-Hydroxy-4-trityloxybutyramide 17c. Yield after purification: 90%. m.p. 107.5-108.5º C. 
[α]D25 −18.4 (c 1.00, EtOAc). 1H NMR (CDCl3, 400 MHz) δ ppm, 7.41 (d, 6H, J = 7.8 Hz), 7.34-
7.19 (m, 9H), 6.06 (bs, 1H), 5.64 (bs, 1H), 4.15 (m, 1H), 3.45 (bs, 1H), 3.16 (d, 2H, J = 5.9 Hz), 
2.37 (m, 2H). 13C NMR (CDCl3, 100 MHz) δ ppm, 174.1, 143.6, 128.5, 127.8, 127.1, 86.8, 67.7, 
66.7, 39.2. IR (CHCl3): 3494, 3408, 3019, 2929, 2878, 1675, 1594, 1492, 1448, 1217, 1075, 742 
cm-1. 
 
(S)-4-Methylamino-1-trityloxybutan-2-ol 18a. 3-Hydroxy-N-methyl-4-trityloxy-butyramide 
17a (55.0 g, 146 mmol) was dissolved in anhydrous THF (240 mL) and the reaction flask was 
cooled to 0 °C in an ice-salt bath. LiAlH4 (16.5 g, 434 mmol) was added to the flask at 0 °C 
under dry N2. The ice bath was removed after the generation of hydrogen settled down. The 
mixture was left stirring at room temperature for 12 to 18 h after which time the reaction is 
essentially completed based on NMR spectroscopy. The reaction mixture was then cooled in an 
ice-bath and the reducing agent was quenched by adding 50 mL of a 1:1 mixture of MeOH and 
H2O. The white precipitate formed after addition of water and MeOH was removed by vacuum 
filtration and the filtrate was extracted several times with CHCl3. The combined organic phase 
was dried using Na2SO4 overnight. The solvent was removed on a rotovap and the residue was 
dried on a vacuum pump. The product was obtained as an off white solid (51.4 g, 142 mmol) 
without further purification. Yield: 97% m.p. 120.0°C. [α]D25 −19.0 (c 1.02, EtOH). 1H NMR 
(CDCl3, 400MHz) δ ppm 7.45 (d, 6H, J = 6.8 Hz), 7.28 (t, 6H, J =7.8 Hz), 7.21 (t, 3H, J = 6.8 
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Hz), 4.00 (m, 1H), 3.47 (bs, 2H), 3.17 (dd, 1H, J = 9.8, 5.9 Hz), 3.00 (dd, 1H, J = 9.8, 5.9 Hz), 
2.83 (m, 1H), 2.73 (m, 1H), 2.36 (s, 3H), 1.75 (m, 1H), 1.59 (m, 1H). 13C NMR (CDCl3, 
100MHz) δ ppm 144.0, 128.6, 127.6, 126.8, 86.2, 71.6, 67.4, 49.8, 85.9, 31.8. HRMS ES+ calcd 
for C24H27NO2 [M+1]+ 362.2120,  found 362.2127. IR (CHCl3): 3318, 3061, 3011, 2929, 2872, 
1598, 1491, 1448, 1217, 1075, 766 cm-1. 
 
(S)-4-Ethylamino-1-trityloxybutan-2-ol 18b. Yield: 73% (unoptimized yield). Product is 
obtained as white crystals, m.p. 109.0-110.0° C.  [α]D25 −17.7 (c 1.07, EtOH). 1H NMR (CDCl3, 
400MHz) δ ppm 7.50-7.16 (m, 15H), 4.00 (m, 1H), 3.16 (dd, 1H, J = 8.8, 5.9 Hz), 2.98 (dd, 1H, 
J = 8.8, 5.9 Hz), 2.90 (m, 1H), 2.76 (m, 1H), 2.62 (m, 2H), 1.80-1.70 (m, 1H), 1.58 (m, 1H), 1.07 
(t, 2H, J = 7.3 Hz). 13C NMR (CDCl3, 100 MHz) δ ppm, 144.1, 128.7, 127.7, 126.9, 86.4, 72.0, 
67.5, 47.7, 43.8, 31.9, 14.8. HRMS calcd for C25H30NO2 [M+1]+ 376.2277,  found 376.2281. IR 
(CHCl3): 3062, 3019, 2972, 1491, 1448, 1216, 1075, 757 cm-1. 
 
(S)-4-Amino-1-trityloxy-butan-2-ol 18c. Yield: 93%  m.p. 104.0-106.0º C. [α]D25 −16.0 (c 1.01, 
EtOH,). 1H NMR (CDCl3, 400 MHz) δ ppm, 7.62-7.18 (m, 15H), 3.98 (m, 1H), 3.14 (dd, 1H, J = 
8.8, 5.9 Hz), 3.04 (dd, 1H, J = 8.8, 4.9 Hz), 2.95 (m, 1H), 2.82 (m, 1H), 1.65 (m, 1H), 1.53 (m, 
1H). 13C NMR (CDCl3, 100 MHz) δ ppm, 143.8, 128.4, 127.5, 126.7, 86.2, 70.3, 67.6, 39.3, 
35.1.  IR (CHCl3): 3377, 3061, 3015, 2929, 2873, 1596, 1491, 1448, 1217, 1073, 767 cm-1. 
(S)-3-Methyl-6-trityloxymethyl-1,3-oxazinan-2-one 19a. 4-Methylamino-1-trityloxy-butan-2-ol  
18a (10.9 g, 30.0 mmol) was dissolved in anhydrous THF or dioxane (50.0 mL). After the 
compound 18a was completely dissolved, carbonyldiimidazole (9.98 g, 60.0 mmol) was added to 
the flask and the solution was stirred under refluxing for 24 h. The solvent was evaporated on the 
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rotovap and the remaining solid was extracted in EtOAc. The organic phase was washed with 
about 10.0 mL of H2O several times and with 30.0 mL of brine. The EtOAc phase was 
concentrated on the rotovap to afford a brown solid that was purified on SiO2 gel with a gradient 
of solvent of hexane: ethyl acetate 5:1 to 1:1. The purified product was obtained as a white 
crystalline solid (10.9 g, 28.0 mmol). Yield: 93%. m.p. 161.0-162.0° C. [α]D25 +36.2 (c 1.08, 
EtOAc). 1H NMR (CDCl3, 400 MHz) δ 7.42 (d, 6H, J = 6.8 Hz), 7.32-7.20 (m, 9H), 4.32 (m, 
1H), 3.32 (m, 1H), 3.21 (m, 1H), 2.96 (s, 3H), 2.07 (m, 1H), 1.96 (m. 1H). 13C NMR (CDCl3, 
100 MHz) δ 153.3, 143.3, 128.3, 127.56, 126.9, 86.5, 75.4, 64.5, 45.8, 36.2, 24.3. HRMS ES+ 
calcd for C25H26NO3 [M+1]+ 388.1913, ES found: 388.1928. IR (CHCl3): 3061, 3018, 2938, 
2880, 1690, 1494, 1448, 1217, 1083, 760 cm-1. 
 
(S)-3-Ethyl-6-trityloxymethyl-1,3-oxazinan-2-one 19b Yield: 79%. Product was obtained as 
white crystals, m.p. 141.0-142.0° C. [α]D25  +26.7 (c 1.07, EtOAc). 1H NMR (CDCl3, 400 MHz) 
δ ppm 7.52-7.16 (m, 15H), 4.32 (m, 1H), 3.42-3.26 (m, 4H), 3.24-3.14 (m, 2H), 2.10 (m, 1H), 
1.93 (m, 1H), 1.12 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz) δ ppm, 153.0, 143.5, 128.6, 
127.8, 127.1, 86.7, 75.5, 64.7, 44.0, 43.4, 24.7, 12.1. HRMS calcd for C26H28NO3 [M+1]+ 
402.2069,  found 402.2079. IR (CHCl3): 3062, 3019, 2982, 2938, 1685, 1491, 1450, 1280, 1217, 
1094, 763 cm-1. 
 
(S)-6-Trityloxymethyl-1,3-oxazinan-2-one 19c Yield: 70%  m.p. 182.5-183.5º C. [α]D25 +20.8 
(c 1.01, EtOAc). 1H NMR (CDCl3, 400 MHz) δ ppm, 7.60-7.18 (m, 15H), 7.42 (d, 6H, J = 7.8 
Hz), 7.29 (t, 6H, J = 7.8 Hz), 7.21 (d, 3H, J = 7.8 Hz), 5.25 (bs, 1H), 4.38 (m, 1H), 3.34 (m, 3H), 
3.23 (dd, 1H, J = 9.8, 5.9 Hz), 2.03 (dd, 1H, J = 12.7, 2.9 Hz), 1.92 (m, 1H), 1.55 (bs, 1H). 13C 
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NMR (CDCl3, 100 MHz) δ ppm 154.5, 143.5, 128.5, 127.9, 127.1, 86.8, 76.1, 64.7, 38.7, 23.6.  
IR (CHCl3): 3448, 3261, 3062, 3018, 2939, 2882, 1707, 1490, 1450, 1292, 1217, 1110, 1079, 
750 cm-1. 
 
(S)-6-Hydroxymethyl-3-methyl-1,3-oxazinan-2-one 20a. The solution of 3-methyl-6-
trityloxymethyl-1,3-oxazinan-2-one 19a (5.00 g, 13.0 mmol) in a mixture of TFA and CH2Cl2 
(20 mL, 1:1) was stirred for 12 h at room temperature. The TFA and the solvent were evaporated 
to dryness on a rotovap. Ice water was then added to the viscous liquid residue and a solid 
precipitate formed. The solid was removed by vacuum filtration and the water phase was 
extracted with hexane to remove trace amount of trityl compound. The water phase was then 
evaporated on an oil pump and MeOH was added to the product and then evaporated several 
times. The product was obtained as a light brown viscous liquid (1.90 g, 13.0 mmol) and was 
used directly in the next step. Yield: 100% [α]D25 +75.6 (c 1.09, EtOH). 1H NMR (CDCl3, 400 
MHz) δ 4.29 (m, 1H), 3.74 (dd, 1H, J = 11.7, 3.9 Hz), 3.65 (dd, 1 H, J = 11.7, 4.9 Hz), 3.38 (m, 
1H), 3.22 (m, 1H), 2.95 (s, 3H), 2.77 (bs, 1H), 1.97 (m, 2H). 13C NMR (CDCl3, 100 MHz) δ 
154.0, 77.5, 63.7, 46.0, 36.3, 23.3. HRMS ES+ calcd for C6H12NO3 [M+1]+ 146.0817, found 
146.0820. IR (CHCl3): 3381, 3009, 2939, 1677, 1499, 1450, 1256, 1079, 756 cm-1. 
 
(S)-3-Ethyl-6-hydroxymethyl-1,3-oxazinan-2-one 20b Yield: quantitative, [α]D25 +64.1 (c 
0.91, EtOH). 1H NMR (CDCl3, 400 MHz) δ ppm 4.28 (m, 1H), 3.79 (m, 1H), 3.66 (m, 1H), 3.38 
(m, 3H), 3.26 (dd, 1H, J = 5.9, 2.9 Hz), 1.95 (m, 2H), 1.16 (t, 3H, J =6.8 Hz). 13C NMR (CDCl3, 
100 MHz) δ ppm 153.5, 77.5, 63.6, 43.8, 43.4, 23.3, 12.0. HRMS ES+ calcd for C7H14NO23 
[M+1]+ 160.0974,  found 160.0972. IR (CHCl3): 3393, 3013, 2927, 1664, 755 cm-1. 
46 
 
 (S)-Methanesulfonic acid 3-methyl-2-oxo-1,3-oxazinan-6-ylmethyl ester 21a. 6-
Hydroxymethyl-3-methyl-1,3-oxazinan-2-one 20a (1.87 g, 13.0 mmol) was dissolved in dry 
dichloromethane (20.0 mL). Pyridine (12.0 mL, 156 mmol) and methanesulfonyl chloride (5.00 
mL, 65.0 mmol) were added and the solution was stirred at room temperature for 12 h. NaHCO3 
(5.00 g, 59.0 mmol) was then added to the flask and the mixture was stirred for 30 min after 
which the solvent was removed on a rotavap. The residue was cooled in an ice bath and water 
(30.0 to 40.0 mL) was added to quench the unreacted sulfonyl chloride. The water phase was 
extracted 5 times using 30.0 mL of EtOAc each time. The combined organic extracts were dried 
using Na2SO4 and the solvent was evaporated to give the product as dark brown solid without 
further purification (2.38 g, 11.0 mmol). Yield: 85%.  m.p. 81.5-82.0° C.  [α]D25  +59.1 (c 1.14, 
EtOAc). 1H NMR (CDCl3, 400 MHz) δ 4.49 (m, 1H), 4.34 (dd, 1H, J = 11.7, 3.9 Hz), 4.30 (dd, 
1H, J = 11.7, 3.9 Hz), 3.42 (m, 1H), 3.27 (m, 1H), 3.08 (s, 3H), 2.98 (s, 3H), 2.04 (m, 2H). 13C 
NMR (CDCl3, 100 MHz) δ ppm 152.5, 73.9, 69.6, 45.6, 37.5, 36.3, 23.2. HRMS calcd for 
C7H13NO5S [M+1]+ 224.0593, found 224.0583. IR (CHCl3): 3019, 2942, 1693, 1496, 1448, 
1356, 1177, 756 cm-1. 
 
 
(S)-Methanesulfonic acid 3-ethyl-2-oxo-1,3-oxazinan-6-ylmethyl ester 21b After purification 
by chromatography, product was obtained as a white crystal, Yield: 92% m.p. 68.0-70.0° C.  
[α]D25 +52.2 (c 1.14, EtOAc). 1H NMR (CDCl3, 400 MHz) δ ppm, 4.47 (m, 1H), 4.34 (dd, 1H, J 
= 11.7, 3.9 Hz), 4.30 (dd, 1H, J = 11.7, 4.9 Hz), 3.38 (m, 3H), 2.29 (m, 1H), 3.08 (s, 3H), 2.10-
1.92 (m, 2H), 1.15 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz) δ ppm, 152.1, 73.9, 69.5, 
47 
 
44.2, 43.2, 37.8, 23.6, 12.1. HRMS ES+ calcd for C8H16NO5S [M+1]+ 238.0749, found 
238.0745. IR (CHCl3): 3436, 3020, 1694, 1491, 1456, 1217, 758 cm-1. 
 
(S)-6-(Benzylaminomethyl)-3-methyl-1,3-oxazinan-2-one 22a. Methanesulfonic acid 3-
methyl-2-oxo-[1,3]oxazinan-6-ylmethyl ester 21a (0.810 g, 3.67 mmol) and benzylamine (0.800 
mL, 8.00 mmol)  were dissolved in anhydrous DMSO (10.0 mL). The mixture was stirred at 75 
to 80 °C for 48 h under anhydrous atmosphere. The reaction mixture was cooled to room 
temperature and ice water (10 – 20 mL) was added to the flask. The water phase was extracted 
several times with dichloromethane. The combined organic phase was dried using Na2SO4 and 
concentrated on a rotavap to remove the solvent to give the crude product as a yellow viscous 
liquid. The crude compound was purified by silica gel chromatography using a gradient of 
solvent system of hexane:THF/9:1 to hexane:CH2Cl2:THF/6:3:1 to CH2Cl2:MeOH/9.9:0.1. The 
product was obtained as a light brown viscous liquid (0.770 g, 3.30 mmol). Yield: 91% [α]D25 
+68.2 (c 1.07, EtOH). 1H NMR (CDCl3, 400 MHz) δ 7.24-7.13 (m, 5H), 4.34 (m, 1H), 3.77 (m, 
2H), 3.34 (m, 1H), 3.17 (m, 1H), 2.94 (s, 3H), 2.80 (dd, 1H, J = 12.7, 6.8 Hz), 2.75 (dd, 1H, J = 
12.7, 3.9 Hz), 1.92 (m, 2H), 1.83 (bs, 1H). 13C NMR (CDCl3, 100 MHz) δ 153.7, 139.4, 128.3, 
128.0, 127.0, 76.3, 53.5, 52.3, 46.2, 36.3, 25.0. HRMS calcd for C13H19N2O2 [M+1]+ 235.1447, 
found 235.1447. IR (CHCl3): 3330, 3009, 2938, 1690, 1496, 1449, 1409, 1354, 754 cm-1. 
(S)-6-(Benzylaminomethyl)-3-ethyl-1,3-oxazinan-2-one 22b The reaction temperature was 65 
°C and time was 36 h. Crude yield 96%, 1H NMR spectroscopy indicated quantitative 
conversion). After purification on SiO2 gel with a gradient of hexane: CH2Cl2 6:1 to hexane: 
CH2Cl2:THF 6:3:1. Yield: 78%. [α]D25  +55.3 (c 0.64, EtOH). 1H NMR (CDCl3, 400 MHz) δ 
ppm, 7.40-7.18 (m, 5H), 4.34 (m, 1H), 3.80 (d, 1H, J = 12.7 Hz), 3.76 (d, 1H, J = 12.7 Hz), 3.34 
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(m, 2H), 3.20 (m, 1H), 2.81(dd, 1H, J = 12.7, 6.8 Hz), 2.76 (dd, 1H, J = 12.7, 4.9 Hz), 1.94 (m, 
2H), 1.85 (s, 1H), 1.13 (t, 3H, J =6.8 Hz) 13C NMR (CDCl3, 100 MHz) δ ppm, 153.2, 139.8, 
128.4, 128.1, 127.0, 76.4, 53.7, 52.6, 44.0, 43.6, 25.3, 12.1. HRMS ES+ calcd for C14H21N2O2 
[M+1]+ 249.1603,  found 249.1597. IR (CHCl3): 3472, 2974, 2934, 1682, 1492, 1455, 1282, 
1221, 1095, 755 cm-1. 
 
(S)-3-Benzyl-5-(2-methylaminoethyl)-oxazolidin-2-one 23a. 6-(Benzylaminomethyl)-3-
methyl-1,3-oxazinan-2-one 22a (0.160 g, 0.070 mmol), anhydrous DMSO (5.00 mL) and K2CO3 
(0.200 g, 1.40 mmol) were mixed and stirred at 95-100°C for 24 h. 1H NMR spectrum indicated 
complete conversion to the 5-membered ring product. The flask was cooled to room temperature 
and ice water (5 mL) was added to the solution. The water phase was then extracted with CH2Cl2 
several times. The combined organic phase was concentrated on a rotovap and the yellow liquid 
obtained was purified by SiO2 chromatography using a gradient of hexane:THF 9:1 to 
hexane:CH2Cl2:THF 6:3:1 to CH2Cl2:MeOH 9.9:0.1. The pure product was obtained as a light 
brown viscous liquid (0.130 g, 0.057 mmol). Yield: 81%. [α]D25  +68.5 (c 1.00, EtOH). 1H NMR 
(CDCl3, 400 MHz) δ 7.36-7.21 (m, 5H), 4.57 (m, 1H), 4.41 (d, 1H, J = 14.7 Hz), 4.36 (d, 1H, J = 
14.7 Hz), 3.47 (t, 1H, J = 8.8 Hz), 3.03 (t, 1H, J = 7.8 Hz), 2.69 (t, 2H, J = 6.8 Hz), 2.38 (s, 3H), 
1.88 (m, 1H), 1.74 (m, 1H),1.62 (bs, 1H). 13C NMR (CDCl3, 100 MHz) δ 158.0, 135.7, 128.8, 
128.1, 127.9, 72.3, 49.4, 48.3, 47.5, 36.4, 35.1. HRMS calcd for C13H19N2O2 [M+1]+ 235.1447, 
found 235.1449. IR (CHCl3): 3018, 2936, 1742, 1493, 1442, 1217, 756 cm-1. 
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Chapter III. Synthesis of Chiral 2-Oxazolidinones,  
2-Oxazolines and Their Analogs. 
 
Abstract 
Small chiral molecules are very important building blocks in the synthesis of biologically active 
compounds. These building blocks include nitrogen and oxygen-containing heterocycles such as 
oxazolidinones, oxazinanones, oxazolines, oxazines, morpholine and morpholinones. Because of 
their interesting properties, chiral heterocycles have stirred great interest in the synthetic chemist 
community to develop useful and efficient strategies to these molecules. In this chapter, chiral 5-
membered ring 2-oxazolidinones and 6-membered ring 1,3-oxazinan-2-ones are synthesized 
from the corresponding amino alcohols with either complete inversion or retention of 
stereochemistry. Chiral 5-substituted 2-oxazolines and 6-substituted 2-oxazines are also 
synthesized from the same starting materials with inversion of stereochemistry through an 
intramolecular SN2 reaction. These compounds are useful intermediates in organic synthesis and 
crucial building blocks for many pharmaceutical compounds.  
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Introduction 
Small chiral molecules are very important building blocks in the synthesis of biologically 
relevant compounds. Chiral 5-substituted-2-oxazolidinones 1 and 2 shown in figure 3.1 are 
important core structures in many drug molecules and useful intermediates in the synthesis of 
chiral aminoalcohols. 5-Hydroxymethyl or 5-aminomethyl-2-oxazolidinones (1 and 2) are 
important in the preparation of oxazolidinone antibacterial agents.1-10 Representative 2-
oxazolidinones antibiotics include Linezolid (Zyvox®) 51-2 and dihydrothiazine analog 65. 2-
Oxazolidinones have been used in the synthesis of chiral aminoalcohols such as beta-blocker 
carvedilol (Eucardic®).11-20 The 6-membered ring 1,3-oxazinan-2-ones 3 and 4 derivatives also 
exhibit biological activities, such as anti-inflammatory,21 anti-thrombotic,22 and antibacterial 
activities.23 These heterocycles can be synthesized from amino alcohols or related starting 
materials. Another class of heterocyclic compounds that can be interconverted from amino 
alcohols is the oxazolines.24-25 They are also important pharmacophores in many drug molecules; 
for instance natural product 7 has antibiotic activity,26 compound 8 is a tubulin polymerization 
inhibitor and is a potential anticancer agent, while Deflazacort (Calcort®) 9 is a commercially 
available anti-inflammatory drug (Figure 3.2).27 The homologous oxazine rings are also found in 
many compounds with interesting chemical and biological properties.28-32 Besides being 
important building blocks for the preparation of biologically active compounds, 2-
oxazolidinones, 1,3-oxazinan-2-ones and 2-oxazolines are also used as chiral auxiliaries or as 
protected forms of amino alcohols in the synthesis of complex molecules.33-38  Because of the 
importance of these heterocycles as pharmaceutical core structures and in asymmetric synthesis, 
there have been great interests in developing their effective syntheses. The preparations of 
optically pure cyclic carbamates include the conversion of a chiral hydroxyl amide by Hofmann 
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rearrangement39 and the carbonylation reaction of chiral 1,3-amino alcohols.40 Many examples 
are available for the synthesis of cyclic carbamates from chiral amino alcohols with retention of 
stereochemistry.41-55 There are fewer methods for the preparation of cyclic carbamates with 
opposite stereochemistry to the starting amino alcohol derivatives.44, 56-59 
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Figure 3.1. 2-oxazolidinones and 1,3-oxazinan-2-ones compounds. 
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Figure 3.2. Biologically active molecules containing the 2-oxazoline moiety. 
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For the preparation of the opposite stereoisomers, the hydroxyl group is usually converted to a 
better leaving group through mesylation or Mitsunobu reaction, and the nitrogen is derivatized 
with Boc2O or CbzCl. The SN2 cyclization from the displacement of the activated hydroxyl 
group affords the cyclic carbamate with opposite stereochemistry.  
 
A general precursor for oxazoline synthesis is a β-hydroxy amide. The hydroxyl group is usually 
converted to a better leaving group such as a sulfonate or halide, then an intramolecular SN2 
cyclization reaction gives the corresponding oxazoline. Many chiral 1,2-amino alcohols can be 
prepared from naturally occurring α-amino acids, and the oxazolines formed from these amino 
alcohols are 2,4-disubstituted oxazolines. Relatively fewer 5-substituted 2-oxazolines have been 
synthesized because of the lack of accessibility of the corresponding amino alcohols. There are 
also fewer 6-membered ring 2-oxazines comparing to 5-membered ring oxazolines, for the same 
reason as above, 1,3-amino alcohols are less accessible than the amino acid derived 1,2-amino 
alcohols which are used often in the synthesis of 2-oxazolines.   
 
(S)-3-hydroxy-γ-butyrolactone is a commercially available compound that can be synthesized 
readily from starch or lactose.60 The lactone has been converted to chiral (S)-1,2-amino alcohols, 
(S)-1,3-amino alcohols and their derivatives via efficient methods.39,61  These chiral amino 
alcohols have structures that are complementary to those of natural amino acids derived amino 
alcohols. As part of our effort in synthesizing chiral building blocks that are useful in drug 
discovery, we devised new routes for several chiral heterocycles from intermediates generated 
from (S)-3-hydroxy-γ-butyrolactone. These chiral heterocycles include 5-substituted 2-
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oxazolines, 6-substituted 2-oxazines, and both enantiomers of 5-trityloxymethy-2-oxazolidinones 
and 6-trityloxymethyl-1,3-oxazinan-2-ones.   
 
 Results and discussion 
For the preparation of the 5-membered ring compounds, we started from the trityloxymethyl 
oxazolidinones 10a and 10b (Scheme 3.1). These can be prepared from (S)-3-hydroxyl-γ-
butyrolactone according to literature procedures.22,39 Compound 10 was decarbonylated by 
refluxing with NaOH in a mixture of THF, ethanol and water to give the trityl protected amino 
alcohol 11 with excellent yield. The amino alcohol 11 was then treated with trifluoroacetic 
anhydride at low temperature to give the corresponding amide 7, followed by mesylation of the 
free hydroxyl group in 7 to give the intermediate 13. The mesylate 13b (R = Me) was cyclized to 
N-methyl-oxazolidinone 14 ([α]D25 = -41.0, EtOAc, c = 1.00) under basic condition using 
potassium carbonate in DMF. Compound 14 has a stereochemistry opposite to that of the starting 
material 10b ([α]D25 = +40.9, EtOAc, c = 1.00). The cyclization to the oxazolidinone occurred 
through intramolecular SN2 displacement of the mesylate and subsequent rearrangement. The 
yield for the transformation is excellent with complete inversion of stereochemistry.62  
A small amount of compounds 10b and 14 were deprotected using TFA to remove the trityl 
group and the free alcohol treated with Mosher’s acid chloride to form the corresponding esters 
10b’ and 14’ (Figure 3.3). Integration of the signals on the 1H NMR spectrum of the crude 
reaction products allowed us to confirm the optical purity with the optical rotation data. The 
crude 500MHz 1H NMR spectrum of compound 10b’ indicated no presence of diastereomer, the 
chemical shifts of protons a and b are: δ (ppm), 4.76 (sb, Ha), 4.58 (d, 1H, Hb, J = 0,11.7Hz), 
4.41 (dd, Hb′,  J = 3.9, 11.7Hz),  compound 25:  4.78 (sb, Ha), 4.58 (dd, 1H, Hb, J = 2.9, 12.2), 
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4.37 (dd, Hb′,  J = 3.9, 12.2Hz), a small doublet impurity signal at 4.41 estimated less than 1% of 
the Hb′ integration indicates that the purity of the enantiomer is 99%.      
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Figure 3.3. Mosher’s esters 10b’ and 14’. 
When the amide contains a hydrogen atom such as in compounds 13a (R = H), under the same 
mild basic conditions, the 2,5-disubstituted oxazoline 15 with inverted stereochemistry was 
obtained. The oxazoline was then hydrolyzed to give the amino alcohol 16 ([α]D25 = +15.3, 
EtOH, c = 1.10), which has inverted stereochemistry compared to compound 11a ([α]D25 = -15.9, 
EtOH, c = 1.00). Because the oxazoline 15 is formed through an intramolecular reaction, it is 
expected to have high integrity of stereochemistry. Therefore, the stereochemistry of the amino 
alcohol 11a can be inverted through a 4-step sequence as shown in Scheme 3.1.    
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Scheme 3.1. Synthesis of 2-oxazolidinone 14 and trityl protected 2-oxazoline 15. 
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In the preparation of the 6-membered ring analogs, the trityl protected amino alcohols 17b-c 
were used as starting materials. These compounds are synthesized by reacting (S)-3-hydroxy-γ-
butyrolactone with amines to produce the corresponding dihydroxyl butyramides followed by the 
reduction of the trityl protected amides with lithium aluminum hydride.60  As shown in Scheme 
4. 2, by a similar method as for the 5-membered ring oxazolidinone synthesis, the amino alcohols 
17 were converted to the trifluoroacetamide 18. From compounds 18b-c, direct acyl transfer 
cyclization under anhydrous basic conditions led to the formation of (S)-1,3-oxazinan-2-ones 
19b ([α]D25 = +32.5, EtOAc, c = 1.03), and 19c ([α]D25 = +29.0, EtOAc, c = 1.01) in  excellent 
yields. This demonstrated the feasibility of converting the amino alcohols into cyclic carbamates 
using trifluoroacetamide intermediate through elimination of the trifluoromethyl group. To 
prepare the carbamates with opposite stereochemistry, the mesylates 20b-c were treated with 
potassium carbonate to afford the cyclization products 21b ([α]D25 = -31.9, EtOAc, c = 1.03) and 
21c ([α]D25 = -28.6, EtOAc, c = 1.00) in moderate yields. Although the reaction suffered from 
lower yields, the optical purities of the oxazinanones with inverted stereochemistry are over 99% 
ee.63  
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Scheme 3.2. Synthesis of both enantiomers of trityl protectected  
1,3-oxazinan-2-ones (19, 21) and oxazine 22. 
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The 6-membered ring 2-oxazine homolog 22 can be synthesized by a similar method as the 
synthesis of 2-oxazoline 15. The mesylate 20a was converted to the 2-oxazine 22 and the 
hydrolysis of 22 using cesium carbonate gave the amino alcohol 23 with excellent yield. The 
isolated product amino alcohol 23 ([α]D25 = +15.0, EtOH, c = 1.00) has reasonably good optical 
purity as compared to the optical rotation data of compound 17a ([α]D25 = -15.7, EtOH, c = 
1.01).   
 
The intramolecular SN2 cyclizations in the 6-membered ring formation suffered lower yields than 
the 5-membered ring system. Several attempts using different bases, solvents and lengths of 
reaction time failed to improve the yield of the 1,3-oxazinan-2-ones. The N-benzyl derivative 
21c was obtained in 63% yield from the corresponding mesylate 20c; we then synthesized the N-
methyl derivatives considering the substituents on the nitrogen might affect the reaction 
outcome. The reaction of N-methyl derivative afforded poorer yield than the N-benzyl derivative. 
Compound 20b in DMF treated with potassium carbonate and other bases only gave a small 
amount (20%) of the desired product 21b with a large percentage of decomposition. When the 
reaction was done in DMSO with K2CO3 as the base, the desired product was obtained with a 
55% yield. Therefore, this rearrangement reaction proved to be more effective for the formation 
of 5-membered ring system, which follows the established Baldwin’s rules on the intramolecular 
cyclization reactions.  
 
In the direct acyl transfer reaction leading to the cyclic carbamate with the same stereochemistry 
as the starting material, the cyclization occurred presumably by nucleophilic addition to the 
carbonyl group followed by elimination. Similar reactions are commonly used in the formation 
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of cyclic carbamates, these include using a t-Boc or Cbz derivative of the amines. For the SN2 
cyclization reaction leading to heterocycles with opposite stereochemistry, a possible mechanism 
is shown in Scheme 3.3 using the oxazolidinone as an example. The first step here is the 
displacement of the mesylate and maybe through the formation of an unstable intermediate 24. 
The second step involves the attack of a base to the intermediate 24, a hydroxide ion or other 
base present in the reaction attacks the carbon-2 and gives the tetrahedral intermediate 25 which 
then undergoes elimination to afford the 2-oxazolidinone 14.  
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Scheme 3.3. A possible mechanism for the formation of 2-oxazolidinone 14. 
 
In our effort to go further in our exploration and development of synthetic methods to 2-
oxazoline and 2-oxazine rings, we used 2-oxazolidinone 10a and 1,3-amino alcohol 17a as 
starting materials to carry out the synthesis of respectively 2-aminomethyl-1,3-oxazolines and 2-
aminomethyl-1,3-oxazines, with complete inversion of the stereochemistry. Compared to their 2-
trifluoromethyl analogs 15 and 22, they possess a secondary amine site which could undergo 
further substitutions. These molecules could therefore be useful intermediates in the synthesis of 
more complex molecules such as hetereocyclic tertiary amines with a pharmacological potential.  
 
The synthesis of 2-oxazolines 29a-c was started with (S)-5-trityloxymethyl-oxazolidin-2-one 10a 
(Scheme 3.4), which was decarbonylated by refluxing with NaOH in a mixture of THF, ethanol 
and water to give aminoalcohol 11a. Compound 11 was reacted with bromoacetic anhydride, 
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which affords mono and di-acetylated compounds. The ester was selectively hydrolyzed using 
sodium bicarbonate at room temperature to give β-hydroxyamide 26 quantitatively. The 
secondary alcohol of 26 was transformed into a good leaving group by mesylation with a very 
good yield to afford 27. At this stage, cyclization into a 2-oxazoline was already possible, but the 
presence of the bromine atom proved to interfere and lower the yield. Substitution of the bromine 
of 27 with a primary amine to obtain 28 solved the problem, while it also increased the versatility 
of the molecule by adding another site of functionalization. Intermediate 28 was then cyclized 
into 2-oxazoline 29 with a good yield using potassium carbonate in DMSO at 80 °C. The 
reaction proceeds with complete inversion of stereochemistry from the starting (S)-2-
oxazolidinone to the product (R)-2-oxazoline. 
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Scheme 3.4. Synthesis of 2-aminomethyl-oxazolines from 2-oxazolidinone 10a. 
 
 
 
The synthesis of 2-oxazines 33a-c started with the (S)-3-hydroxy-4-trityloxy-butyramine 17a. 
The 17a was selectively acylated using stoichiometric amount of bromoacetic acid to afford 30. 
The secondary alcohol function was then mesylated to give 31 in a very good yield and the 
bromine atom was displaced by a primary amine to give intermediate 32. The cyclization to the 
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2-oxazine 33 was achieved with a good yield and with complete inversion of the stereochemistry 
from the starting oxazinan-2-one. 
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Scheme 3.5. Synthesis of 2-aminomethyl-oxazines from (S)-3-hydroxy-4-trityloxy-butyramide. 
 
From bromoacetamide intermediates 26 and 30a, the morpholin-3-one and the oxazepan-3-one 
respectively can also be synthesized. These heterocycles, like the previous ones synthesized in 
this project, can be found in pharmaceutically active compounds and present a good potential as 
synthetic intermediates. The synthesis of morpholin-3-one 34 was achieved by intramolecular 
cyclization of 26 using sodium hydroxide in refluxing dichloromethane (scheme 3.6). Compound 
34 was subsequently reduced into morpholine 35, which in turn could undergo further 
transformations towards the synthesis of biologically active molecules. 
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Scheme 3.6. Synthesis of morpholin-3-one 34 and morpholine 35. 
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Following a similar procedure as the one used with intermediate 26, the cyclization of the 
homologous bromoacetamide 30a into oxazepan-3-one 36 was achieved by refluxing in 
dichloromethane in the presence of sodium hydroxide (Scheme 3.7). 
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Scheme 3.7. Synthesis of oxazepan-3-one 36 from intermediate 30a. 
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Conclusions 
We have developed an efficient method to convert chiral trityl protected 3-amino-1,2-propane 
diol and 4-amino-1,2-butane diol to the corresponding optically pure cyclic carbamate 
derivatives. Direct acyl transfer reactions under basic conditions led to cyclic carbamates with 
retention of stereochemistry; while intramolecular SN2 cyclization yielded 2-oxazolidinones or 
1,3-oxazinan-2-ones with inversion of stereochemistry. The direct acyl transfer cyclization using 
trifluoroacetamide intermediate can be used as a complementary method to cyclizations using t-
Boc or Cbz carbamates as intermediates to synthesize cyclic carbamates. From bromoacetamide 
derivatives, direct acyl transfer lead to morpholin-3-ones and oxazepan-3-ones cycles. The 
intramolecular SN2 cyclization methods can be used to synthesize oxazolidinones with inverted 
stereochemistry.  Chiral 2,5-disubstituted oxazolines, 2,6-disubstituted oxazines, were also 
synthesized from the corresponding amino alcohols; hydrolysis of these heterocycles yielded 
amino alcohols with opposite configuration to that of the starting materials. The effective 
synthesis of these chiral heterocycles allows feasible access to a variety of biologically active 
compounds including antibacterial agents.   
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Experimental Section 
 
(S)-3-Methyl-5-(trityloxymethyl)oxazolidin-2-one 10b. (S)-5-(Trityloxymethyl)oxazolidin-2-
one 10a (118 mg, 0.328 mmol) was dissolved in anhydrous THF (5 mL). The reaction flask was 
cooled to 0 °C and potassium tert-butoxide (74.0 mg, 0.660 mmol) was added to the solution 
which was stirred for 1 h. Iodomethane (0.051 mL, 0.819 mmol) was added to the mixture and 
the reaction was stirred at room temperature for 2 h after which NMR of the crude mixture 
showed all starting material had been transformed. The reaction flask was cooled to 0 °C and the 
reaction was quenched with cold methanol. The solvents were evaporated and the crude residue 
was taken up in dichloromethane. The solid residue was filtered out and the solvent was 
evaporated to afford a crude residue that was purified on silica gel with a solvent system of 
hexane:CH2Cl2:THF 8:1:1. The pure product was isolated as a white solid (108 mg, 0.290 
mmol). Yield: 88%. m.p. 157-158 °C [α]D25 = +40.9 (EtOAc, c = 1.00). 1H NMR (CDCl3, 250 
MHz); δ 7.49-7.22 (m, 15H), 4.56 (m, 1H), 3.49 (t, 1H, J = 8.7 Hz), 3.34 (m, 2H), 3.22 (dd, 1H, 
J = 10.2, 4.5 Hz), 2.89 (s, 3H). 13C NMR (CDCl3, 62.5 MHz); δ 158.1, 143.4, 128.5, 127.9, 
127.2, 86.8, 71.7, 64.3, 48.8. 30.9. HRMS calcd for C24H23NO3. [M+H]+ 374.1756, found 
374.1748. 
 
(S)-1-Amino-3-trityloxy-2-propanol 11a.  (S)-5-Trityloxymethyl-2-oxazolidinone 10a (2.00 g, 
5.56 mmol) was dissolved in a (1:1) mixture of ethanol and THF (40 mL). Sodium hydroxide 
(1.35 g, 33.8 mmol) in distilled water (10 mL) was added dropwise to the solution. The mixture 
was refluxed overnight. The solvents were evaporated and the residue taken-up in THF. A 
precipitate was formed and filtered out. The solution was concentrated to dryness under vacuum 
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and the crude was dried on the vacuum pump without further purification to afford a white semi-
solid (1.85 g, 5.55 mmol). Yield: 100%. [α]D25 = -15.9 (EtOH, c = 1.00). 1H NMR (CDCl3, 400 
MHz); δ 7.47-7.21 (m, 15H), 3.75 (m, 1H), 3.15 (d, 2H, J = 5.0 Hz), 2.77 (m, 2H), 2.09 (bs, 3H). 
13C NMR (CDCl3, 100 MHz); δ 143.8, 128.6, 127.8, 127.1, 86.6, 71.3, 65.6, 44.4. HRMS Calcd 
for C22H23NO2 [M+Na]+ 356.1651,  found 356.1626.   
 
(S)-1-(Methylamino)-3-(trityloxy)propan-2-ol 11b. (S)-3-Methyl-5-
(trityloxymethyl)oxazolidin-2-one 10b (154 mg, 0.412 mmol) was dissolved in a mixture of  
THF and ethanol (2 mL each). Lithium hydroxide (100 mg, 4.18 mmol) and sodium hydroxide 
(85.0 mg, 2.12 mmol) were dissolved in water (4 mL) and added to the solution. The mixture 
was refluxed for 48 h and the solvents were evaporated. The crude residue was taken-up in THF 
and the insoluble salts were filtered out; the THF was evaporated and the crude product was 
purified on silica gel with a gradient of hexane:CH2Cl2  1:9 to CH2Cl2:methanol 9:1. The product 
was obtained as a light brown semi-solid (120 mg, 0.345 mmol). Yield: 84%. [α]D25 = -14.2 
(EtOAc, c = 1.00). 1H NMR (CDCl3, 250 MHz); δ 7.47-7.19 (m, 15H), 3.90 (m, 1H), 3.17 (m, 
2H), 2.67 (m, 2H), 2.42 (s, 3H), 2.34 (bs, 2H). 13C NMR (CDCl3, 62.5 MHz); δ 143.8, 128.6, 
127.7, 126.9, 86.6, 68.6, 66.2, 54.3, 35.9. HRMS calcd for C23H25NO2.  [M+H]+ 348.1964, found 
348.1961. 
 
(S)-2,2,2-Trifluoro-N-(2-hydroxy-3-(trityloxy)propyl)acetamide 12a. (S)-1-Amino-3-
(trityloxy)propan-2-ol 11a (1.00 g, 3.00 mmol) was dissolved in anhydrous THF (25 mL). The 
solution was stirred at 0 °C for about 5 min then potassium carbonate (2.50 g, 18.1 mmol) was 
added to the solution. After another 5 min, trifluoroacetic anhydride (0.500 mL, 3.54 mmol) was 
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added and the mixture was stirred for 30 min at 0 °C. The solution was diluted with CH2Cl2 and 
the K2CO3 was filtered out. The organic solvents were evaporated on the rotovap, the crude 
mixture taken up in CH2Cl2 and washed with water twice. The dichloromethane was then 
evaporated and the crude mixture purified on SiO2 gel using a gradient of solvent of pure hexane 
to hexane:CH2Cl2:THF 6:3:1. The pure product was obtained as an off-white solid (1.01 g, 2.33 
mmol). Yield: 78%. m.p. 98-100 °C  [α]D25 = -19.2 (EtOH, c = 1.03). 1H NMR (CDCl3, 250 
MHz); δ  7.41-7.12 (m, 15H), 7.04 (bs, 1H), 3.82 (m, 1H), 3.49 (m, 1H), 3.23 (dd, 1H, J = 12.8, 
5.9 Hz), 3.17 (dd, 1H, J = 9.1, 4.1 Hz), 3.08 (dd, 1H, J = 9.1, 5.4 Hz), 3.00 (bs, 1H). 13C NMR 
(CDCl3, 75 MHz); δ 157.5 (q, C=O, 2J = 36.5 Hz), 143.2, 128.4, 127.9, 127.2, 115.7 (q, CF3, 1J 
= 287.9), 87.0, 68.8, 64.9, 42.7. HRMS calcd for C24H22F3NO3 [M+Na]+ 452.1449, found 
452.1440. 
 
(S)-2,2,2-Trifluoro-N-(2-hydroxy-3-(trityloxy)propyl)-N-methylacetamide 12b. (S)-1-
(Methylamino)-3-(trityloxy)propan-2-ol 11b (172 mg, 0.495 mmol) was dissolved in anhydrous 
THF (4 mL) and the reaction was cooled to -20 °C. DIPEA (0.431 mL, 2.47 mmol) was added 
and the reaction was stirred for 5 min. Trifluoroacetic anhydride (0.077 mL, 0.545 mmol) was 
then added and the reaction was stirred for about 40 min at -20 °C. The solvent was evaporated 
to dryness and the crude residue was purified on silica gel with a solvent system of 
hexane:CH2Cl2:THF 20:1:1. The clean product was isolated as a brown oil (158 mg, 0.356 
mmol). Yield: 72% [α]D25 = -17.7 (EtOAc, c = 1.01). 1H NMR (CDCl3, 250 MHz); δ  7.49-7.23 
(m, 15H), 4.08 (m, 1H), 3.61 (dd, 1H, J = 13.9, 3.6 Hz ), 3.51 (dd, 1H, J = 13.6, 7.9 Hz), 3.30 
(dd, 1H, J = 9.5, 4.8 Hz), 3.17 (m, 1H), 3.16 (s, 3H). 13C NMR (CDCl3, 62.5 MHz); δ (major 
rotomer) 157.9 (q, C=O, 2J = 35.9 Hz), 143.4, 128.5, 127.9, 127.2, 116.4 (q, CF3, 1J = 287.6 Hz), 
70 
 
87.0, 69.3, 65.2, 53.1, 36.7 (q, CH3, 4J = 3.7 Hz). (minor rotomer) 157.8 (q, C=O, 2J = 35.9 Hz), 
143.3, 128.5, 127.9, 127.3, 116.5 (q, CF3, 1J = 287.9 Hz), 87.1, 69.7, 65.4, 53.2 (q, CH2N, 4J = 
2.1 Hz), 35.9. HRMS calcd for C25H24F3NO3. [M+Na]+ 466.1606, found 466.1614. 
 
(S)-1-(2,2,2-Trifluoroacetamido)-3-(trityloxy)propan-2-yl methanesulfonate 13a. (S)-2,2,2-
Trifluoro-N-(2-hydroxy-3-(trityloxy)propyl)acetamide 12a (880 mg, 2.05 mmol) was dissolved 
in anhydrous dichloromethane (20 mL). The solution was cooled to 0 °C and methanesulfonate 
chloride (0.240 mL, 3.09 mmol) was added. After 1 min, diisopropylethylamine (1.00 mL, 5.74 
mmol) was added and the mixture was stirred for 40 min. Ice water (2-3 mL) was added to 
quench the reaction and the organic phase was separated. Dichloromethane was evaporated and 
the crude mixture purified on SiO2 gel using a gradient of pure hexane to hexane:CH2Cl2:THF 
8:1:1. The pure product was obtained as a white solid (948 mg, 1.87 mmol). Yield: 91%. m.p. 
118-119 °C [α]D25 = -10.1 (EtOAc, c = 1.04). 1H NMR (CDCl3, 250 MHz); δ 7.37-7.18 (m, 
15H), 6.83 (bs, 1H), 4.75 (m, 1H), 3.71 (m, 1H), 3.47 (m, 1H), 3.39 (dd, 1H, J = 11.3, 4.4 Hz), 
3.27 (dd, 1H, J = 10.9, 5.5 Hz), 2.97 (s, 3H). 13C NMR (CDCl3, 75 MHz); δ 157.6 (q, C=O, 2J = 
38.4 Hz), 142.9, 128.4, 128.1, 127.5, 115.6 (q, CF3, 1J = 287.9 Hz), 87.5, 78.2, 63.3, 40.9, 38.4. 
HRMS calcd for C25H24F3NO5S [M+Na]+ 530.1225, found 530.1219. 
 
(S)-1-(2,2,2-Trifluoro-N-methylacetamido)-3-(trityloxy)propan-2-yl-methanesulfonate 13b. 
(S)-2,2,2-Trifluoro-N-(2-hydroxy-3-(trityloxy)propyl)-N-methylacetamide 12b (336 mg, 0.758 
mmol) was dissolved in anhydrous dichloromethane (10.0 mL). The solution was stirred at 0 °C 
for 5 min and methanesulfonyl chloride (0.100 mL, 1.29 mmol) followed by DIPEA (0.400 mL, 
2.29 mmol) were added to the mixture and the reaction was stirred at 0 °C for 30 min. The 
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solvent was evaporated to dryness and the crude residue purified on silica gel with a solvent 
system of hexane:dichloromethane:THF 10:1:1 to afford a white solid (375 mg, 0.720 mmol). 
Yield: 95%. m.p. 47-48 °C [α]D25 = -8.4 (EtOAc, c = 1.00). 1H NMR (CDCl3, 250 MHz); δ  
7.97-7.26 (m, 15H), 7.25 (bs ,1H), 5.00 (m, 1H), 3.75 (dd, 1H, J = 14.2, 4.0 Hz), 3.63 (dd, 1H, J 
= 14.2, 8.2 Hz), 3.47 (dd, 1H, J =11.1, 3.5 Hz), 3.31 (dd, 1H, J =11.1, 5.6 Hz), 3.20 (s, 3H), 3.00 
(s, 3H). 13C NMR (CDCl3, 62.5 MHz); δ (major tautomer) 157.7 (q, C = O, 2J = 36.5 Hz), 143.0, 
128,5, 128.0, 127.9, 116.1 (q, CF3, 1J = 287.7 Hz), 87.5, 78.0, 63.4, 51.2, 38.4, 36.9 (q, CH3, 4J = 
3.8 Hz). (minor tautomer) 157.8 (q, C=O, 2J = 38.4 Hz), 142.9, 128.4, 128.1, 127.5, 116.2 (q, 
CF3, 1J = 288.7 Hz), 87.6, 77.9, 63.3, 50.2, 38.7, 35.6. HRMS calcd for C26H26F3NO5S [M+Na]+ 
544.1381, found 544.1392. 
 
(R)-3-Methyl-5-(trityloxymethyl)oxazolidin-2-one 14. (S)-1-(2,2,2-Trifluoro-N-
methylacetamido)-3-(trityloxy)propan-2-yl-methanesulfonate 13b (87.0 mg, 0.167 mmol) was 
dissolved in DMF (4.00 mL). Potassium carbonate (92.0 mg, 0.667 mmol) was added and the 
solution was stirred at 120 °C for 45 min. The K2CO3 was filtered out and the solvent was 
evaporated to dryness under nitrogen and then under vacuum. The pure product was obtained as 
a white solid (57.0 mg, 0.153 mmol). Yield: 92%. m.p. 154-155 °C [α]D25 = -41.0 (EtOAc, c = 
1.00). 1H NMR (CDCl3, 250 MHz); δ  7.46-7.22 (m, 15H), 4.60 (m, 1H), 3.55 (t, 1H, J = 8.7 
Hz), 3.35 (m, 2H), 3.22 (dd, 1H, J = 10.2, 4.6 Hz), 2.90 (s, 3H). 13C NMR (CDCl3, 62.5 MHz); δ 
158.1, 143.4, 128.5, 127.9, 127.2, 86.7, 71.7, 48.8, 30.9. HRMS calcd for C24H23NO3 [M+H]+ 
374.1756, found 374.1764. 
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(R)-2-(Trifluoromethyl)-5-(trityloxymethyl)-oxazoline 15. (S)-1-(2,2,2-Trifluoroacetamido)-3-
(trityloxy) propan-2-yl methanesulfonate 13a (106 mg, 0.210 mmol) was dissolved in anhydrous 
N,N-dimethylformamide (10.0 mL). Potassium carbonate (60.0 mg, 0.434 mmol) was added and 
the solution was stirred at 85 °C for 1 h. The K2CO3 was then filtered out and the DMF 
evaporated. The crude mixture was clean enough after drying under vaccum and did not require 
purification. The product was obtained as a white solid (81.6 mg, 0.198 mmol). Yield: 94%. m.p. 
180-182 °C [α]D25 = -43.5 (EtOAc, c = 1.00). 1H NMR (CDCl3, 300 MHz); δ 7.50-7.26 (m, 
15H), 4.99 (m, 1H), 4.07 (m, 1H), 3.93 (dd, 1H, J = 14.3, 6.6 Hz), 3.21 (dd, 1H, J = 10.7, 4.7 
Hz). 13C NMR (CDCl3, 75 MHz); δ 155.2 (q, C=N, 2J = 39.9 Hz), 143.3, 128.5, 127.9, 127.2, 
116.4 (q, CF3, 1J = 274.4 Hz), 86.7, 81.3, 64.3, 56.4. HRMS calcd for C24H20F3NO2 [M+Na]+ 
412.1524, found 412.1542. 
 
(R)-1-Amino-3-(trityloxy)propan-2-ol 16. (R)-2-(Trifluoromethyl)-5-(trityloxymethyl)-
oxazoline 15 (88.9 mg, 0.216 mmol) was dissolved in a mixture of THF and EtOH (5.00 mL 
each). Sodium hydroxide (94.0 mg, 2.35 mmol) was dissolved in 2 mL of H2O and added to the 
solution. The reaction was refluxed for 14 h then the solvents were evaporated. The crude 
residue was taken up in CH2Cl2 and the solid salts were filtered out. The solvent was evaporated 
and the crude product was purified on SiO2 gel using solvent system of CH2Cl2:MeOH 95:5. 
After drying under vacuum a colorless semi-solid was obtained (43.0 mg, 0.129 mmol). Yield: 
60%. [α]D25 = +15.3 (EtOH, c = 1.10). 1H NMR (CDCl3, 300 MHz); δ 7.48-7.19 (m, 15H), 3.79 
(m, 1H), 3.17 (m, 5H), 2.84 (m, 1H), 2.72 (m, 1H). 13C NMR (CDCl3, 75 MHz); δ 143.7, 128.6, 
127.8, 126.9, 86.6, 70.6, 65.6, 44.2. 
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(S)-4-(Benzylamino)butane-1,2-diol 17c. (S)-N-Benzyl-3-hydroxy-4-(trityloxy)butanamide 
(160 mg, 0.354 mmol) was dissolved in anhydrous THF (4 mL). Lithium aluminum hydride 
(41.0 mg, 1.08 mmol) was added at 0 °C and the mixture was stirred for 48 h. The mixture was 
cooled to 0 °C and the reaction was quenched by addition of cold methanol and water. The 
aluminum salts formed were filtered out, and after concentration, the crude product was purified 
on silica gel with a gradient of CH2Cl2:hexane 9:1 to CH2Cl2:MeOH 20:1. The pure product was 
dried on vacuum pump and obtained as a white solid (109 mg, 0.249 mmol). Yield: 70%. 1H 
NMR (CDCl3, 400 MHz); δ 7.49-7.22 (m, 20H), 4.05 (m, 1H), 3.77 (dd, 2H, J = 19.4, 13.1 Hz), 
3.22 (dd, 1H,  J = 9.0, 5.7 Hz), 3.06 (dd, 1H, J = 9.0, 5.8 Hz), 2.94 (m, 1H), 2.81 (m, 1H), 1.81 
(m, 1H), 1.65 (m, 1H). 13C NMR (CDCl3, 100 MHz); δ 144.0, 139.3, 128.6, 128.4, 128.1, 127.7, 
127.1, 126.9, 86.3, 71.9, 67.4, 53.7, 47.4, 32.2. HRMS calcd for C30H31NO2 [M+H]+ 438.2433, 
found 438.2418. 
 
(S)-2,2,2-Trifluoro-N-(3-hydroxy-4-(trityloxy)butyl) acetamide 18a.  (S)-4-Amino-1-
(trityloxy)butan-2-ol 17a (583 mg, 1.68 mmol) was dissolved in anhydrous THF (10.0 mL). 
Pyridine (0.405 mL, 5.03 mmol) was added to the solution which was stirred for 30 min. 
Trifluoroacetic anhydride (0.475 mL, 3.36 mmol) was added to the mixture and after stirring for 
another 30 min, the reaction was quenched with ice-water (2 mL). The solvent was then 
evaporated and the crude residue was dissolved in CH2Cl2 and washed twice with water and once 
with brine. The organic phase was then evaporated and the crude residue was purified on SiO2 
gel using a gradient of pure hexane to hexane:CH2Cl2:THF 9:1:1. The pure product was obtained 
as a white solid (565 mg, 1.27 mmol). Yield: 76%. m.p. 80-82 °C [α]D25 = +16.3 (CH2Cl2, c = 
1.04). 1H NMR (CDCl3, 250 MHz); δ 7.60 (bs, 1H), 7.48-7.24 (m, 15H), 3.93 (m, 1H), 3.65 (m, 
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1H), 3.32 (m, 1H), 3.21 (dd, 1H, J = 9.5, 3.8 Hz), 3.13 (m, 1H), 2.93 (bs, 1H), 1.63 (m, 2H). 13C 
NMR (CDCl3, 62.5 MHz); δ 157.1 (q, C=O, 2J = 36.5 Hz), 143.5, 128.5, 127.9, 127.2, 115.9 (q, 
CF3, 1J = 287.9 Hz), 86.9, 70.7, 67.3, 37.9, 30.9. HRMS calcd for C25H24F3NO3 [M+Na]+ 
466.1606,  found 466.1598. 
 
(S)-2,2,2-Trifluoro-N-(3-hydroxy-4-(trityloxy)butyl)-N-methylacetamide 18b. This 
compound was prepared via a similar method as the one used for the synthesis of 18a. 
Compound 17b (300 mg, 0.830 mmol) was used as the starting material. The crude product was 
purified on silica gel with a solvent system of hexane:CH2Cl2:THF 15:1:1. The pure product was 
obtained as a white solid (318 mg, 0.700 mmol). Yield: 86%. m.p. 106-107 °C [α]D25 = -14.0 
(EtOAc, c = 1.00). 1H NMR (CDCl3, 250 MHz); δ  7.52-7.23 (m, 15H), 3.73 (m, 2H), 3.43 (m, 
1H), 3.20 (m, 2H), 3.10 (s, 2H), 2.98 (s, 1H), 2.84 (bs, 1H), 1.71 (m, 2H). 13C NMR (CDCl3, 
62.5 MHz); δ  (major tautomer) 156.9 (q, C=O, 2J = 35.7 Hz), 143.6, 128.5, 127.7, 126.9, 116.3 
(q, CF3, 1J = 287.7 Hz), 86.6, 67.9, 67.4, 46.5, 35.0 (q, CH3, 4J = 3.8 Hz), 30.2. (minor tautomer) 
156.7 (q, C=O, 2J = 35.7 Hz), 143.5, 128.4, 127.8, 127.0, 116.4 (q, CF3, 1J = 287.6 Hz), 86.7, 
68.2, 67.3, 46.4, 34.5, 32.0. HRMS calcd for C26H26F3NO3 [M+Na]+ 480.1762, found 480.1764. 
 
(S)-N-Benzyl-2,2,2-trifluoro-N-(3-hydroxy-4-(trityloxy)butyl)-acetamide 18c. This 
compound was prepared via a similar method as the one used for the synthesis of 18a. 
Compound 17c (88.6 mg, 0.202 mmol) was used as the starting material. The crude product was 
purified on silica gel with a solvent system of hexane:CH2Cl2:THF 15:1:1. The pure product was 
obtained as a white solid (85.0 mg, 0.159 mmol). Yield: 79%. m.p. 139-140 °C [α]D25 = -16.8 
(EtOAc, c = 1.00). 1H NMR (CDCl3, 250 MHz); δ  7.47-7.21 (m, 20H), 4.67 (m, 2H), 3.74 (m, 
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1H), 3.56 (m, 1H), 3.40 (m, 1H), 3.17 (m, 1H), 3.10 (m, 1H), 1.74 (m, 2H). 13C NMR (CDCl3, 
62.5 MHz); δ  (major rotomer) 157.3 (q, C=O, 2J = 35.7 Hz), 143.5, 134.8, 128.7, 128.5, 127.9, 
127.8, 127.2, 127.1, 116.5 (q, CF3, 1J = 287.9 Hz), 86.7, 68.1, 67.2, 49.4, 43.4, 30.3. (minor 
rotomer)  157.3 (q, C=O, 2J = 35.7 Hz), 143.7, 135.4, 128.9, 128.7, 128.1, 127.9, 127.2, 127.1, 
116.6 (q, CF3, 1J = 287.9 Hz), 86.8, 68.4, 67.3, 50.9 (q, CH2Ph, 4J = 3.1 Hz), 43.7 (q, CH2N, 4J = 
2.9 Hz), 32.2. HRMS calcd for C32H30F3NO3 [M+Na]+ 556.2075, found 556.2090. 
 
(S)-3-Methyl-6-(trityloxymethyl)-1,3-oxazinan-2-one 19b. (S)-2,2,2-Trifluoro-N-(3-hydroxy-
4-(trityloxy)butyl)-N-methylacetamide 18b (54.0 mg, 0.118 mmol) was dissolved in anhydrous 
DMF (5.00 mL). Lithium hydroxide (31.0 mg, 1.30 mmol) was added and the solution was 
stirred at 65 °C for 12 h. The organic solvent was evaporated and the crude mixture taken-up in 
CH2Cl2. The solid LiOH was filtered out and the solvent evaporated under nitrogen. The crude 
residue was purified on silica gel with a solvent system of hexane:THF:CH2Cl2 15:1:1. The pure 
product was isolated as white crystals (41.2 mg, 0.106 mmol). Yield: 90%. m.p. 160.5-161 °C. 
[α]D25 = + 32.5 (EtOAc, c = 1.03). (CDCl3, 400 MHz); δ  7.45-7.19 (m, 15H), 4.34 (m, 1H), 3.35 
(dd, 1H, J = 9.8, 4.7 Hz), 3.31 (dd, 1H, J = 11.5, 5.7 Hz), 3.21 (m, 2H), 2.97 (s, 3H), 2.08 (m, 
1H), 1.97 (m, 1H). 13C NMR (CDCl3, 100 MHz); δ 153.6, 143.5, 128.6, 127.8, 127.1, 86.8, 75.7, 
64.7, 46.1, 36.5, 24.6. HRMS calcd for C25H25NO3 [M+Na]+ 410.1732, found 410.1737. 
 
(S)-3-Benzyl-6-(trityloxymethyl)-1,3-oxazinan-2-one 19c. (S)-N-Benzyl-2,2,2-trifluoro-N-(3-
hydroxy-4-(trityloxy)butyl)-acetamide 18c (156 mg, 0.292 mmol) was dissolved in anhydrous 
THF (4.00 mL). The mixture was cooled to 0 °C and sodium hydride (14.0 mg, 0.583 mmol) was 
added. The solution was stirred for 20 min and quenched by addition of methanol. The solvent 
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was evaporated and the crude mixture was taken up in CH2Cl2. The organic solvent was washed 
with H2O three times, separated from the aqueous solvent and dried on Na2SO4. After filtration, 
the solvent was evaporated and the residue was dried under vacuum. The pure product (120 mg, 
0.260 mmol) was obtained without further purification. Yield: 89%. m.p. 167-168 °C [α]D25 = 
+29.0 (EtOAc, c = 1.01). 1H NMR (CDCl3, 250 MHz); δ 7.52-7.25 (m, 20H), 4.60 (dd, 2H, J = 
21.1, 14.9 Hz), 4.43 (m, 1H), 3.43 (dd, 1H, J = 9.7, 4.7 Hz), 3.23 (m, 3H), 2.10 (m, 1H), 1.96 (m, 
1H). 13C NMR (CDCl3, 100 MHz); δ 153.5, 143.4, 136.5, 128.5, 128.4, 127.9, 127.7, 127.5, 
127.0, 86.6, 75.7, 64.6, 52.4, 43.2, 24.5. HRMS calcd for C31H29NO3 [M+H]+ 464.2226, found 
464.2222. 
 
(S)-4-(2,2,2-Trifluoroacetamido)-1-(trityloxy)butan-2-yl methanesulfonate 20a. (S)-2,2,2-
Trifluoro-N-(3-hydroxy-4-(trityloxy)butyl)acetamide 18a (486 mg, 1.10 mmol) was dissolved in 
anhydrous CH2Cl2 (10.0 mL). The solution was cooled to 0 °C. Methanesulfonyl chloride (0.130 
mL, 1.67 mmol) was added, followed by diisopropylethylamine (0.570 mL, 3.30 mmol). The 
mixture was stirred at 0 °C for 30 min and some ice-water was added to quench the reaction. The 
solution was diluted with dichloromethane and washed twice with water. The organic solvent 
was evaporated and the crude residue purified on SiO2 gel using a gradient of pure hexane to 
hexane:CH2Cl2:THF 8:1:1. The pure product was obtained as a colorless semi-solid (536 mg, 
1.03 mmol). Yield: 94%. [α]D25 = - 17.7 (EtOAc, c = 1.00). 1H NMR (CDCl3, 250 MHz); δ  
7.45-7.22 (m, 15H), 7.18 (bs, 1H), 4.61 (m, 1H), 3.59 (m, 1H), 3.38 (m, 2H), 3.27 (m, 1H), 3.02 
(s, 3H), 1.81 (m, 2H). 13C NMR (CDCl3, 62.5 MHz); δ  157.3 (q, C=O, 2J = 36.5 Hz), 143.0, 
128.4, 128.0, 127.4, 115.7 (q, CF3, 1J = 287.9 Hz), 87.6, 79.7, 65.4, 38.6, 35.4, 30.6. HRMS 
calcd for C26H26F3NO5S [M+Na]+ 544.1381,  found 544.1368. 
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(S)-4-(2,2,2-Trifluoro-N-methylacetamido)-1-(trityloxy)butan-2-ylmethanesulfonate 20b. 
This compound was prepared via a similar method as the one used for the synthesis of 20a. 
Compound 18b (194 mg, 0.424 mmol) was used as the starting material. The crude product was 
purified on silica gel with a solvent system of hexane:CH2Cl2:THF 15:1:1. The pure product was 
obtained as a brown oil (215 mg, 0.401 mmol). Yield: 95%. [α]D25 = +5.8 (EtOAc, c = 1.05). 1H 
NMR (CDCl3, 250 MHz); δ  7.47-7.24 (m, 15H), 4.77 (m, 1H), 3.42 (m, 4H), 3.10 (s, 2H), 3.04 
(s, 2H), 3.03 (s, 1H), 2.99 (s, 1H), 1.98 (m, 2H). 13C NMR (CDCl3, 62.5 MHz); δ (major 
tautomer) 156.9 (q, C=O, 2J = 35.7 Hz), 143.1, 128.5, 127.9, 127.3, 116.3 (q, CF3, 1J = 287.7 
Hz), 87.4, 79.6, 64.9, 46.0, 38.7, 35.2 (q, CH3, 4J = 3.9 Hz), 28.7. (minor tautomer) 156.9 (q, 
C=O, 2J = 35.7 Hz), 143.0, 128.4, 128.0, 127.4, 116.4 (q, CF3, 1J = 287.3 Hz), 87.5, 78.7, 64.5, 
45.7 (q, CH2N, 4J = 2.9 Hz), 38.6, 34.6, 30.7. HRMS calcd for C27H28F3NO5S [M+Na]+ 
558.1538, found 558.1532. 
 
(S)-4-(N-Benzyl-2,2,2-trifluoroacetamido)-1-(trityloxy)butan-2-yl methanesulfonate 20c. 
This compound was prepared via a similar method as the one used for the synthesis of 20a. 
Compound 18c (1.03 g, 1.93 mmol) was used as the starting material. The crude product was 
purified on silica gel with a solvent system of hexane:CH2Cl2:THF 15:1:1. The pure product was 
obtained as a colorless semi-solid (1.11 g, 1.81 mmol). Yield: 94%. [α]D25 = +3.50 (EtOAc, c = 
1.03). 1H NMR (CDCl3, 250 MHz); δ 7.43-7.14 (m, 20H), 4.67 (m, 1H), 4.60 (m, 2H), 3.33 (m, 
2H), 3.26 (m, 2H), 2.98 (s, 3H), 1.94 (m, 2H). 13C NMR (CDCl3, 62.5 MHz); δ (major tautomer) 
157.1 (q, C=O, 2J = 35.1 Hz), 143.1, 134.4, 129.0, 128.9, 128.4, 127.9, 127.4, 127.3, 116.4 (q, 
CF3, 1J =  287.9 Hz), 87.2, 78.5, 64.5, 49.6, 42.9, 38.7, 28.7. (minor tautomer) 157.7 (q, C=O, 2J 
= 35.1 Hz), 143.1, 135.1, 129.0, 128.9, 128.3, 128.1, 127.4, 127.3, 116.5 (q, CF3, 1J =  288 Hz), 
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87.4, 78.5, 64.6, 51.2, 42.8, 38.6, 30.8. HRMS calcd for C33H32F3NO5S [M+Na]+ 634.1851, 
found 634.1853. 
 
(R)-3-Methyl-6-(trityloxymethyl)-1,3-oxazinan-2-one 21b. (S)-4-(2,2,2-Trifluoro-N-
methylacetamido)-1-(trityloxy)butan-2-ylmethanesulfonate 20b (147 mg, 0.247 mmol) was 
dissolved in anhydrous DMSO (4.00 mL). Potassium carbonate (114 mg, 0.825 mmol) was 
added and the solution was stirred at 120 °C for 3 h. The mixture was cooled to room 
temperature, diluted with CH2Cl2 and washed with cold water 3 to 4 times. The dichloromethane 
was evaporated and the crude mixture was purified on silica gel with a solvent system of 
hexane:CH2Cl2:THF 12:1:1. The pure product was isolated as a white solid (58.0 mg, 0.150 
mmol). Yield: 55%. m.p. 163-164 °C [α]D25 = -31.9 (EtOAc, c = 1.03). 1H NMR (CDCl3, 400 
MHz); δ 7.45-7.20 (m, 15H), 4.33 (m, 1H), 3.35 (dd, 1H, J = 9.7, 4.7 Hz), 3.30 (dd, 1H, J = 10.9, 
5.5 Hz), 3.21 (m, 2H), 2.96 (s, 3H), 2.07 (m, 1H), 1.96 (m, 1H). 13C NMR (CDCl3, 100 MHz); δ 
153.6, 143.5, 128.6, 127.8, 127.1, 86.7, 75.7, 64.7, 46.0, 36.5, 24.6. HRMS calcd for C25H25NO3 
[M+H]+ 388.1913, found 388.1897. 
 
(R)-3-Benzyl-6-(trityloxymethyl)-1,3-oxazinan-2-one 21c. (S)-4-(N-Benzyl-2,2,2-
trifluoroacetamido)-1-(trityloxy)butan-2-yl methanesulfonate 20c (600 mg, 0.980 mmol) was 
dissolved in anhydrous DMF (5.00 mL) and potassium carbonate (0.542 g, 3.92 mmol) was 
added to the solution. The mixture was stirred at 120 °C for 20 h. The organic was evaporated 
under nitrogen overnight and the residue taken up in CH2Cl2. The solid K2CO3 was filtered out 
and the solution concentrated to dryness. The crude product was purified on silica gel with a 
gradient of hexane:THF 19:1 to hexane:CH2Cl2:THF 8:1:1. The pure product was dried under 
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vacuum and obtained as a white solid (281 mg, 0.606 mmol). Yield: 63%. m.p. 166-167 °C 
[α]D25 = -28.6 (EtOAc, c = 1.00). 1H NMR (CDCl3, 250 MHz); δ 7.52-7.23 (m, 20H), 4.58 (dd, 
2H, J = 21.9, 14.9 Hz), 4.39 (m, 1H), 3.42 (dd, 1H, J = 9.7, 4.8 Hz), 3.23 (m, 1H), 3.15 (m, 2H), 
1.97 (m, 2H). 13C NMR (CDCl3, 62.5 MHz); δ 153.5, 143.4, 136.5, 128.5, 128.4, 127.8, 127.7, 
127.4, 127.0, 86.6, 75.7, 64.6, 52.3, 43.2, 24.4. HRMS calcd for C31H29NO3 [M+H]+ 464.2226, 
found 464.2232. 
 
(R)-2-(Trifluoromethyl)-6-(trityloxymethyl)-5,6-dihydro-4H-1,3-oxazine 22. (S)-4-(2,2,2-
Trifluoroacetamido)-1-(trityloxy)butan-2-yl methanesulfonate 20a (91.5 mg, 0.175 mmol) was 
dissolved in anhydrous dimethylformamide (5.00 mL). Potassium carbonate (97.0 mg, 0.702 
mmol) was added and the solution stirred at 85 °C for 45 min. The solvent was then evaporated 
under nitrogen and the crude mixture purified on SiO2 gel using a solvent system of 
hexane:CH2Cl2:THF 8:1:1. The pure product was obtained as an off-white solid (58.4 mg, 0.137 
mmol). Yield: 78%. m.p. 106-108 °C [α]D25 = - 46.1 (CH2Cl2, c = 1.03). 1H NMR (CDCl3, 250 
MHz); δ 7.49-7.21 (m, 15H), 4.42 (m, 1H), 3.54 (m, 2H), 3.27 (m, 2H), 1.89 (m, 2H). 13C NMR 
(CDCl3, 62.5 MHz); δ 148.4 (q, C=N, 2J = 38.4 Hz), 143.9, 129.0, 128.4, 127.6, 117.2 (q, CF3, 1J 
= 276.4 Hz), 87.2, 75.9, 65.6, 42.2, 23.8. HRMS calcd for C25H22F3NO2 [M+H]+ 426.1681,  
found 426.1672. 
 
(R)-4-Amino-1-(trityloxy)butan-2-ol 23. (R)-2-(Trifluoromethyl)-6-(trityloxymethyl)-5,6-
dihydro-4H-1,3-oxazine 22 (65.6 mg, 0.154 mmol) was dissolved in absolute ethanol (6 mL). 
Cesium carbonate (0.500 g, 1.53 mmol) dissolved in 2.00 mL of water was added to the solution 
which was refluxed for 36 h. The solvents were evaporated and the crude mixture was taken up 
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in CH2Cl2. The insoluble salts were filtered out and the organic phase was washed one with 
water. After drying on Na2SO4, the solvent was evaporated and after drying under vacuum, the 
product was obtained as a colorless semi-solid (52.6 mg, 0.151 mmol). Yield: 98%. [α]D25 = 
+15.0 (EtOH, c = 1.00). 1H NMR (CDCl3, 250 MHz); δ 7.53-7.19 (m, 16H), 4.02 (m, 1H), 3.18 
(dd, 1H, J = 9.1, 6.1 Hz), 3.08 (dd, 1H, J = 9.1, 5.4 Hz), 2.95 (m, 1H), 2.85 (m, 1H), 1.67 (m, 
1H), 1.55 (m, 1H). 13C NMR (CDCl3, 62.5 MHz); δ 143.9, 128.6, 127.8, 126.9, 86.4, 71.2, 67.6, 
38.9, 35.1. 
 
(S)-2-Bromo-N-(2-hydroxy-3-trityloxypropyl)-acetamide 26. (S)-1-Amino-3-trityloxy-
propan-2-ol 11a (0.990 g, 2.97 mmol) was dissolved in anhydrous THF (10.0 mL). The reaction 
was put at 0 °C and bromoacetic anhydride (0.926 g, 3.56 mmol) and potassium carbonate (0.820 
g, 5.94 mmol) were added to the solution. After stirring at 0 °C for 30 min and at room 
temperature for 2 to 3 h, the K2CO3 was filtered out and the THF evaporated on the rotovap. Ice-
water (2-3 mL) was then added and the di-acetylated product was extracted with EtOAc. After 
evaporating the ethyl acetate, the product was directly stirred with NaHCO3 in a (1:1:1) mixture 
of ethanol, THF and H2O at room temperature for 12 h. The EtOH and THF were removed by 
concentration on the rotovap and the mono-acetylated product was extracted with CH2Cl2. After 
removing the dichloromethane on the rotovap a white-brown semi-solid product was obtained 
(1.34 g, 2.94 mmol). Yield: 99%. 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.54-7.15 (m, 15H), 
6.77 (bs, 1H), 3.91 (m, 1H), 3.78 (s, 2H), 3.54 (m, 1H), 3.27 (m, 1H), 3.17 (m, 2H). 13C NMR 
(CDCl3, 100 MHz); δ (ppm): 166.3, 143.5, 128.5, 127.9, 127.2, 86.9, 69.7, 64.9, 43.1, 28.9. 
HRMS ES+ calcd for C24H24BrNO3 [M+Na]+ 476.0837,  found 476.0839. 
 
81 
 
(S)-Methanesulfonic acid 2-(2-Bromo-acetylamino)-1-trityloxymethyl-ethyl ester 27a. (S)-2-
Bromo-N-(2-hydroxy-3-trityloxypropyl)-acetamide 26 (310 mg, 0.682 mmol), was dissolved in 
anhydrous CH2Cl2 (5 mL) and the reaction was put in an ice-bath, at 0 °C. Methanesulfonyl 
chloride (0.080 mL, 1.02 mmol) was added to the solution, then Diisopropylethylamine (0.350 
mL, 2.05 mmol) and the reaction was stirred for 5 min. The solution was then washed with ice-
cold H2O (2 X 2 mL) and with brine (2 mL). The organic phase was evaporated under nitrogen. 
The crude mixture was purified on SiO2 gel with a gradient of pure hexane to 
hexane:CH2Cl2:THF 7:2:1 to afford a white solid (357 mg, 0.670 mmol). Yield: 98%. [α]D25 = + 
11.1 (c 1.04, EtOAc).1H NMR (CDCl3, 400 MHz); δ (ppm): 7.45-7.24 (m, 15H), 6.78 (bs, 1H), 
4.84 (m, 1H), 3.78 (q, 2H, J = 13.7 Hz), 3.67 (m, 1H), 3.50-3.40 (m, 2H), 3.30 (m, 1H), 3.01 (s, 
3H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 166.2, 143.0, 128.5, 127.9, 127.4, 87.3, 79.4, 63.3, 
41.2, 38.5, 28.6. HRMS ES+ calcd for C25H26BrNO5 S [M+Na]+ 554.0613,  found 554.0612. 
 
(S)-Methanesulfonic acid 3-(2-bromo-acetylamino)-1-(t-butyl-dimethyl-silyloxymethyl)-
propyl ester 27b. Yield: 61% 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.23 (bs, 1H), 4.66 (m, 
1H), 3.99 (s, 2H), 3.70 (m, 2H), 3.59 (m, 1H), 3.25 (m, 1H), 3.07 (s, 2H), 1.89 (m, 1H), 1.76 (m, 
1H), 0.86 (s, 9H), 0.04 (s, 6H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 166.7, 81.4, 65.0, 42.4, 
38.4, 35.4, 30.5, 25.7, -5.6. 
 
(S)-Methanesulfonic acid 2-(2-benzylamino-acetylamino)-1-trityloxymethyl-ethyl ester 28a. 
(S)-Methanesulfonic acid 2-(2-Bromo-acetylamino)-1-trityloxymethyl-ethyl ester 27a (200 mg, 
0.376 mmol) was dissolved in anhydrous THF (5.00 mL). Benzylamine (0.120 mL, 1.10 mmol) 
was added and the reaction was stirred at 35 ºC for 1 h. The THF was evaporated and the solid 
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residue was taken up in dichloromethane and washed with water and brine. The CH2Cl2 was then 
evaporated and the crude mixture purified on SiO2 gel with a gradient of pure hexane to 
hexane:CH2Cl2:THF 6:3:1 to afford the pure product as a light yellow oil (187 mg, 0.334 mmol). 
Yield: 89%. [α]D25 = +7.6 (c 1.05, EtOAc). 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.43-7.23 (m, 
15H), 6.73 (bs, 1H), 4.83 (s, 1H), 3.80 (q, 2H, J = 17.6, 13.7 Hz), 3.69 (m, 1H), 3.47 (m, 1H), 
3.42 (m, 1H), 3.30 (dd, 1H, J = 10.7, 4.9 Hz), 3.02 (s, 3H). 13C NMR (CDCl3, 100 MHz); δ 
(ppm): 172.14, 143.07, 128.49, 127.96, 127.31, 87.19, 80.26, 63.38, 53.70, 51.61, 39.95, 38.50. 
HRMS ES+ calcd for C32H34N2O5S [M+Na]+ 581.6900,  found 579.9791. 
 
(S)-Methanesulfonic acid 2-(2-benzylamino-acetylamino)-1-(tert-butyl-dimethyl-
silanyloxymethyl)-ethyl ester 28c. Yield: 72%. 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.41-
7.17 (m, 5H), 4.72 (m, 1H), 4.11 (m, 2H), 3.70 (m, 2H), 3.52 (m, 1H), 3.30 (m, 2H), 3.01 (s, 
3H), 0.81 (s, 9H), 0.01 (d, 6H, J = 2.5 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 165.6, 130.4, 
129.0, 129.5, 80.8, 63.3, 51.4, 47.7, 40.4, 38.7, 25.7, 18.1, -5.5. 
 
 
(R)-2-(Benzylaminomethyl)-5-trityloxymethyl-oxazoline 29a. (S)-Methanesulfonic acid 2-
(2-benzylamino-acetylamino)-1-trityloxymethyl-ethyl ester 28a (22.6 mg, 0.040 mmol) was 
dissolved in anhydrous DMSO (3.00 mL). Potassium carbonate (12.0 mg, 0.087 mmol) was 
added to the medium and the solution was stirred at 80 ºC for 2 h. The solvent was then 
evaporated off and CH2Cl2 added to the residue. K2CO3 was filtered out, the solvent was 
removed and after drying on the vaccum pump without further purification, the product was 
obtained as a brown oil (15.0 mg, 0.032 mmol). Yield: 80%. [α]D25 = - 8.0 (c 0.71, EtOAc).1H 
NMR (CDCl3, 400 MHz); δ (ppm): 7.48-7.20 (m, 20H), 4.71 (m, 1H), 3.86 (m, 3H), 3.65 (dd, 
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1H, J = 13.8, 7.5 Hz), 3.48 (s, 2H), 3.20 (m, 2H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 166.2, 
143.6, 139.5, 128.6, 127.8, 127.1, 86.5, 78.6, 65.2, 56.5, 53.3, 45.5. HRMS ES+ calcd for 
C31H30N2O2 [M+1]+ 463.5800,  found 463.4865. 
 
 
(R)-2-(Methylaminomethyl)-5-trityloxymethyl-oxazoline 29b. Yield: 86%. 1H NMR 
(CDCl3, 400 MHz); δ (ppm): 7.47-7.18 (m, 15H), 4.70 (m, 1H), 3.85 (m, 1H), 3.63 (dd, 1H, J = 
13.8, 7.5 Hz), 3.43 (s, 2H), 3.20 (m, 2H), 2.47 (s, 3H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 
166.2, 143.6, 128.6, 127.8, 127.1, 86.5, 78.6, 65.2, 56.4, 48.1, 36.1. 
 
(R)-2-(Benzylaminomethyl)-5-(tert-butyl-dimethylsilyloxymethyl)-oxazoline 29c. Yield: 
46%. 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.32-7.18 (M, 5H), 4.60 (m, 1H), 3.83 (m, 1H), 3.80 
(s, 2H), 3.74 (m, 1H), 3.66 (m, 2H), 3.40 (s, 2H), 0.86 (s, 9H), 0.04 (d, 6H, J = 4.4 Hz). 13C 
NMR (CDCl3, 100 MHz); δ (ppm): 166.5, 138.9, 128.5, 128.3, 128.2, 80.5, 64.1, 55.4, 55.1, 
53.3, 52.9, 45.1, 25.6, 18.1, -5.5. 
 
(S)-2-Bromo-N-(3-hydroxy-4-trityloxy-butyl)-acetamide 30a. (S)-4-Amino-1-trityloxy-2-
butanol 17a (3.85 g, 11.1 mmol) was dissolved in anhydrous THF (60.0 mL). Potassium 
carbonate (3.06 g, 22.1 mmol) then bromoacetic anhydride (3.80 g, 14.6 mmol) were added and 
the solution was stirred at room temperature for 5 to 6 h. The K2CO3 was filtered out and the 
THF was evaporated on the rotovap. The solid residue was purified on SiO2 gel with a gradient 
of pure hexane to hexane/CH2Cl2/THF 6:3:1 and the pure product was isolated as a white solid 
(3.89 g, 8.31 mmol). Yield: 75%. 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.46-7.23 (m, 15H), 
7.18 (s, 1H), 3.87 (m, 1H), 3.84 (s, 2H), 3.58 (m, 1H), 3.26 (m, 1H), 3.14 (m, 2H), 2.93 (bs, 1H), 
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1.65 (m, 1H), 1.56 (m, 1H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 165.7, 143.6, 128.5, 127.8, 
127.1, 86.8, 69.8, 67.4, 37.8, 32.0, 29.2. 
 
(S)-Methanesulfonic acid 3-(2-bromo-acetylamino)-1-trityloxymethyl-propyl ester 31a. (S)-
2-Bromo-N-(3-hydroxy-4-trityloxy-butyl)-acetamide 30a (570 mg, 1.21 mmol) was dissolved in 
anhydrous CH2Cl2 (10.0 mL) at 0 ºC. Methanesulfonyl chloride (0.122 mL, 1.57 mmol) was 
added and the solution was stirred for one minute then DIPEA (0.560 mL, 3.22 mmol) was 
added and the solution was stirred for 30 min. Ice H2O was added to the mixture, more CH2Cl2 
was added and the product was extracted. The organic phase was washed with H2O then brine 
and the organic solvent was evaporated. The crude mixture was purified on SiO2 gel with a 
gradient of pure hexane to hexane/CH2Cl2/THF 6:3:1. The pure product was obtained as a light 
yellow oil (610 mg, 1.12 mmol). Yield: 92%. 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.44-7.23 
(M, 15H), 6.96 (bs, 1H), 4.75 (m, 1H), 3.82 (s, 2H), 3.57 (m, 1H), 3.36 (m, 2H), 3.21 (m, 1H), 
3.05 (s, 3H), 1.84 (m, 2H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 165.9, 143.1, 128.5, 127.9, 
127.4, 87.4, 79.9, 65.5, 38.7, 35.8, 31.0, 28.9. 
 
(S)-Methanesulfonic acid 3-(2-bromo-acetylamino)-1-(t-butyl-dimethyl-silyloxymethyl)-
propyl ester 31b. Yield: 61%. 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.23 (bs, 1H), 4.66 (m, 
1H), 3.99 (s, 2H), 3.70 (m, 2H), 3.59 (m, 1H), 3.25 (m, 1H), 3.07 (s, 2H), 1.89 (m, 1H), 1.76 (m, 
1H), 0.86 (s, 9H), 0.04 (s, 6H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 166.7, 81.4, 65.0, 42.4, 
38.4, 35.4, 30.5, 25.7, -5.6. 
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 (S)-Methanesulfonic acid 3-(2-benzylamino-acetylamino)-1-trityloxymethyl-propyl ester 
32a. (S)-Methanesulfonic acid 3-(2-bromo-acetylamino)-1-trityloxymethyl-propyl ester 31a (688 
mg, 1.26 mmol) was dissolved in anhydrous THF (10.0 mL). Benzylamine (0.700 mL, 6.41 
mmol) was added and the solution was stirred at room temperature for 2 h. The solvent was then 
evaporated off and the crude mixture was taken up in dichloromethane. Insoluble residue was 
filtered out and the solvent removed on the rotovap. The residue was purified on SiO2 gel with a 
gradient of pure hexane to hexane/CH2Cl2/THF 6:3:1. The pure product was obtained as a light 
yellow oil (714 mg, 1.25 mmol). Yield: 99%. [α]D25 = +4.3 (c 1.10, EtOAc). 1H NMR (CDCl3, 
400 MHz); δ (ppm): 7.50-7.23 (m, 20H), 4.80 (m, 1H), 3.77 (s, 2H), 3.50 (m, 1H), 3.34 (m, 2H), 
3.27 (s, 2H), 3.23 (m, 1H), 3.03 (s, 3H), 1.84 (m, 2H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 
171.7, 143.1, 139.2, 128.5, 127.9, 127.3, 87.2, 80.1, 65.3, 53.8, 51.8, 38.6, 34.6, 31.5. 
 
(S)-Methanesulfonic acid 2-(2-benzylamino-acetylamino)-1-(tert-butyl-dimethyl-
silanyloxymethyl)-ethyl ester 32b. Yield: 72%. 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.41-
7.17 (m, 5H), 4.72 (m, 1H), 4.11 (m, 2H), 3.70 (m, 2H), 3.52 (m, 1H), 3.30 (m, 2H), 3.01 (s, 
3H), 0.81 (s, 9H), 0.01 (d, 6H, J = 2.5 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 165.6, 130.4, 
129.0, 129.5, 80.8, 63.3, 51.4, 47.7, 40.4, 38.7, 25.7, 18.1, -5.5. 
 
(R)-2-Benzylaminomethyl-6-trityoxymethyl-oxazine 33a. (S)-Methanesulfonic acid 3-(2-
benzylamino-acetylamino)-1-trityloxymethyl-propyl ester 32a (450 mg, 0.786 mmol) was 
dissolved in anhydrous DMSO (10.0 mL). Potassium carbonate (217 mg, 1.57 mmol) was added 
to the solution and the mixture was stirred at 80 ºC for 1 h. CH2Cl2 was then added and the 
solution was washed 4 times with about 3 mL of H2O and with brine.  The organic solvent was 
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evaporated on the rotovap and the crude mixture purified on SiO2 gel with a gradient of pure 
hexane to hexane/CH2Cl2/THF 6:3:1 and finally CH2Cl2/THF 7:1 to obtain a yellow oil (263 mg, 
0.552 mmol). Yield: 70%. [α]D25 = +7.2 (c 1.08, EtOAc).1H NMR (CDCl3, 400 MHz); δ (ppm): 
7.51-7.21 (m, 20H), 4.26 (m, 1H), 3.83 (s, 2H), 3.40 (m, 3H), 3.31 (s, 2H), 3.17 (m, 1H), 1.88 
(m, 1H), 1.76 (m, 1H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 158.1, 143.6, 139.9, 128.5, 127.7, 
126.9, 86.5, 73.6, 65.7, 53.3 51.1, 41.6, 24.1. HRMS ES+ calcd for C32H32N2O2 [M+1]+ 
477.6100,  found 477.3175. 
 
(S)-6-(Trityloxymethyl)-morpholin-3-one 34. (S)-2-bromo-N-(2-hydroxy-3-(trityloxy)propyl)-
acetamide 26 (211 mg, 0.464 mmol) was dissolved in anhydrous dichloromethane (8.00 mL). 
Sodium hydroxide (93.0 mg, 2.33 mmol) was added to the solution, which was refluxed for 1.5 
h. The solid residue was filtered out and the organic solution was washed twice with saturated 
ammonium chloride, twice with water and once with brine. The aqueous phase was separated 
and the organic phase dried on Na2SO4. The sodium sulfate was filtered out, the solvent was 
evaporated and the pure product (139 mg, 0.372 mmol) was obtained as a white crystalline solid 
after drying under vacuum without further purification. Yield: 80%. m.p. 187-187.5 °C [α]D25 = -
47.4 (CH2Cl2, c = 1.04). 1H NMR (CDCl3, 300 MHz); δ (ppm): 7.52-7.22 (m, 16H), 4.24 (dd, 
2H, J = 31.1, 16.9 Hz), 3.87 (m, 1H), 3.37 (m, 3H), 3.15 (dd, 1H, J = 9.6, 5.9 Hz). 13C NMR 
(CDCl3, 75 MHz); δ (ppm): 169.4, 143.4, 128.5, 127.8, 127.1, 86.8, 72.0, 67.4, 63.8, 43.9. 
HRMS calcd for C24H23NO3 [M+Na]+ 374.1756, found 374.1773. 
 
(S)-6-(trityloxymethyl)-morpholine 35. (S)-6-(trityloxymethyl)-morpholin-3-one 34 (55.0 mg, 
0.147 mmol) was dissolved in anhydrous THF (5.00 mL). The solution was put at 0 °C and 
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stirred for 10 min. LiAlH4 (17.0 mg, 0.448 mmol) was added to the solution under nitrogen and 
the reaction was stirred for 2 h. Ice-water was added to quench the reaction, and the precipitated 
aluminum salts were filtered out. The THF was evaporated and the product was extracted with 
CH2Cl2. The organic solvent was washed with water and brine, then evaporated and the product 
was dried under nitrogen and under vacuum to afford a colorless semi-solid without further 
purification. (37.0 mg, 0.103 mmol). Yield: 70%. [α]D25 = +13.0 (EtOH, c = 1.00 ). 1H NMR 
(CDCl3, 250 MHz); δ (ppm): 7.49-7.19 (m, 16H), 3.86 (m, 1H), 3.69 (m, 1H), 3.59 (dd, 1H, J = 
11.2, 3.4 Hz), 3.22 (dd, 1H, J = 9.3, 5.1 Hz), 3.04 (m, 2H), 2.81 (m, 2H), 2.62 (m, 1H). 13C NMR 
(CDCl3, 75 MHz); δ (ppm): 143.9, 128.6, 127.8, 127.0, 86.5, 75.9, 67.9, 65.1, 49.0, 45.9. 
 
(S)-7-(trityloxymethyl)-1,4-oxazepan-3-one 36. (S)-2-Bromo-N-(3-hydroxy-4-(trityloxy)butyl) 
acetamide 30a (156 mg, 0.333 mmol) was dissolved in anhydrous dichloromethane (10.0 mL). 
Sodium hydroxide (66.6 mg, 1.67 mmol) was added to the solution and the mixture was stirred 
for 6 h. The solid residue was filtered out and the organic solvent washed with saturated NH4Cl 
twice, then H2O and brine. After drying on Na2SO4 and filtration, the solvent was evaporated and 
the residue dried under vacuum to afford a fluffy white solid (107 mg, 0.276 mmol). Yield: 83%. 
m.p. 88-90 °C [α]D25 = -36.2 (CH2Cl2, c = 1.02 ). 1H NMR (CDCl3, 250 MHz); δ (ppm): 7.41-
7.11 (m, 15H), 6.42 (bs, 1H), 4.32 (d, 1H, J = 15.9 Hz), 4.05 (d, 1H, J = 15.9 Hz), 3.70 (m, 1H), 
3.34 (m, 1H), 3.20 (dd, 1H, J = 9.6, 5.9 Hz), 2.94 (dd, 1H, J = 9.6, 5.0 Hz), 1.92 (m, 1H), 1.70 
(m, 1H). 13C NMR (CDCl3, 75 MHz); δ (ppm): 175.4, 143.8, 128.6, 127.8, 86.6, 79.9, 71.5, 65.8, 
39.2, 32.5. HRMS calcd for C25H25NO3 [M+Na]+ 410.1732, found 410.1734. 
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62. A small amount of compounds 10b and 14 were deprotected using TFA to remove the trityl 
group and the free alcohol treated with Mosher’s acid chloride to form the corresponding 
esters 10b’ and 14’, integration of the signals on the 1H NMR spectrum of the crude reaction 
products allowed us to confirm the optical purity with the optical rotation data. The crude 
500MHz 1H NMR spectrum of compound 10b’ indicated no presence of diastereomer, the 
chemical shifts of protons a and b are: δ (ppm), 4.76 (sb, Ha), 4.58 (d, 1H, Hb, J = 0,11.7Hz), 
4.41 (dd, Hb′,  J = 3.9, 11.7Hz),  compound 25:  4.78 (sb, Ha), 4.58 (dd, 1H, Hb, J = 2.9, 
12.2), 4.37 (dd, Hb′,  J = 3.9, 12.2Hz), a small doublet impurity signal at 4.41 estimated less 
than 1% of the Hb′ integration indicates that the purity of the enantiomer is 99%.      
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63. A small amount of compound 14b, 16b, and their 1:1 mixture are converted to the 
corresponding hydroxyl trifluoromethyl ester derivatives by treating with TFA and 
trifluoroacetic anhydride. GC analysis of the derivatives using cyclodextrin column indicates 
that the optical purities of compound 14 and 21b are both over 99% ee, there is no detectable 
presence of the opposite isomer.  
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Chapter IV. Synthesis and Antibacterial Activities of  
1,3-Oxazinan-2-ones Derivatives. 
 
Abstract 
 
1,3-Oxazinan-2-ones and 2-oxazolidinones are very important heterocycles in synthetic organic 
chemistry because they are useful intermediates in the synthesis of biologically relevant 
molecules; they are also found in many pharmaceutical compounds, including drugs that are  
commercially available today such as antibiotic Linezolid (Zyvox®)1-2 or the HIV reverse-
transcriptase inhibitor Efavirenz (Sustiva®).3 Knowing these properties the efficient syntheses of 
these heterocycles become of prime importance as well as their insertion in molecules with a 
potential as drugs. In this chapter, the design, synthesis, and antibacterial activities of novel 
classes of compounds containing chiral 1,3-oxazinan-2-ones and 2-oxazolidinones as the basic 
core structures are reported. These compounds are tertiary amines containing the core structures 
and two aryl substituents. Several of these molecules exhibit potent antibacterial activities 
against the tested Gram-positive bacteria, including Staphylococcus aureus, Enterococcus 
faecalis, and Bacillus subtilis. These compounds represent new structure scaffolds and can be 
further optimized to give new antibacterial agents with structures significantly different from 
those of existing classes of antibiotics. 
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Introduction 
Antibiotic resistance is a growing problem that threatens human health globally.  The emergence 
of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci 
(VRE)4-5 is very dangerous and can be life threatening especially for patients whose immune 
system has been compromised due to HIV, surgery or other illnesses. During the recent decades, 
the effort to discover novel antibacterial agents has slowed down; in fact, 2-oxazolidinones are 
the only new class of synthetic antibacterial agents over the past 30 years that possesses totally 
new structures compared to existing antibacterial agents.6-9 The first compound of this class, 
Linezolid 1 (Figure 4.1), was approved by the FDA in 2000 for the treatment of multi-drug 
resistant bacterial infections including diseases caused by MRSA, VRE and Streptoccus 
pneumoniae. 2-Oxazolidinones bind to the 50S subunit of the bacterial ribosome and inhibit 
protein synthesis at a very early stage by preventing the initiation of mRNA translation. Because 
they target the bacterial protein synthesis at an early stage, drug resistance was expected to be 
rare; however resistance to Zyvox® (Linezolid) has already been reported.1, 10 Typical examples 
of the existing synthetic antibacterial agents are shown in Figure 4.1; these include Linezolid 1, 
Ciprofloxacin 2, Sulfonamide 3 and Chloramphenicol 4. The very general features of these 
agents are that they all contain aromatic and/or heterocyclic structures and they have heteroatom 
substituents such as halo, amino and hydroxyl groups. Linezolid 1 has the oxazolidinone as the 
core structure, which is important for its activity. Ciprofloxacin 2 is one example of the 
fluoroquinolone class of antibiotics.11-15 They kill bacteria by inhibiting DNA gyrase enzyme 
which is essential for DNA replication. The structure of 2 contains an aromatic ring with a 
fluorine and a polar piperazine unit. Sulfonamide 3 contains phenyl sulfonyl phenyl amines.  
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Figure 4.1. Structures of some common synthetic antibacterial agents. 
 
The sulfonamides are inhibitors of the bacterial enzymes required for the synthesis of 
tetrahydrofolate,16 an essential nutrient for bacterial growth. Chloramphenicol 4 contains 
substituted nitrophenol with dichloromethyl acetamido functional groups. It also inhibits 
bacterial protein synthesis and is a broad spectrum antibiotic for both Gram positive and Gram 
negative bacteria; unfortunately compound 4 has shown some serious side effects.17 The general 
features of these compounds can be used to design new structures that can be potentially useful 
antibacterial agents.  
 
Many new antibacterial agents are designed based on modification of the existing structural 
classes; since the antibiotic assay is easy to carry out, the modes of action of the agents are often 
discovered after finding them active. With the advancement of synthetic organic chemistry, it is 
now quite common to identify drug-like structures and incorporate them into a de novo design of 
a new agent; this method can be efficiently used to discover new drugs and is somewhat related 
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to the concept of chemical structure evolution. Through the combination of drug-like properties 
in existing drug classes, it is possible to create new drugs with significantly different structure 
motifs. In our efforts to discover new classes of antibacterial agents, we designed and 
synthesized a small library of compounds containing very general structural features of existing 
synthetic antibacterial agents, using chiral cyclic carbamates as the core structures. The general 
structure 5 of the library compounds is shown in Figure 4.2. 
N
ON O
Ar'
R
R = Me, Et
Ar' = X
5
P1
P2
P3
 
Figure 4.2. The general structures of the preliminary compound library. 
 
The basic platform is a tertiary amine composed of a 1,3-oxazinan-2-one and two aromatic 
groups. The core structure is a homolog of the 2-oxazolidinone in Linezolid but with the opposite 
stereochemistry. Three sites P1, P2, P3 can be optimized to obtain better potencies. One main 
reason for this design is the easy access to the compounds synthetically; the second most 
important reason is that tertiary amines and heteroatom substituted aryl groups are found often in 
different classes of drugs, therefore, it is foreseeable that this design could give rise to good 
biological activities. The 1,3-oxazinan-2-one chiral core structure has been found in many 
natural product and drug classes as well.18-24 Another advantage of this platform is that we can 
easily modify the structures of the three sites by N-alkylation or N-arylation reactions. Site P1 
contains the chiral core structure 1,3-oxazinan-2-one or other chiral heterocycles, groups P2 and 
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P3 can be substituted aromatic groups or heterocycles. The synthesis of 1,3-oxazin-2-one ring 
derivatives is shown in Scheme 4.1.  
 
Results and discussions 
The starting material compound 13 was synthesized according to literature procedures using a 
carbohydrate derivative (S)-3-hydroxyl-γ-butyrolactone 6 as the starting material.25-26 Alkylation 
with alkyl halides using potassium carbonate in THF or DMF at 70-90 °C gave the desired 
product 14. These compounds were synthesized by solution phase synthesis and purified by flash 
chromatography.   
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Scheme 4.1. The synthetic route to the target compound library. 
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For structure comparison purposes, we also synthesized a few compounds containing the 2-
oxazolidinone core structure (Scheme 4.2). From the optically pure trityl protected 2-
oxazolidinone 15,27 alkylation by treating with a base and alkyl halides gave intermediate 16. 
Deprotection of trityl group followed by mesylation afforded 17. After displacement of the 
mesylate with an amine and subsequent alkylation, we obtained compounds with the general 
structure 18.  
OTr
O
HN
O
RI
KOt-Bu OTr
O
N
O
R 2) MsCl OMs
O
N
O
R
1) R'NH2
2) R''Br N
O
N
O
R
R'
R''
18
1) TFA
15 17
Py
16  
Scheme 4.2. Synthesis of oxazolidinone derivatives. 
 
The library compounds synthesized present general structures A, B and C as shown in Figure 
3.3. The structures A and B are close analogs with the substituents on ring nitrogen differing 
from ethyl to methyl group. Structure C contains the smaller 2-oxazolidinone ring instead of the 
1,3-oxazinan-2-one. The antibacterial activities of these compounds were evaluated by standard 
methods. These include the assay against several strains of Gram positive bacteria, 
Staphylococcus aureus 29213, Staphylococcus aureus 43300, Enterococcus faecalis 29212, and 
Bacillus subtilis PY79. The inhibition of bacterial growth was monitored using a standard 
colorimeter at 600 nm using a serial dilution at concentrations 238, 119, 59.5, 29.8, 14.9, 7.44, 
3.72, 1.86, 0.93, 0.46 μg/ml. Their minimum inhibition concentration (MIC) results at 50% 
growth inhibition are shown in Table 4.1. We also tested chloramphenicol as a control, it inhibits 
bacteria growth (MIC90) at 7.44, 7.44, 4.0, 2.0 μg/mL respectively to the four bacteria listed in 
Table 4.1. 
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Figure 4.3. The structures of the small compound library synthesized. 
Compound Structure of R ClogP 
S. aureus 
29213 
S. aureus 
43300 
E. faecalis 
29212 
B. subtilis 
PY79 
A1 4-nitrophenyl 4.68 N N 45.0 N 
A2 3-nitrophenyl 4.68 90.0 22.0 47.0 108 
A3 2-nitrophenyl 4.60 72.0 100 43.0 100 
A4 4-cyanophenyl 4.37 180 59.5 12.0 10.0 
A5 3-cyanophenyl 4.37 238 N 45.0 238 
A6 2-cyanophenyl 4.51 130 180 33.0 160 
A7 4-fluorophenyl 5.08 64.0 47.0 35.0 42.5 
A8 2,4-difluorophenyl 5.23 45.0 50.5 59.5 38.0 
A9 2,6-difluorophenyl 5.23 47.0 70.0 59.5 77.0 
A10 3,5-diflurophenyl 5.16 40.0 45.0 37.0 43.0 
A11 3,4-dichlorophenyl 6.25 5.60 6.56 N 5.00 
A12 2-naphthalenyl 6.11 15.0 N 13.0 29.0 
A13 1-naphthalenyl 6.11 10.0 35.0 7.40 7.60 
A14 3-pyridinyl 3.44 N N 238 N 
A15 2-pyridinyl 3.44 N N N N 
A16 3-methoxyphenyl 4.86 90.0 90.0 80.5 95.0 
A17 2-methylphenyl 5.39 22.0 22.5 8.10 26.0 
B1 4-nitrophenyl 4.15 81.0 N 119 98.0 
B2 3-nitrophenyl 4.15 138 N 119 238 
B3 2-nitrophenyl 4.07 179 N 238 238 
B4 4-cyanophenyl 3.84 200 N 238 238 
B5 3-cyanophenyl 3.84 180 238 7.40 180 
B6 2-cyanophenyl 3.98 166 180 59.5 180 
B7 4-fluorophenyl 4.55 87.1 119 120 95.0 
B8 2,4-difluorophenyl 4.69 50.0 72.0 59.5 55.0 
B9 2-naphthalenyl 5.58 11.5 13.0 14.9 12.0 
C1 4-fluorophenyl 3.99 N N N N 
C2 2,4-difluorophenyl 4.14 85.0 119 N 90.0 
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C3 3,4-difluorophenyl 4.07 119 N N 80.0 
C4 4-bromophenyl 4.71 20.0 59.5 N 22.0 
C5 2-bromophenyl 4.71 18.0 21.0 7.40 22.0 
 
 
Table 4.1. The minimum inhibition concentration (MIC, μg/mL) of the compound library 
against four bacterial strains. The MICs are reported as the concentrations at 50% inhibition of 
bacteria growth, N stands for no inhibition. 
 
The biological assay data have shown that several compounds have moderate to potent activity 
against all four strains of bacteria. Some active compounds also exhibited certain strain-
specificity. It is common for some bacteria strains to be resistant and others susceptible to a 
particular antibiotic.28,29 For instance, the tested strain S. aureus 29213 is methicillin susceptible, 
while S. aureus 43300 is methicillin resistant. The E. faecalis 29212 is vancomycin susceptible, 
another strain E. faecalis 51299 is vancomycin resistant. Compound A12 showed promising 
activity against S. aureus 29213 but no activity against S. aureus 43300. Meanwhile, A11 
showed excellent activity against both strains of S. aureus and B. subtilis PY79 but no activity 
against E. faecalis 29212. These indicate that the potent compounds can be developed into 
narrow spectrum antibiotics. This may have some advantages in controlling the spread of 
resistance. In Table 4.1, the most potent compounds are A11, A13, A17, and B9. Their 
concentrations of inhibition of S. aureus 29213 and B. Subtilis 79 at 90% are shown in Figure 
4.4.  
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Figure 4.4. The compound structures and their concentrations of 90% inhibition  
of bacterial growth. 
 
Compounds A17 and the oxazolidinone derivative C5 also inhibit over 90% growth of E. 
facecalis 29212 at concentrations of 14.9 and 29.8 µg/mL, respectively. The most potent 
compound A11 has MIC90 below 10 µg/mL, it is in the same range as chloramphenicol. These 
are reasonable good activities considering the simplicity of the structure and the differences with 
Linezolid or other existing antibacterial agents. The structure–activity relationship (SAR) of site 
P2 can be analyzed when P1 contains an 1,3-oxazinan-2-one ring. The nature of substituents and 
their positions on the benzyl group affected the activity significantly. A general trend is that non-
polar groups are more favorable than polar groups on the benzyl ring. It seems that ortho 
position substituents on the P2 site favor the activity as well. Ortho-methyl and halogen groups 
are generally good substituents. Fluoro substituents frequently appear in many antibacterial drug 
structures, however, for our tertiary amine systems, chloro and bromo substituted compounds 
seem to be more potent than fluoro-containing compounds. The polar nitro substituent is not very 
active. Naphthalenyl groups showed better activity than benzene ring only. When replacing one 
of the phenyl rings with a pyridinyl ring (A14 and A15), the activity is completely lost. This also 
indicates that it is favorable to have a non-polar group at the site P2. For site P1, substituents on 
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the 3-nitrogen of the 1,3-oxazinan-2-one ring also influence the activity. The similar structures 
with methyl instead of ethyl groups showed somewhat diminished activity. This trend can be 
proved by testing the propyl, butyl, and pentyl substituents in the future. For the oxazolidinone 
series, molecules with the same P2 and P3 groups indicated that the 6-membered ring 1,3-
oxazinan-2-one is slightly more potent than the 5-membered ring oxazolidinones. But with 
bromo substituents on the benzene ring (P2), oxazolidinone compounds still showed good 
activity especially when the bromine is at ortho position. 
N
Terbinafine  
It is worth noting that compounds A13 and B9 have some structure similarities with an 
antifungal drug, the tertiary amine Terbinafine (Lamisil®).30 They all contain a naphthalenyl 
substituted tertiary amine as the general structure. Terbinafine inhibits the synthesis of 
ergosterol, an essential component for the fungi cell wall. It has a different mode of action 
compared to ‘azole’ antifungal agents. The structure resemblance to Terbinafine may indicate 
that our tertiary amine systems also can have antifungal activities in addition to the observed 
antibacterial activities. These are currently under evaluation. From the above discussions, we can 
draw several preliminary conclusions of SAR. For site P2 aromatic systems, naphthalene is more 
active than benzene; bromo, methyl are good candidates for the substituent on benzene ring. The 
6-membered ring 1,3-oxazinan-2-one seems to have a slightly better activity than the 2-
oxazolidinone for the compounds tested so far. It is necessary to have one or two substituted aryl 
systems for antibacterial activities. The minimum inhibition concentrations of several 
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compounds are around 10 µg/mL, which should be a good starting point for us to optimize the 
structure and obtain more potent antibacterial agents with this novel scaffold.  
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Conclusions 
1,3-oxazinan-2-ones and 2-oxazolidinones rings are important heterocycles in organic synthesis, 
both as useful synthetic intermediates of as intricate part of biologically active molecules. We 
have designed, synthesized, and evaluated the antibacterial activities of a small, focused 
compound library of tertiary amines containing novel chiral 1,3-oxazinan-2-one core structures, 
2-oxazolidinone rings  and aryl substituents. Several compounds with the general scaffold have 
shown promising antibacterial activities. They exhibit promising activity against several types of 
Gram-positive bacteria including S. aureus, E. faecalis, and B. subtilis. The structure–activity 
relationship of one aryl substitution site P2 was evaluated thoroughly. We found that bromo, 
chloro, and methyl groups generally give rise to good antibacterial activity. The structures of 
these compounds and the structure–activity relationship observed from this library can be used to 
further optimize the structures to obtain potent novel antimicrobial drugs.  
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Experimental Section 
I. General procedure for the alkylation reaction:  
(S)-6-(Benzylamino-methyl)-3-methyl-1,3-oxazinan-2-one 13 (60.8 mg, 0.260 mmol) was 
dissolved  in 5 to 10 mL of anhydrous THF. 4-nitrobenzylbromide (56.0 mg, 0.260 mmol) and 
potassium carbonate (72.0 mg, 0.520 mmol) were added. The solution was stirred at 60 to 70ºC 
for 48 h. The reaction was then cooled to room temperature and filtered on paper to remove 
inorganic materials. The solvent was evaporated and the residue was purified by SiO2 gel 
chromatography using a gradient of solvent systems of Hexane/THF 9:1 to Hexane/CH2Cl2/THF 
6:3:1. The product was obtained as a brown oil (49.0 mg, 0.133 mmol). In the case of substituted 
benzyl chlorides, DMF is generally used as the solvent instead of THF. The general yield range: 
51%-90%.  
 
Compound A1 1H NMR (CDCl3, 400 MHz); δ (ppm): 8.15 (d, 2H, J = 8.8 Hz), 7.53 (d, 2H, J = 
8.8 Hz), 7.31-7.21 (m, 5H), 4.28 (m, 1H), 3.81 (d, 1H, J = 14.6 Hz), 3.71 (d, 1H, J = 14.6 Hz), 
3.68 (d, 1H, J = 12.7 Hz), 3.57 (d, 1H, J = 12.7 Hz), 3.30 (q, 2H, J = 14.6, 6.8 Hz), 3.22 (dt, 1H, 
J = 11.2, 4.9 Hz), 3.08 (m, 1H), 2.75 (dd, 1H, J = 13.7, 5.9 Hz), 2.64 (dd, 1H, J = 13.7, 5.9 Hz), 
1.95 (m, 1H), 1.69 (m, 1H), 1.08 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 
152.9, 147.3, 138.4, 129.4, 128.8, 128.4, 127.4, 123.5, 75.3, 59.4, 58.7, 56.7, 43.9, 43.3, 25.5, 
12.1. 
 
Compound A2 1H NMR (CDCl3, 400 MHz); δ (ppm): 8.24 (s, 1H), 8.09 (d, 1H, J = 7.8 Hz), 
7.67 (d, 1H, J = 7.8 Hz), 7.47 (t, 1H, J = 7.8 Hz), 7.33-7.23 (m, 5H), 4.28 (m, 1H), 3.82 (d, 1H, J 
= 13.7 Hz), 3.71 (d, 2H, J = 3.9 Hz), 3.68 (d, 1H, J = 3.9 Hz), 3.57 (d, 1H, J =  13.7 Hz), 3.31(q, 
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2H, J = 14.6, 6.8 Hz), 3.22 (dt, 1H, J = 11.7, 4.9 Hz), 3.08 (m, 1H), 2.76 (dd, 1H, J = 13.7, 5.9 
Hz), 2.66 (dd, 1H, J = 13.7, 6.8 Hz), 1.99 (m, 1H), 1.69 (m, 1H), 1.09 (t, 3H, J = 7.8 Hz). 13C 
NMR (CDCl3, 100 MHz); δ (ppm): 152.9, 148.3, 141.6, 138.3, 134.8, 129.2, 128.8, 128.4, 127.4, 
123.3, 122.2, 75.3, 59.3, 58.6, 56.5, 43.9, 43.3, 25.5, 12.0. HRMS (m/z): calcd for C21H26N3O4 
[M + H]+, 384.1923; found, 384.1904. IR (CH2Cl2; cm-1): 3046, 2977, 1685, 1415, 1262, 735, 
694 cm-1.  
 
Compound A3 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.76 (d, 1H, J = 8.8 Hz), 7.53 (m, 2H), 
7.40 (t, 1H, J = 6.8 Hz), 7.32-7.14 (m, 5H), 4.23 (d, 1H, J = 13.7 Hz), 4.13 (m, 1H), 3.75 (d, 1H, 
J = 14.6 Hz), 3.56 (d, 1H, J = 13.7 Hz), 3.38 (d, 1H, J = 12.7 Hz), 3.28 (m, 2H), 3.15 (dt, 1H, J = 
11.7, 4.9 Hz), 2.96 (m, 1H), 2.64 (dd, 1H, J = 13.7, 4.9 Hz), 2.53 (dd, 1H, J = 12.7, 7.8 Hz), 1.90 
(m, 1H), 1.36 (m, 1H), 1.06 (t, 3H, J = 7.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 153.1, 
150.1, 138.0, 133.8, 132.3, 131.8, 129.2, 128.3, 127.3, 124.4, 74.3, 59.6, 57.6, 56.8, 43.9, 43.3, 
25.5, 12.1. 
 
Compound A4 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.59 (d, 2H, J = 7.8 Hz), 7.46 (d, 2H, J = 
7.8 Hz), 7.33-7.23 (m, 5H), 4.25 (m, 1H), 3.77 (d, 1H, J = 14.6 Hz), 3.68 (d, 1H, J = 5.9 Hz), 
3.64 (d, 1H, J = 5.9 Hz), 3.55 (d, 1H, J = 13.7 Hz), 3.30 (q, 2H, J = 13.7, 6.8 Hz), 3.20 (dt, 1H, J 
= 11.7, 5.9 Hz), 3.06 (m, 1H), 2.73 (dd, 1H, J = 13.7, 5.9 Hz), 2.62 (dd, 1H, J = 13.7, 5.9 Hz), 
1.94 (m, 1H), 1.66 (m, 1H), 1.08 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 
152.9, 145.1, 138.4, 132.1, 129.4, 128.8, 128.4, 127.4, 118.8, 110.9, 75.2, 59.4, 59.1, 56.6, 43.9, 
43.2, 25.5, 12.1. 
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Compound A5 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.64 (bs, 1H), 7.57 (d, 1H, J = 7.8 Hz), 
7.52 (d, 1H, J = 6.8 Hz), 7.40 (t, 1H, J = 7.8 Hz), 7.33-7.23 (m, 5H), 4.25 (m, 1H), 3.74 (d, 1H, J 
= 14.6 Hz), 3.67 (d, 1H, J = 13.7 Hz), 3.61 (d, 1H, J = 13.7 Hz), 3.53 (d, 1H, J = 13.7 Hz), 3.30 
(q, 2H, J = 14.6, 7.8 Hz), 3.21 (dt, 1H, J = 11.7, 59 Hz), 3.07 (m, 1H), 2.73 (dd, 1H, J = 13.7, 5.9 
Hz), 2.62 (dd, 1H, J = 13.7, 6.8 Hz), 1.95 (m, 1H), 1.68 (m, 1H), 1.08 (t, 3H, J = 7.8 Hz). 13C 
NMR (CDCl3, 100 MHz); δ (ppm): 152.9, 141.0, 138.4, 133.3, 132.1, 130.8, 129.1, 128.8, 128.4, 
127.4, 118.9, 112.4, 75.2, 59.4, 58.7, 56.5, 43.9, 43.3, 25.5, 12.01. 
 
Compound A6 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.64 (D, 1H, J = 7.8 Hz), 7.53 (m, 2H, J 
= 4.9 Hz), 7.34 (m, 1H), 7.30-7.19 (m, 5H), 4.27 (m, 1H), 3.99 (d, 1H, J = 13.7 Hz), 3.73 (d, 1H, 
J = 13.7 Hz), 3.67 (d, 1H, J = 13.7 Hz), 3.51 (d, 1H, J = 13.7 Hz), 3.28 (q, 2H, J = 14.6, 6.8 Hz), 
3.17 (dt, 1H, J = 11.7, 5.9 Hz), 2.99 (m, 1H), 2.75 (dd, 1H, J = 13.7, 4.9 Hz), 2.63 (dd, 1H, J = 
13.7, 6.8 Hz), 2.05 (m, 1H), 1.51 (m, 1H), 1.06 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); 
δ (ppm): 152.9, 142.9, 138.3, 133.3, 132.6, 130.6, 129.1, 128.3, 127.8, 127.3, 118.0, 112.8, 74.7, 
59.3, 58.4, 56.8, 43.8, 43.2, 25.6, 12.0. HRMS (m/z): calcd for C22H26N3O2 [M + H]+, 364.2025; 
found, 364.2013. IR (CH2Cl2; cm-1): 3054, 2986, 1689, 1454, 740, 705 cm-1. 
 
Compound A7 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.33-7.21 (m, 6H), 6.98 (t, 2H, J = 8.8 
Hz), 4.20 (m, 1H), 3.69 (d, 1H, J = 13.7), 3.66 (d, 1H, J =  6.8 Hz), 3.52 (d, 1H, J = 13.7 Hz), 
3.49 (d, 1H, J = 6.8 Hz), 3.28 (q, 2H, J = 14.6, 6.8 Hz), 3.14 (dt, 1H, J = 10.7, 4.9 Hz), 3.00 (m, 
1H), 2.70 (dd, 1H, J = 13.7, 4.9 Hz), 2.60 (dd, 1H, J = 13.7, 7.8 Hz), 1.97 (m, 1H), 1.62 (m, 1H), 
1.06 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 162.2 (d, C4-F, 1J = 244.1 Hz), 
152.9, 138.9, 134.8, 130.6 (d, C2-F, C6-F, 3J = 9.2 Hz), , 128.8, 128.3, 127.1, 115.3 (d, C3-F, C5-
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F, 2J = 21.4 Hz), 75.1, 59.4, 58.7, 56.1, 43.8, 43.1, 25.3, 12.0. HRMS (m/z): calcd for 
C21H26N2O2F [M + H]+, 357.1978; found, 357.1982. IR (CH2Cl2; cm-1): 3054, 2983, 1690, 1446, 
1266, 739, 700 cm-1.  
 
Compound A8 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.37-7.19 (m, 6H), 6.83 (t, 1H, J = 7.8 
Hz), 6.76 (t, 1H, J = 8.8 Hz), 4.22 (m, 1H), 3.72(d, 1H, J = 13.7 Hz), 3.68 (d, 1H, J = 13.7 Hz), 
3.59 (d, 1H, J = 13.7 Hz), 3.51 (d, 1H, J = 13.7 Hz), 3.29 (q, 2H, J = 14.6, 7.8 Hz), 3.16 (dt, 1H, 
J = 11.7, 5.9 Hz), 3.01 (m, 1H), 2.72 (dd, 1H, J = 13.7, 4.9 Hz), 2.59 (dd, 1H, J = 13.7, 7.8 Hz), 
1.97 (m, 1H), 1.60 (m, 1H), 1.07 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 
162.4 (dd, C4-F, 1J = 250.2 Hz, 3J = 12.2 Hz), 161.6 (dd, C2-F, 1J = 247.2 Hz, 3J = 12.2 Hz), 
152.9, 138.8, 132.4 (t, C6-F, 3J = 9.2 Hz),  128.8, 128.2, 127.2, 121.9 (d, C1-F, 2J = 15.3 Hz), 
111.3 (d, C5-F, 2J = 21.4 Hz), 103.9 (t, C3-F, 2J = 24.4 Hz), 75.1, 59.3, 56.2, 51.9, 43.9, 43.2, 
25.3, 12.0. 
 
Compound A9 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.28-7.18 (m, 6H), 6.86 (t, 2H, J = 7.8 
Hz), 4.23 (m, 1H), 3.80 (d, 1H, J = 13.7 Hz), 3.73 (d, 1H, J = 6.8 Hz), 3.70 (d, 1H, J = 6.8 Hz), 
3.50 (d, 1H, J = 13.7 Hz), 3.28 (m, 2H), 3.12 (dt, 1H, J = 11.7, 5.9 Hz), 2.96 (m, 1H), 2.72 (dd, 
1H, J = 13.7, 4.9 Hz), 2.56 (dd, 1H, J = 13.7, 8.8 Hz), 2.02 (m, 1H), 1.54 (m, 1H), 1.06 (t, 3H, J 
= 6.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 162.3 (dd, C2-F, C6-F, 1J = 250.2 Hz, 3J = 9.2 
Hz), 153.1, 139.0, 129.6 (t, C4-F, 3J = 12.2 Hz), 129.2, 128.1, 127.1, 114.5 (t, C1-F, 2J = 18.3 
Hz), 111.5 (dd, C3-F, C5-F, 2J = 18.3 Hz, 4J = 6.1 Hz), 74.9, 59.5, 55.8, 46.4, 43.9, 43.2, 25.1, 
12.0. HRMS (m/z): calcd for C21H25N2O2F2 [M + H]+, 375.1884; found, 375.1883. IR (CH2Cl2; 
cm-1): 3054, 2987, 1687, 1471, 740, 705 cm-1. 
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Compound A10 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.33-7.21 (m, 5H), 6.88 (d, 2H, J = 6.8 
Hz), 6.67 (t, 1H, J = 8.8 Hz), 4.24 (m, 1H), 3.71 (d, 1H, J = 3.9 Hz), 3.68 (d, 1H, J = 3.9 Hz), 
3.56 (d, 1H, J = 6.8 Hz), 3.53 (d, 1H, J = 6.8 Hz), 3.31 (q, 2H, J = 13.7, 6.8 Hz), 3.21 (dt, 1H, J 
= 11.7, 5.9 Hz), 3.07 (m, 1H), 2.73 (dd, 1H, J = 13.7, 4.8 Hz), 2.63 (dd, 1H, J = 13.7, 7.8 Hz), 
1.99 (m, 1H), 1.70 (m, 1H), 1.09 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 
163.3 (dd, C3-F, C5-F, 1J = 250.2 Hz, 3J = 12.2 Hz), 152.9, 143.9 (t, C1-F, 3J = 9.2 Hz), 138.5, 
128.8, 128.4, 127.3, 111.4 (dd, C2-F, C6-F, 2J = 18.3 Hz, 4J = 6.1 Hz), 102.7 (t, C4-F, 2J = 24.4 
Hz), 75.3, 59.4, 58.8, 56.4, 43.9, 43.3, 25.5, 12.1. 
 
Compound A11 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.42 (bs, 1H), 7.36 (d, 1H, J = 7.8 Hz), 
7.33-7.23 (m, 5H), 7.17 (d, 1H, J = 7.8 Hz), 4.23 (m, 1H), 3.68 (d, 1H, J = 1.9 Hz), 3.65 (d, 1H, 
J = 1.9 Hz), 3.54 (d, 1H, J = 2.9 Hz), 3.50 (d, 1H, J = 2.9 Hz), 3.30 (q, 2H, J = 14.6, 6.8 Hz), 
3.19 (dt, 1H, J = 11.7, 4.9 Hz), 3.05 (m, 1H), 2.71 (dd, 1H, J = 13.7, 5.9 Hz), 2.60 (dd, 1H, J = 
13.7, 6.8 Hz), 1.96 (m, 1H), 1.67 (m, 1H), 1.08 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); 
δ (ppm): 152.9, 139.7, 138.5, 132.3, 130.9, 130.5, 130.2, 128.8, 128.4, 128.1, 127.3, 75.2, 59.3, 
58.3, 56.3, 43.9, 43.2, 25.5, 12.1. HRMS (m/z): calcd for C21H25N2O2Cl2 [M + H]+, 407.1293; 
found, 407.1292. IR (CH2Cl2; cm-1): 3048, 2969, 1690, 1462, 1266, 740, 703 cm-1. 
 
Compound A12 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.79 (d, 3H, J = 7.7 Hz), 7.72 (s, 1H), 
7.50-7.42 (m, 3H), 7.37-7.22 (m, 5H), 4.23 (m, 1H), 3.87 (d, 1H, J = 13.7 Hz), 3.76 (d, 1H, J = 
13.7 Hz), 3.67 (d, 1H, J = 13.7 Hz), 3.57 (d, 1H, J = 13.7 Hz), 3.25 (q, 2H, J = 14.3, 7.1 Hz), 
3.09 (dt, 1H, J = 10.9, 4.9 Hz), 2.94 (m, 1H), 2.77 (dd, 1H, J = 13.7, 4.9 Hz), 2.67 (dd, 1H, J = 
13.7, 7.7 Hz), 1.99 (m, 1H), 1.63 (m, 1H), 1.02 (t, 3H, J = 7.1 Hz). HRMS (m/z): calcd for 
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C25H29N2O2 [M + H]+, 389.2229; found, 3891.2236. IR (CH2Cl2; cm-1): 3054, 2987, 1688, 1438, 
1266, 740, 705 cm-1. 
 
Compound A13 1H NMR (CDCl3, 400 MHz); δ (ppm): 8.07 (m, 1H), 7.78 (m, 2H), 7.48-7.24 
(m, 9H), 4.15 (d, 1H, J = 12.7 Hz), 4.03 (m, 1H), 3.92 (d, 1H, J = 12.7 Hz), 3.82 (d, 1H, J = 13.7 
Hz), 3.62 (d, 1H, J = 13.7 Hz), 3.20 (m, 2H), 2.86-2.61 (m, 4H), 1.69 (m, 1H), 1.32 (m, 1H), 
0.99 (t, 3H,  J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 152.8, 138.7, 134.5, 133.7, 
132.1, 129.3, 128.3, 128.1, 128.0, 127.7, 127.2, 125.5, 125.4, 125.1, 124.6, 74.9, 60.6, 58.3, 56.0, 
43.7, 42.7, 24.9, 11.9. HRMS (m/z): calcd for C25H29N2O2 [M + H]+, 389.2229; found, 389.2236. 
IR (CH2Cl2; cm-1): 3046, 2977, 1692, 1465, 1292, 766, 706 cm-1. 
 
Compound A14 1H NMR (CDCl3, 400 MHz); δ (ppm): 8.57 (bs, 1H), 7.73 (d, 1H, J = 7.8 Hz), 
7.34-7.21 (m, 6H), 4.27 (m, 1H), 3.77 (d, 1H, J = 14.6 Hz), 3.72 (d, 1H, J = 14.6 Hz), 3.63 (d, 
1H, J = 14.6 Hz), 3.58 (d, 1H, J = 14.6 Hz), 3.30 (q, 2H, J = 13.7, 6.8 Hz), 3.20 (dt, 1H, J = 11.7, 
5.9 Hz), 3.04 (m, 1H), 2.75 (dd, 1H, J = 13.7, 4.9 Hz), 2.65 (dd, 1H, J = 13.7, 6.8 Hz), 1.96 (m, 
1H), 1.66 (m, 1H), 1.08 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 153.0, 139.1, 
136.7, 133.2, 132.7, 128.9, 128.3, 127.9, 127.7, 127.6, 127.1, 126.0, 125.6, 75.2, 59.8, 56.2, 43.9, 
43.1, 25.3, 12.0. HRMS (m/z): calcd for C20H26N3O2 [M + H]+, 340.2025; found, 340.2025. IR 
(CH2Cl2; cm-1): 3054, 2987, 1692, 1422, 1266, 740, 705 cm-1. 
 
Compound A15 1H NMR (CDCl3, 400 MHz); δ (ppm): 8.51 (d, 1H, J = 4.9 Hz), 7.65 (t, 1H, J = 
6.8 Hz), 7.47 (d, 1H, J = 6.8 Hz), 7.35-7.21 (m, 5H), 7.15 (t, 1H, J = 5.9 Hz), 4.27 (m, 1H), 3.86 
(d, 1H, J = 14.6 Hz), 3.77 (d, 1H, J = 5.9 Hz), 3.74 (d, 1H, J = 5.9 Hz), 3.64 (d, 1H, J = 14.6 Hz), 
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3.30 (q, 2H, J = 13.7, 6.8 Hz), 3.18 (dt, 1H, J = 11.7, 5.9 Hz), 3.04 (m, 1H), 2.82 (dd, 1H, J = 
13.7, 5.9 Hz), 2.67 (dd, 1H, J = 13.7, 6.8 Hz), 2.00 (m, 1H), 1.67 (m, 1H), 1.07 (t, 3H, J = 6.8 
Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 159.4, 153.1, 149.0, 138.9, 136.4, 128.9, 128.3, 
127.2, 123.2, 122.1, 75.2, 61.1, 59.8, 56.7, 43.9, 43.3, 25.5, 12.1. 
 
Compound A16 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.33-7.18 (m, 6H), 6.90 (d, 2H, J = 6.8 
Hz), 6.76 (d, 1H, J = 7.8 Hz), 4.20 (m, 1H), 3.78 (s, 3H), 3.69 (d, 1H, J = 13.7 Hz), 3.67 (d, 1H, 
J = 8.8 Hz), 3.52 (d, 1H, J = 13.7 Hz), 3.49 (d, 1H, J = 7.8 Hz), 3.27 (q, 2H, J = 9.8, 6.8 Hz), 
3.12 (dt, 1H, J = 10.7, 4.9 Hz), 2.98 (m, 1H), 2.71 (dd, 1H, J = 13.7, 4.9 Hz), 2.61 (dd, 1H, J = 
12.7, 7.8 Hz), 2.01 (m, 1H), 1.64 (m, 1H), 1.05 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); 
δ (ppm): 159.5, 152.9, 140.8, 139.0, 129.2, 128.8, 128.2, 127.0, 121.1, 114.5, 112.2, 75.1, 59.5, 
56.2, 55.1, 43.8, 43.1, 25.3, 12.0. HRMS (m/z): calcd for C22H29N2O3 [M + H]+, 369.2178; 
found, 369.2160. IR (CH2Cl2; cm-1): 3054, 2985, 1686, 1469, 1285, 738, 692 cm-1. 
 
Compound A17 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.33-7.21 (m, 6H), 7.14 (m, 3H), 4.11 
(m, 1H), 3.73 (d, 1H, J = 6.8 Hz), 3.69 (d, 1H, J = 5,9 Hz), 3.51 (m, 2H), 3.52 (d, 1H, J = 1.9 
Hz), 3.49 (d, 1H, J = 1.9 Hz), 3.26 (m, 2H), 3.04 (dt, 1H, J = 11.7, 5.9 Hz), 2.88 (m, 1H), 2.69 
(dd, 1H, J = 13.7, 4.9 Hz), 2.62 (dd, 1H, J = 12.7, 7.8 Hz), 2.29 (s, 3H), 1.91 (m, 1H), 1.52 (m, 
1H), 1.05 (t, 3H, J = 6.8 Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 152.9, 138.9, 137.2, 136.9, 
130.3, 129.9, 129.2, 128.2, 127.2, 125.6, 127.1, 74.9, 60.2, 58.0, 56.3, 43.8, 42.9, 25.2, 19.2, 
12.0. HRMS (m/z): calcd for C22H29N2O2 [M + H]+, 353.2229; found, 353.2221. IR (CH2Cl2; cm-
1): 3054, 2987, 1688, 1431, 1266, 747, 705 cm-1. 
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Compound B1 1H NMR (CDCl3, 400 MHz); δ (ppm): 8.16 (d, 2H, J = 8.8 Hz), 7.53 (d, 2H, J = 
8.8 Hz), 7.42-7.22 (m, 5H), 4.28 (m, 1H), 3.81 (d, 1H, J = 14.3 Hz), 3.73 (d, 1H, J = 8.8 Hz), 
3.67 (d, 1H, J = 14.8 Hz), 3.58 (d, 1H,  J = 13.2 Hz), 3.24 (dt, 1H, J = 11.5, 5.5 Hz), 3.07 (m, 
1H), 2.91 (s, 3H), 2.76 (dd, 1H, J = 13.7, 5.5 Hz), 2.65 (dd, 1H, J = 13.7, 6.0 Hz), 1.92 (m, 1H), 
1.72 (m, 1H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 153.5, 147.2, 147.2, 138.4, 129.3, 128.8, 
128.4, 127.4, 123.6, 75.5, 59.4, 58.8, 56.7, 46.0, 36.4, 25.5. 
 
Compound B2 1H NMR (CDCl3, 400 MHz); δ (ppm): 8.24 (bs, 1H), 8.09 (d, 1H, J = 7.8 Hz), 
7.67 (d, 1H, J = 7.8 Hz), 7.47 (t, 2H,  J = 7.8 Hz), 7.36-7.21 (m, 4H), 4.28 (m, 1H), 3.82 (d, 1H, 
J = 14.6 Hz), 3.72 (d, 1H, J = 14.6 Hz), 3.69 (d, 1H, J = 13.7 Hz), 3.59 (d, 1H, J = 13.7 Hz), 3.24 
(dt, 1H, J = 11.7, 5.9 Hz), 3.07 (m, 1H), 2.91 (s, 3H), 2.76 (dd, 1H, J = 13.7, 4.9 Hz), 2.66 (dd, 
1H, J =  13.7, 5.9 Hz), 1.96 (m, 1H), 1.73 (m, 1H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 
153.5, 148.3, 141.7, 138.3, 134.8, 128.3, 128.9, 128.5, 127.4, 123.3, 122.2, 75.5, 59.4, 58.7, 56.6, 
46.1, 36.4, 25.5. 
 
Compound B3 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.76 (d, 2H, J = 7.8 Hz), 7.57-7.13 (m, 
7H), 4.22 (d, 1H, J = 13.7 Hz), 4.13 (m, 1H), 3.76 (d, 1H, J = 13.7 Hz), 3.55 (d, 1H, J = 12.7 
Hz), 3.39 (d, 1H, J = 13.7 Hz), 3.18 (dt, 1H, J = 10.7, 4.9 Hz), 2.93 (m, 1H), 2.87 (s, 3H), 2.64 
(dd, 1H, J = 13.7, 4.9 Hz), 2.53 (dd, 1H, J = 13.7, 7.8 Hz), 1.88 (m, 1H), 1.36 (m, 1H). 13C NMR 
(CDCl3, 100 MHz); δ (ppm): 153.7, 150.1, 137.9, 133.8, 132.3, 131.7, 129.2, 128.4, 128.2, 
127.3, 124.3, 74.5, 59.7, 57.6, 56.8, 46.1, 36.4, 25.5. HRMS (m/z): calcd for C20H24N3O4 [M + 
H]+, 370.1767; found, 370.1753. IR (CH2Cl2; cm-1): 3055, 2971, 1694, 1531, 1431, 1266, 740, 
700 cm-1. 
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Compound B4 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.59 (d, 2H, J = 7.8 Hz), 7.47 (d, 2H, J = 
7.8 Hz), 7.33-7.21 (m, 5H), 4.26 (m, 1H), 3.76(d, 1H, J = 13.7 Hz), 3.68 (d, 1H, J = 5.9 Hz), 
3.65 (d, 1H, J = 4.9 Hz), 3.57 (d, 1H, J = 12.7 Hz), 3.23 (dt, 1H, J = 11.7, 5.9 Hz), 3.05 (m, 1H), 
2.90 (s, 3H), 2.74 (dd, 1H, J = 13.7, 5.0 Hz), 2.63 (dd, 1H, J = 13.7, 5.9 Hz), 1.91 (m, 1H), 1.69 
(m, 1H). 13C NMR (CDCl3, 100 MHz); δ (ppm): 153.5, 145.1, 138.4, 132.1, 129.3, 128.8, 128.4, 
127.4, 118.8, 110.9, 75.4, 59.4, 59.1, 56.6, 46.0, 36.4, 25.4. HRMS (m/z): calcd for C21H24N3O2 
[M + H]+, 350.1869; found, 350.1873. IR (CH2Cl2; cm-1): 3055, 2987, 1695, 1495, 1462, 1266, 
744, 705 cm-1 
 
Compound B5 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.64 (bs, 1H), 7.54 (m. 1H), 7.40 (t, 1H, J 
= 7.8 Hz), 4.25 (m, 1H), 3.73 (d, 1H, J = 14.6 Hz), 3.66 (d, 1H, J = 8.8 Hz), 3.62 (d, 1H, J = 9.7 
Hz), 3.55 (d, 1H, J = 12.7 Hz), 3.23 (dt, 1H, J = 10.7, 4.9 Hz), 3.05 (m, 1H), 2.90 (s, 3H), 2.67 
(dd, 1H, J = 13.7, 4.9 Hz), 2.63 (dd, 1H, J = 13.7, 6.8 Hz), 1.92 (m, 1H), 1.70 (m, 1H). 13C NMR 
(CDCl3, 100 MHz); δ (ppm): 153.5, 140.9, 138.4, 133.2, 132.1, 130.1, 129.1, 128.8, 128.4, 
127.4, 118.9, 112.3, 75.4, 59.3, 58.7, 56.4, 45.9, 36.4, 25.5. 
 
Compound B6 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.59 (d, 1H, J = 7.8 Hz), 7.50 (m, 2H), 
7.33-7.14 (m, 6H), 4.24 (m, 1H), 3.94 (d, 1H, J = 13.7 Hz), 3.71(d, 1H, J = 13.7 Hz), 3.62 (d, 
1H, J = 12.7 Hz), 3.49 (d, 1H, J = 13.7 Hz), 3.17 (dt, 1H,  J = 11.7, 5.9 Hz), 2.95 (m, 1H), 2.71 
(dd, 1H, J = 13.7, 4.9 Hz), 2.60 (dd, 1H, J = 13.7, 6.8 Hz), 1.98 (m, 1H), 1.50 (m, 1H). 13C NMR 
(CDCl3, 100 MHz); δ (ppm): 153.4, 142.7, 138.1, 132.9, 132.4, 130.3, 128.8, 128.1, 127.7, 
127.1, 117.8, 112.5, 74.7, 59.0, 58.1, 56.6, 45.8, 36.1, 25.4. HRMS (m/z): calcd for C21H24N3O2 
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[M + H]+, 350.1869; found, 350.1872. IR (CH2Cl2; cm-1): 3056, 2937, 1694, 1496, 1450, 1266, 
1133, 1077, 738, 701 cm-1. 
 
Compound B7 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.42-7.18 (m, 7H), 6.98 (t, 2H, J = 7.8 
Hz), 4.20 (m, 1H), 3.68 (d, 1H, J = 5.9 Hz),  3.65 (d, 1H, J = 5.9 Hz), 3.54 (d, 1H, J = 5.9 Hz), 
3.51 (d, 1H, J = 5.9 Hz), 3.17 (dt, 1H, J = 11.7, 5.9 Hz), 2.99 (m, 1H), 2.71 (dd, 1H, J = 12.7, 4.9 
Hz), 2.61 (dd, 1H, J = 13.7, 6.8 Hz), 1.95 (m, 1H), 1.65 (m, 1H). 13C NMR (CDCl3, 100 MHz); δ 
(ppm): 162.0 (d, C4-F, 1J = 247.2 Hz), 153.6, 138.9, 134.8, 130.4 (d, C2-F, C6-F, 3J = 9.2 Hz), 
128.8, 128.3, 127.2, 115.2 (d, C3-F, C5-F, 2J = 21.2 Hz), 75.3, 59.4, 58.7, 56.2, 45.9, 36.4, 25.4. 
 
Compound B8 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.40-7.20 (m, 6H), 6.80 (m, 2H), 4.22 (m, 
1H), 3.72 ( d, 1H, J = 13.7 Hz), 3.64 (d, 1H, J = 16.6 Hz), 3.60 (d, 1H, J = 13.7 Hz), 3.54 (d, 1H, 
J = 13.7 Hz), 3.19 (dt, 1H, J = 11.7, 5.9 Hz), 3.00 (m, 1H), 2.89 (s, 3H), 2.73 (dd, 1H, J = 13.7, 
4.9 Hz), 2.60 (dd, 1H, J = 13.7, 7.8 Hz), 1.95 (m, 1H), 1.62 (m, 1H). 13C NMR (CDCl3, 100 
MHz); δ (ppm): 162.2 (dd, C4-F, 1J = 247.2 Hz, 3J = 12.2 Hz), 161.5 (dd, C2-F, 1J = 247.2 Hz, 3J 
= 9.2 Hz), 153.5, 138.7, 132.3 (t, C6-F, 3J = 9.2 Hz), 128.7, 128.1, 127.1, 121.7 (d, C1-F, 2J = 
15.3 Hz), 111.1 (d, C5-F, 2J = 21.4 Hz), 103.7 (t, C3-F, 2J = 24.4 Hz), 75.3, 59.2, 56.2, 51.9, 45.9, 
36.3, 25.2. HRMS (m/z): calcd for C20H23N2O2F2 [M + H]+, 361.1728; found, 361.1736. IR 
(CH2Cl2; cm-1): 3055, 2985, 1694, 1504, 1438, 1266, 1137, 740, 705 cm-1. 
 
Compound B9 1H NMR (CDCl3, 400 MHz); δ (ppm): 7.91-7.21 (m, 12H), 4.23 (m, 1H), 3.85 
(d, 1H, J = 13.7 Hz), 3.85 (d, 1H, J = 12.7 Hz), 3.75 (d, 1H, J = 14.6 Hz), 3.70 (d, 1H, J = 13.7 
Hz), 3.60 (d, 1H, J = 13.7 Hz), 3.13 (dt, 1H, 11.7, 5.9 Hz), 2.94 (m, 1H), 2.85 (s, 3H), 2.78 (dd, 
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1H, J = 13.7, 4.9 Hz), 2.68 (dd, 1H, J = 13.7, 7.8 Hz), 1.98 (m, 1H), 1.65 (m, 1H). 13C NMR 
(CDCl3, 100 MHz); δ (ppm): 153.6, 139.1, 136.6, 133.1, 132.7, 128.9, 128.3, 127.9, 127.0, 
125.9, 125.6, 75.4, 59.8, 59.6, 56.3, 45.9, 36.4, 25.4. HRMS (m/z): calcd for C24H27N2O2 [M + 
H]+, 375.2073; found, 375.2077. IR (CH2Cl2; cm-1): 3055, 2992, 2930, 1694, 1496, 1446, 1266, 
1132, 1076, 740, 705 cm-1. 
 
Compound C1 1H NMR (CDCl3, 400 MHz); δ (ppm):  7.21-7.35 (m, 7H), 7.00 (t, 2H, J = 
8.8Hz), 4.46 (m, 1H), 3.69 (d, 2H, J =13.7Hz), 3.55 (d, 2H, J =13.7Hz), 3.38 (t, 1H, J = 8.8Hz), 
3.00 (dd, 1H, J= 6.8, 8.8Hz), 2.74 (s, 3H), 2.73 (dd, 1H, J = 5.9, 13.7Hz), 2.65 (dd, 1H, J = 6.8, 
13.7Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm):  162.0 (d, C-F, J = 244Hz), 159.1, 138.8, 134.6, 
130.4 (d, meta to F, 3J = 6.1Hz), 128.9, 128.4, 127.3, 115.2 (d, ortho to F, 2J = 21.4Hz), 71.4, 
59.3, 58.7, 56.3, 50.3, 30.8.  
 
Compound C2 1H NMR (CDCl3, 400 MHz); δ (ppm):   7.17-7.32 (m, 6H), 6.88 (m, 2H), 4.49 
(m, 1H), 3.83 (d, 1H of AB system, J = 12.7Hz), 3.77 (d, 1H of AB system, J = 12.7Hz), 3.69 (d, 
1H, J = 13.7 Hz), 3.55 (d, 1H, J = 13.7Hz), 3.37 (m, 1H), 3.03 (dd, 1H, J = 6.8, 8.8Hz), 2.76 (dd, 
1H, J = 4.8, 13.7 Hz), 2.72 (s, 3H), 2.62 (dd, 1H, J = 7.8, 13.7 Hz). 13C NMR (CDCl3, 100 
MHz); δ (ppm):  162.2 (dd, C2-F, 1J = 250.2, 3J = 12.2Hz), 161.4 (dd, C4-F, 1J = 250.2, 3J = 
12.2Hz), 158.0, 138.6, 132.1 (m, C1), 128.8, 128.3, 127.3, 127.4 (m, C6), 111.1 (d, C5, 2J = 21.4 
Hz), 103.7 (dd≈t, C3, 2J = 24.4 Hz), 71.3, 59.2, 56.2, 51.9, 50.2, 30.8.  
 
Compound C3 1H NMR (CDCl3, 500 MHz); δ (ppm):  7.25-7.38 (m, 5H), 7.19 (m, 1H), 7.11 
(m, 1H), 7.02-7.08 (m, 1H), 4.53 (m, 1H), 3.71 (d, 2H, J = 13.7 Hz), 3.58 (d, 2H, J =13.7Hz), 
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3.44 (dd, 1H, J = 7.8, 8.8 Hz),  3.05 (dd, 1H, J = 6.8, 8.8 Hz), 2.79 (s, 3H), 2.77 (dd, 1H, J = 5.9, 
13.7Hz), 2.69 (dd, 1H, J = 5.9, 13.7 Hz).  13C NMR ( CDCl3, 125 MHz); δ (ppm): 157.9, 150.4 
(dd, C3-F, 1J = 247.8 Hz, 2J = 12.8Hz), 149.5 (dd, C4-F, 1J = 247.8Hz, 2J = 12.8Hz), 138.4, 136.1 
(m, C1), 128.9, 128.5, 127.4, 124.5 (dd, C6, 3J = 6.0, 4J = 3.4Hz), 117.3 (d, 2J = 17.1Hz), 117.0 
(d, 2J = 17.1Hz), 71.5, 59.2, 58.5, 56.4, 50.3, 30.9.  
 
Compound C4 1H NMR (CDCl3, 400 MHz); δ (ppm):  7.42 (d, 2H, J = 8.8Hz), 7.19 (d, 2H, J = 
8.8Hz), 7.22-7.33 (m, 5H), 3.68 (d, 1H, J = 13.7Hz), 3.67(d, 1H, J = 13.7Hz), 3.55(d, 1H, J = 
13.7Hz), 3.54 (d, 1H, J = 13.7Hz), 3.38 (t, 1H, J = 8.8Hz), 3.00 (m, 1H), 2.74 (s, 3H), 2.73 (dd, 
1H, J = 5.9, 13.7Hz), 2.65 (dd, 1H, J = 5.9, 13.7Hz).  13C NMR (CDCl3, 100 MHz); δ (ppm): 
157.9, 138.6, 138.0, 131.4, 130.5, 128.8, 128.3, 127.3, 120.9, 71.4, 59.3, 58.7, 56.3, 50.2, 30.8.  
 
Compound C5 1H NMR (CDCl3, 400 MHz); δ (ppm):  7.52 (d, 1H, J = 7.8Hz), 7.47 (d, 1H, J = 
7.8Hz), 7.19-7.32 (m, 6H), 7.10 (dd, 1H, J = 1.95, 7.8Hz), 4.43 (m, 1H), 3.83 (d, 1H, J = 
13.7Hz), 3.72 (d, 1H, J = 13.7Hz), 3.71 (d, 1H, J = 13.7Hz), 3.60 (d, 1H, J = 13.7Hz), 3.34 (t, 
1H, J = 8.8Hz), 2.96 (dd, 1H, J = 5.9, 8.8 Hz), 2.78 (dd, 1H, J = 5.9, 13.7Hz), 2.69(s, 3H), 
2.66(dd, 1H, J = 6.8, 13.7Hz). 13C NMR (CDCl3, 100 MHz); δ (ppm): 157.9, 138.5, 137.9, 
132.8, 131.1, 129.0, 128.7, 128.2, 127.3, 127.2, 124.5,  71.1, 59.4, 59.1, 56.4, 50.3, 30.7.  
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Chapter V. Synthesis of a Ring-Oxygenated Variant of the 
2-Carboxy-6-hydroxyoctahydroindole Core of Aeruginosin 298-A 
from D-Mannose 
 
Abstract 
Cardiovascular diseases are the leading cause of death in the United States as they are 
responsible for more than 35% of all the deaths per year.1-2 Among the most prominent 
cardiovascular diseases are thromboembolic disorders which are caused by the formation of clots 
in the blood vessels. Thromboembolism occurrence is usually due to many factors, a major one 
being abnormally high blood coagulation.  Thrombin (factor IIa) is an enzyme from the trypsin 
family, which plays a key role in the blood coagulation cascade by converting the fibrinogen into 
fibrin monomers, thus regulating hemostasis. Because of its influence on the coagulation 
process, inhibiting thrombin’s action allows for a better blood flow and potentially solves the 
problems encountered with blood clots. Aeruginosins are a family of marine natural products 
isolated from a blue-green algae, which display inhibitory activity against serine proteases such 
as thrombin, trypsin, and factor VIIa. Most aeruginosins contain a 2-carboxy-6-
hydroxyoctahydroindole (Choi) ring; this Choi moiety is a rigid bicyclic unnatural amino acid 
and is the core structure in the aeruginosins, indispensable to their biological activity. A 
synthesis of a ring-oxygenated variant of the Choi from D-mannose is reported in this chapter. 
The ring-oxygenated variant of 2-carboxy-6-hydroxyoctahydroindole can potentially be used as a 
surrogate of Choi in the design and synthesis of aeruginosin-based thrombin inhibitors. 
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Introduction 
The process of the blood coagulation is initiated when a vascular injury occurs; the plasma 
protein Factor VIIa then comes in contact with its cofactor, the Tissue Factor (TF), which is a 
membrane protein normally not in contact with blood. These two proteins (TF/VIIa) will form a 
complex, which will activate Factors IX and X and trigger a cascade of reactions, ultimately 
resulting in the generation of thrombin and of a blood clot.3-5 Thrombin, also known as Factor 
IIa,  is the key enzyme in the last step of this coagulation cascade, in which it cleaves the 
fibrinogen into fibrin monomers and also activates several other coagulation factors; therefore, 
thrombin has been seen as a very attractive target for the synthesis of inhibitors in the treatment 
of thrombotic disorders.6-13 Many antithrombotics drugs are currently commercially available; 
the first class of molecules are the indirect thrombin inhibitors, molecules that limit and decrease 
the endogenous production of thrombin by inhibiting blood coagulation factors such as Factor 
VIIa or Factor Xa, or by activating internal anticoagulation mechianisms.14,15 This class is made 
essentially of heparins and coumarins: heparin, a highly sulfated glycosaminoglycan, is one of 
the oldest anticoagulant isolated16 and is still widely used clinically. However, added to the risk 
of hemorrhage, one of its main side effect is the heparin induced thrombocytopenia (HIT) which 
severely limits its effectiveness on long-term treatments. Many low molecular weight heparins 
(LMWH) such as fondaparinux, or enoxaparin have been synthesized and present improved 
safety profiles.17-21 Warfarin is a synthetic derivative of naturally occurring coumarin; it was 
isolated in the 1940s and unlike heparin is available orally; its main side effect is excessive 
bleeding or hemorrhage.22 A more recent class of antithrombotics are the direct thrombin 
inhibitors (DTIs). They consist of the bivalent DTIs, led by hirudin, which bind both to the 
active site and exosite of thrombin, and the univalent DTIs, which bind only to the active site of 
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thrombin; notable compounds are Argatroban, Ximelagatran and Dabigatran.23 Hirudin is a 
naturally occurring peptide isolated from the salivary glands of medicinal leeches; it is made of 
65 amino acids and is the most potent natural inhibitor of thrombin.24-25 However, hirudin is very 
difficult to extract from it natural sources in large amounts; therefore, several analogs such as 
bivalirudin (AngiomaxTM) or lepirudin (Refludan®) have been synthesized and are commercially 
available as anticoagulants.26-27 They are administered parenterally and their main setback is a 
short duration and the risk of hemorrhage. Argatroban is a small molecule that is administered 
intravenously and binds directly to the active site of thrombin. It is mainly indicated in patients 
with HIT.28 Ximelagatran (Exanta®), which had been extensively investigated as a replacement 
for warfarin, has been discontinued in 2006 after reports of hepatotoxicity during trials.29-33 
Dabigatran is currently in phase III of clinical trials and is administered orally. Figure 5.1 shows 
some representative indirect and direct thrombin inhibitors currently in clinical trials.34  
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Figure 5.1. Anticoagulant compounds currently in clinical trials 
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Recently, marine natural products isolated from a blue-green algae Microcystis aeruginosa34-35 
have displayed serine protease inhibitory activities. These molecules belong to the family of the 
aeruginosins, most of which contain a peptidomimetic bicyclic unit, the constrained bicyclic 
amino acid 2-carboxy-6-hydroxyloctahydroindole (Choi) moiety; the Choi 5 (Figure 5.2)36 is the 
core structure in the aeruginosins, and is indispensable to their biological activity. Some of the 
representative aeruginosins and related molecules are also shown in Figure 5.2. These 
compounds have a strong potential to be developed into antithrombotic drugs and have stirred 
the interest of the organic chemists community into designing efficient strategies towards the 
synthesis of the Choi and its variants, this moiety being a key structure in the aeruginosins and 
their analogs. 
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Figure 5.2. Structures of aeruginosins and related compounds. 
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Because of the interesting structure and biological activities of these compounds, several total 
synthesis and preparation for octahydroindole structures have been reported in the literature and 
some of the most representative methods are briefly described here. One strategy uses a chiral 
synthon derived from L-glutamic acid, which can yield the desired bicycle after a ring-closing 
metathesis, followed by a stereoselective epoxidation and eventually an epoxide ring-opening40-
41 to give the N-protected 2-carboxy-5,6-hydroxyloctahydroindole ester 13 (Scheme 5.1), which 
corresponds to the Choi subunit found in compound 8 Chlorodysinosin A.  
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Scheme 5.1. Synthesis of a protected 5,6-dihydroxyl-Choi ester from L-glutamic acid. 
 
Another method uses the N-acyliminium ion cyclization.42-45 The synthesis of 2-carboxy-6-
octahydroindole via the N -acyliminium ion aza-Prins cyclization is detailed in Scheme 5.2. The 
sequence starts with N-Boc-L-glutamate 14 which undergoes enolate alkylation38 to afford 15. N-
deprotection, cyclization and N-Boc protection lead to the corresponding pyroglutamate 16. 
Partial reduction and protection of the lactam carbonyl group give the hemiaminal 17. The 
[4,3,0] bicyclic structure 19 is obtained via the N-acyliminium intermediate 18 by treatment with 
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tin tetrabromide at low temperature. Displacement of the bromide with tetra-n-butyl ammonium 
acetate affords the L-Choi subunit 20. 
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Scheme 5.2. Synthesis of a protected Choi ester Via N-Acyliminium aza-Prins Cyclization. 
 
Aeruginosins are serine protease inhibitors and they also can inhibit thrombin and factor VIIa. 
The X-ray crystal structures of the complex formed between aeruginosins and thrombin 
complexes have been determined.37-39 The interaction mode of aeruginosin 298-A with the 
protein is similar to that of other direct thrombin inhibitors as it binds to the active site of 
thrombin in a noncovalent way forming an antiparallel strand with thrombin.37 The five-
membered ring of the Choi residue occupies the hydrophobic binding site, while its six-
membered ring projects out and loosely interacts with thrombin. The crystal structures of 
oscillarin and dysinosin-A complexes with thrombin revealed similar binding patterns. The 
amide NH from the octahydroindole carboxamide interacts with thrombin, however no 
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interactions were observed with the 6-hydroxyl group of the Choi moiety. The terminal phenyl 
group has no interaction with the enzyme.39 On the basis of the crystal structures and the binding 
sites interactions, organic chemists can design novel inhibitors with similar core structure motifs 
but with different substituents and functionalization to enhance binding, activity, and 
pharmacokinetic properties. Thrombin generally can tolerate imprecise binding from different 
molecules, however the rigid bicyclic amino acid structure is very important in defining the 
conformation of the molecule and it is essential to their antithrombin activity. Modifications on 
the core structure in the area of the 6-hydroxyl group should not impact negatively on binding to 
the protein while some changes will increase contact and enhance binding. Such changes include 
introducing an oxygen at the C-4 position and/or adding an additional hydroxyl group to the C-5 
or C-7 position; these would lead to structures such as 21 to 24 as surrogates for 5 (Figure 5.3). 
Because pharmacokinetics are very unpredictable, these changes will result in new biological 
properties and might broaden the scope for improving the pharmacokinetic profile of this 
compound class if required. The availability of different stereoisomers is also important in 
elucidating structure-activity relationships. Studies to rationalize electronic and steric influence 
of different inhibitors have not given good correlations so far. Modification from the natural 
analogues can allow us to understand the stereoelectronic factors that determine the activity of 
these inhibitors. The proposed Choi analogues shown in Figure 5.3, compounds 21 and 22 can be 
prepared from  D-glucose,36 23 and 24 can be prepared from D-mannose; they present a great 
potential for the discovery of better antithrombotics agents. 
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Figure 5.3. O-Choi variants from D-glucose or D-mannose. 
 
The synthesis of a ring-oxygenated variant of Choi from D-glucose has previously been achieved 
in our laboratory.36 Using a similar strategy, we have designed and carried out the synthesis of a 
ring oxygenated variant of the Choi moiety from D-mannose. The retrosynthetic analysis of our 
strategy shows that Choi analogs 23 and 24 are obtained in 5 steps from a 2,3-O-dibenzyl-
mesylate bromide 36, which itself is obtained from commercially available D-mannose in 10 
steps. 
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Scheme 5.3. Retrosynthetic strategy to 23 and 24 from D-mannose. 
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Results and discussion 
We designed and carried out the synthesis of the ring-oxygenated Choi analog D-mannose; our 
first goal was the synthesis of intermediate 2,3-O-dibenzyl-4,6-O-benzylidene-1-deoxy-mannose 
34 (Scheme 5.4).  D-mannose 25 was peracetylated using acetic anhydride in the presence of 
boron trifluoride diethyl etherate to form pentaacetate 26. Reaction with hydrobromic acid in 
acetic acid afforded the α-bromo-mannose tetraacetate 27. Reduction of the bromide was 
achieved by refluxing in benzene using tert-butyltin hydride catalyzed by AIBN to obtain 1-
deoxy-mannose tetraacetate 28. Removal of the four acetate groups was done by trans-
esterification with sodium methoxide in methanol to give 1-deoxy-mannose tetra-alcohol 29 in 
excellent yield. From intermediate 29, our initial approach was to synthesize 4,6-benzylidene 
acetal 30 using a strategy similar to the one we had successfully used in the Choi analog 
synthesis from D-glucose.36 Unfortunately, forming the 4,6-monoacetal proved to be very 
difficult with mannose; the cis configuration between the C-2 and C-3 positions makes it easier 
to form the 2,3-O-benzylidene acetal as well, leading the reaction to yield a mixture of products. 
Given the poor yield of the reaction to 30, we had to use a different route to obtain 2,3-O-
dibenzyl-monoacetal 34, as shown in scheme 5.5. The difference in stability between the 6-
membered dioxane type acetal and the 5-membered dioxolane acetal has been previously 
reported in the literature.46 The dioxolane type acetal is less stable in controlled reductive 
conditions; using this knowledge, we synthesized the 2,3,4-6-di-O-benzylidene acetal 31 by 
reacting tetra alcohol 29 with an excess of benzaldehyde dimethyl acetal in slightly acidic 
conditions. From compound 31, partial reduction of the dioxolane 2,3-benzylidene acetal was 
achieved by using a complex of LiAlH4 and AlCl3; in 30 minutes, the reaction yields a mixture 
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of the 2-benzyl-3-hydroxy-monoacetal 32 and 3-benzyl-3-hydroxy-monoacetal 33 in good yield. 
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Scheme 5.4. Attempt of synthesis of 4,6-O-benzylidene monoacetal intermediate 30. 
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Scheme 5.5. Synthesis of 2,3-O-dibenzyl-4,6-benzylidene acetal intermediate 34. 
 
The mixture of 32 and 33 was immediately submitted to benzylation conditions using benzyl 
bromide and sodium hydride in DMF to yield a unique product 2,3-O-dibenzyl-4,6-O-
dibenzylidene acetal 34 in reasonable yield. The 4,6-O-benzylidene acetal of 34 was hydrolyzed 
by heating in concentrated acetic acid to yield 4, 6-dihydroxy compound 35 in quantitative 
fashion. Exhaustive mesylation gave the 4,6-dimesylate 36 with a good yield. The 6-mesylate 
group of 36 was selectively turned into a bromine by reaction with sodium bromide in the 
presence of tetrabutyl ammonium bromide to give important intermediate 37. In the next step, we 
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used N-Boc-dimethylamino malonate that we had previously synthesized according to a 
literature procedure.36,47 Reaction of the N-protected malonate with 37 in the presence of sodium 
hydride afforded intermediate 38 in which the 6-bromine has been displaced by the malonate. 
Decarboxylation in basic conditions gave compound 39 in good yield. Deprotection of the Boc 
group using TFA in dichloromethane yielded free amine 40. Cyclization was achieved using 
triethylamine and refluxing in toluene to give diastereomers 41 and 42 in 84% overall yield. 
From these bicycles, deprotection of the benzyl groups can be done in good yield using 
palladium hydroxide in either methanol or ethanol to afford the esterified Choi analog 43 
(Scheme 5.7). 
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Scheme 5.6. Synthesis of intermediate 39. 
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Scheme 5.7. Synthesis of ring-oxygenated Choi esters 43 and 44. 
 
Conclusions 
Aeruginosins are a family of marine natural products isolated from a blue-green algae; they 
display a serine protease inhibitory activity, especially towards several enzymes involved in the 
blood coagulation cascade, such as thrombin or factor VIIa. Most of these compoundsy contain a 
2-carboxy-6-hydroxy-octahydroindole (Choi) rigid bicyclic structure, which is essential to their 
biological activity. The synthesis of variants of the Choi structure, their insertion in aeruginosins 
analogs and the testing of these compounds can provide a better understanding of the interaction 
of aeruginosins with serine proteases and lead to the synthesis of potential antithrombotics. 
Presented in this chapter are the design and synthesis of ring-oxygenated analogs of 2-carboxy-6-
hydroxy-octahydroindole (Choi) from D-mannose. The synthesis proceeds with good yields and 
affords diastereomers of the Choi analog, which can be used to synthesize different aeruginosin 
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analogs. Studies of the activities of the resulting compounds can give more information on the 
influence of the Choi moiety on the serine-protease inhibitory properties of the aeruginosins. 
Also, the different stereochemistry of the diastereomers will help in the structure-activity-
relationship (SAR) studies and give better insight on the interactions between the inhibitor and 
the thrombin active site, leading to the optimization of the inhibitory effect of future synthetic 
analogs. Given the current extent of thrombotic disorders and the side effects associated with 
most of the antithrombotic drugs currently available, the synthesis and study of molecules 
presenting a potential as future antithrombotics such as aeruginosin analogs containing various 
Choi moieties gives us the hope of finding less toxic and more efficient antithrombotic drugs.  
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Experimental Section 
 
Mannose pentaacetate 26. D-mannose 25 (19.0 g, 106 mmol) was dissolved in acetic anhydride 
(55.0 mL, 582 mmol) and the mixture was cooled to 0 °C. Boron trifluoride diethyl etherate 
(8.00 mL, 64.0 mmol) was added dropwise at 0 °C and the mixture was stirred at room 
temperature for 1.5 h. The mixture was poured into a beaker containing 200 mL of ice and stirred 
for 1 h. The product was extracted using CH2Cl2, the organic phase was washed with saturated 
NaHCO3 and water and dried on Na2SO4. After filtration and concentration, drying under 
vacuum afforded the pure product as a brown oil (39.9 g, 102 mmol). Yield: 96%. 1H NMR 
(CDCl3, 400 MHz); δ 5.86 (d, 1H, J = 1.0 Hz), 5.49 (dd, 1H, J = 3.2, 0.9 Hz), 5.29 (t, 1H, J = 9.9 
Hz), 5.13 (dd, 1H, J = 9.9, 3.3 Hz), 4.31 (dd, 1H, J = 12.4, 5.4 Hz), 4.14 (dd, 1H, J = 12.4, 2.3 
Hz), 3.80 (m, 1H), 2.22 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H). 13C NMR 
(CDCl3, 100 MHz); δ 170.2, 169.8, 169.4, 169.3, 168.0, 90.1, 72.8, 70.3, 67.9, 65.2, 61.8, 20.4. 
HRMS calcd for C16H22O11 [M+Na]+ 413.1060, found 413.1055. 
 
α-Bromo-mannose tetraacetate 27. Mannose pentaacetate 26 (19.8 g, 51.0 mmol) was mixed 
with acetic anhydride (14.4 mL, 152 mmol) and the mixture was cooled to 0 °C. HBr (33% in 
acetic acid, 45.0 mL, 2.57 mmol) was added to the solution, which was stirred at room 
temperature for 4.5 h. The mixture was poured in an beaker containing about 200 mL of ice, 
stirred for 10 min and extracted with dichloromethane. The organic phase was washed with 
saturated NaHCO3 and water then dried on Na2SO4. After filtration and concentration, the crude 
mixture was dried under high vacuum and the product is obtained as light yellow oil (20.9 g, 
50.8 mmol). Yield: 99%. 1H NMR (CDCl3, 400 MHz); δ 6.29 (bs, 1H), 5.71 (dd, 1H, J = 10.2, 
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3.4 Hz), 5.44 (dd, 1H, J = 3.4, 1.6 Hz), 5.36 (t, 1H, J = 10.2 Hz), 4.32 (dd, 1H, J = 12.5, 4.9 Hz), 
4.21 (m, 1H), 4.13 (dd, 1H, J = 12.4, 2.1 Hz), 2.17 (s, 3H), 2.09 (s, 3H), 2.07 (s, 3H), 2.00 (s, 
3H). 13C NMR (CDCl3, 100 MHz); δ 170.5, 169.7, 169.6, 169.7, 83.0, 72.8, 72.1, 67.9, 65.3, 
61.4, 20.8, 20.7, 20.6, 20.5. HRMS calcd for C14H19BrO9 [M+Na]+  
 
1-Deoxy-mannose tetraacetate 28. α-Bromo-mannose tetraacetate 27 (16.8 g, 40.9 mmol) was 
dissolved anhydrous benzene (20.0 mL). Tributyltin hydride (11.0 mL, 41.5 mmol) and AIBN (a 
few mg) were added to the solution and the mixture was refluxed for 1.5 h. The mixture  was 
cooled to room temperature and diluted with anhydrous ether (100 mL). Potassium fluoride (7.20 
g, 124 mmol in 30 mL of water) was added to the mixture and stirred for 2 h. The precipitated 
Bu3SnF formed was filtered out and the water phase separated from the ether. The organic phase 
was washed with water and dried on Na2SO4. After filtration and concentration, drying under 
high vacuum afforded the product as a light yellow oil (13.6 g, 40.9 mmol). Yield: 100%. 1H 
NMR (CDCl3, 400 MHz); δ 5.27 (bs, 1H), 5.24 (t, 1H, J = 10.2 Hz), 5.01 (dd, 1H, J = 10.0, 3.5 
Hz), 4.19 (dd, 1H, J = 12.3, 5.6 Hz), 4.08 (dd, 1H, J = 12.2, 2.0 Hz), 4.01 (dd, 1H, J = 13.2, 1.8 
Hz), 3.64 (d, 1H, J = 13.2 Hz), 3.55 (m, 1H), 2.12 (s, 3H), 2.06 (s, 3H), 2.00 (s, 3H), 1.96 (s, 
3H). 13C NMR (CDCl3, 100 MHz); δ 170.6, 170.3, 170.0, 169.5, 76.6, 71.5, 68.5, 68.0, 66.0, 
62.6, 20.8, 20.7, 20.6, 20.5. HRMS calcd for C14H20O9 [M+Na]+ 355.1005, found 355.1015. 
 
1-Deoxy-mannose tetraalcohol 29. 1-Deoxy-mannose tetraacetate 28 (15.5 g, 46.7 mmol) was 
dissolved in anhydrous methanol (20.0 mL). Sodium methoxide (0.252 g, 4.67 mmol) was added 
to the solution and the mixture was stirred for 16 h at room temperature. The methanol was 
evaporated under vacuum and the crude mixture was co-distilled with anhydrous toluene. After 
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drying under high vacuum, the crude product was obtained as a viscous yellow oil (7.40 g, 45.1 
mmol). Yield: 97%. 1H NMR (D2O, 400 MHz); δ 3.78 (m, 3H), 3.50 (m, 4H), 3.15 (m, 1H). 13C 
NMR (D2O, 100 MHz); δ 81.9, 74.9, 71.2, 70.5, 68.7, 62.7. HRMS calcd for C6H12O5 [M+Na]+ 
187.0582, found 187.0584. 
 
1-Deoxy-mannose-4,6-benzylidene acetal 30. 1-Deoxy-mannose-tetraalcohol 29 (3.99 g, 24.3 
mmol) was dissolved in anhydrous DMF (10.0 mL) and the solution was cooled to 0 °C. 
Benzaldehyde dimethylacetal (3.65 mL, 24.3 mmol) and HBF4 (50% in Et2O, 1.28 mL, 7.29 
mmol) were added and the mixture was stirred at room temperature for 12 h.  The mixture was 
cooled to 0 °C, triethylamine (3.39 mL, 24.3 mmol) was added dropwise and the solution was 
stirred at room temperature for 15 min. DMF was evaporated under nitrogen and the crude 
mixture was purified on SiO2 gel using a gradient of solvent of pure hexane to hexane:acetone 
4:1. The pure product was obtained as a white solid (1.40 g, 5.55 mmol). Yield: 23%. 1H NMR 
(CDCl3, 400 MHz); δ 7.48 (m, 2H), 7.37 (m, 3H), 5.53 (s, 1H), 4.27 (dd, 1H, J = 10.0, 5.0 Hz), 
4.00 (d, 1H, J = 12.7 Hz), 3.86 (m, 2H), 3.75 (m, 2H), 3.52 (d, 1H, J = 12.7 Hz), 3.29 (m, 2H). 
13C NMR (CDCl3, 100 MHz); δ 137.2, 129.3, 128.3, 126.3, 102.1, 79.0, 71.3, 71.0, 70.4, 69.3, 
68.4. 
 
2,3,4,6-di-O-benzylidene mannose acetal 31. 1-Deoxy-mannose tetraalcohol 29 (0.157 g, 0.958 
mmol) was dissolved in anhydrous DMF (2.00 mL). p-Toluenesulfonic acid (0.055 g, 0.289 
mmol) and benzaldehyde dimethyl acetal (0.580 mL, 3.86 mmol) were added to the solution and 
the mixture was stirred at 60 °C for 24 h. The solution was cooled to room temperature, diluted 
with dichloromethane and then cooled to 0 °C. The reaction was quenched by addition of 
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saturated NaHCO3. The organic phase was separated from the water layer and washed 3 times 
with 60 mL of H2O. After drying on sodium sulfate, the CH2Cl2 was evaporated and the product 
was dried under high vacuum without further purification to afford a light yellow solid 
containing both endo and exo isomers (0.264 g, 0.776 mmol). Yield: 81%. Mp: 142-143 °C 1H 
NMR (CDCl3, 400 MHz); endo isomer: δ 7.58-7.33 (m, 10H), 6.35 (s, 1H), 5.65 (s, 1H), 4.51 
(m, 1H), 4.37 (m, 2H), 4.20 (dd, 1H, J = 5.3, 2.2 Hz), 3.93 (m, 1H), 3.78 (m, 2H), 3.32 (dt, 1H, J 
= 15.0, 9.9, 5.2 Hz). 13C NMR (CDCl3, 100 MHz); δ 138.9, 137.2, 129.3, 129.0, 128.3, 128.2, 
126.2, 125.9, 103.0, 101.8, 78.2, 76.0, 73.5, 69.2, 68.6, 67.1. HRMS calcd for C20H20O5 [M+H]+ 
341.1389, found 341.1378. exo isomer: δ 7.58-7.33 (m, 10H), 6.00 (s, 1H), 5.54 (s, 1H), 4.51 
(m, 1H), 4.37 (m, 2H), 4.20 (dd, 1H, J = 5.3, 2.2 Hz), 3.93 (m, 1H), 3.78 (m, 2H), 3.32 (dt, 1H, J 
= 15.0, 9.9, 5.2 Hz). 13C NMR (CDCl3, 100 MHz); δ 138.9, 137.1, 129.3, 128.9, 128.4, 128.1, 
126.5, 126.1, 104.2, 101.6, 81.3, 76.4, 74.7, 69.1, 68.6, 66.8. HRMS calcd for C20H20O5 [M+H]+ 
341.1389, found 341.1378. 
 
2-O-Benzyl- and 3-O-Benzyl-1-deoxy-mannose-4,6-O-benzylidene acetal 32 and 33. 2,3,4,6-
di-O-benzylidene mannose acetal 31 (0.207 g, 0.608 mmol) was dissolved in a 1:1 mixture of 
anhydrous CH2Cl2 and ether (2.00 mL). The solution was cooled to 0 °C and aluminum chloride 
(0.081 mg, 0.607 mmol) and lithium aluminum hydride (0.023 g, 0.606 mmol) were added to the 
mixture. After stirring at room temperature for 30 min, the solution was cooled to 0 °C and the 
reaction was quenched by addition of ice. The solution was diluted with CH2Cl2 and the phases 
were separated. The organic phase was washed with a solution of saturated NaHCO3 and with 
H2O. After drying on Na2SO4, the organic phase was evaporated and the product was obtained as 
a colorless oil, mixture of the 2-OBn and 3-OBn isomers (0.176 g, 0.514 mmol). Yield: 85%. A 
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portion of the mixture was purified on SiO2 gel with a gradient of solvent of pure hexane to 
hexane:EtOAc 3:1 to give the following NMR data: 2-OBn isomer 32: 1H NMR (CDCl3, 400 
MHz); δ  7.52-7.29 (m, 10H), 5.58 (s, 1H), 4.79 (d, 1H, J = 1.8 Hz), 4.62 (d, 1H, J = 1.8 Hz), 
4.29 (dd, 1H, J = 10.4, 4.9 Hz), 4.16 (dd, 1H, J = 12.9, 1.6 Hz), 3.85 (m, 4H), 3.51 (dd, 1H, J = 
12.9, 0.7 Hz), 3.35 (td, 1H, J = 13.4, 10.4, 4.9 Hz), 2.29 (bs, 1H). 13C NMR (CDCl3, 100 MHz); 
δ 137.6, 137.3, 129.1, 128.6, 128.2, 128.0, 127.9, 126.3, 102.0, 79.7, 76.7, 72.1, 71.8, 71.4, 68.5, 
67.8. HRMS calcd for C20H22O5 [M+Na]+ 365.1365, found 365.1365. 3-OBn isomer 33: 1H 
NMR (CDCl3, 400 MHz); δ 7.56-7.32 (m, 10H), 5.64 (s, 1H), 4.89 (d, 1H, J = 12.0 Hz), 4.77 (d, 
1H, J = 12.0 Hz), 4.33 (dd, 1H, J = 10.4, 4.9 Hz), 4.13 (t, 1H, J = 9.4 Hz), 4.10 (dd, 1H, J = 12.7, 
1.6 Hz), 4.00 (t, 1H, J = 1.7 Hz), 3.84 (t, 1H, J = 10.3 Hz), 3.69 (dd, 1H, J = 9.4, 3.5 Hz), 3.56 
(dd, 1H, J = 12.7, 1.2 Hz), 3.35 (dt, 1H, J = 14.7, 9.8, 4.9 Hz), 2.79 (bs, 1H). 13C NMR (CDCl3, 
100 MHz); δ 137.8, 137.5, 128.8, 128.3, 128.1, 127.8, 127.7, 125.9, 101.3, 78.9, 77.4, 72.5, 71.6, 
70.1, 68.4, 68.2. HRMS calcd for C20H22O5 [M+Na]+ 365.1365, found 365.1365. 
 
2,3-Dibenzyl-1-deoxy-mannose-4,6-O-benzylidene acetal 34. A mixture of 2-O-Benzyl- and 3-
O-Benzyl-1-deoxy-mannose-4,6-O-benzylidene acetal (155 mg, 0.453 mmol) was dissolved in 
anhydrous DMF (2.50 mL). The solution was cooled to 0 °C and sodium hydride (54.4 mg, 2.27 
mmol) was added. The mixture was stirred at room temperature for 30 to 35 min. Benzyl 
bromide (0.220 mL, 1.85 mmol) was added to the mixture and the reaction stirred for 12 h. The 
solution was cooled to 0 °C and diluted with CH2Cl2. The reaction was quenched by addition of 
ice. After stirring for another 15 min. the organic phase was separated from the water layer and 
washed with saturated NH4Cl and with H2O three times. After drying on Na2SO4, the CH2Cl2 
was evaporated and the crude mixture was purified on SiO2 gel with a gradient of solvent of pure 
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hexane to hexane:CH2Cl2:THF 15:1:1. The pure product was obtained as a white solid (146 mg, 
0.338 mmol). Yield: 75%. Mp: 84-85 °C 1H NMR (CDCl3, 400 MHz); δ 7.55-7.24 (m, 15H), 
5.67 (s, 1H), 4.81 (q, 2H, J = 20.0, 12.4 Hz), 4.77 (q, 2H, J = 50.7, 12.4 Hz), 4.29 (m, 2H), 4.08 
(dd, 1H, J = 12.6, 1.9 Hz), 3.87 (t, 1H, J = 10.3 Hz), 3.81 (m, 1H), 3.69 (dd, 1H, J = 9.8, 3.3 Hz), 
3.45 (d, 1H, J = 12.6 Hz), 3.36 (dt, 2H, J = 14.8, 9.9, 4.9 Hz). 13C NMR (CDCl3, 100 MHz); δ 
138.5, 138.2, 137.7, 128.8, 128.4, 128.3, 128.2, 128.0, 127.7, 127.5, 125.9, 101.3, 79.2, 78.5, 
74.3, 72.6, 72.4, 72.2, 68.9, 68,6. HRMS calcd for C27H28O5 [M+Na]+ 455.1834, found 
455.1827. 
   
2,3-Dibenzyl-4,6-dihydroxy-1-Deoxy-mannose 35. 2,3-Dibenzyl-1-Deoxy-mannose-4,6-
benzylidene acetal 34 (1.71 g, 3.95 mmol) was dissolved in acetic acid (80% in H2O, 20.0 mL). 
The solution was stirred at 45-50 °C for 12 h and cooled to 0 °C. Neutralization was achieved 
using a saturated solution of sodium bicarbonate and the water was evaporated under vacuum. 
The crude mixture was taken up in EtOAc and the organic phase was washed with H2O and dried 
on Na2SO4. After filtration and drying under high vacuum, the product was obtained as a white 
solid (1.36 g, 3.95 mmol). Yield: 100%. Mp: 82-83 °C 1H NMR (CDCl3, 400 MHz); δ 7.41-7.25 
(m, 10H), 4.73 (d, 1H, J = 12.4 Hz), 4.61 (t, 2H, J = 11.8 Hz), 4.46 (d, 1H, J = 11.8 Hz), 4.11 
(dd, 1H, J = 12.8, 2.0 Hz), 4.00 (t, 1H, J = 9.5 Hz), 3.89 (dd, 1H, J = 11.8, 3.3 Hz), 3.79 (d, 1H, J 
= 5.6 Hz), 3.76 (m, 1H), 3.39 (dd, 1H, J = 9.4, 3.2 Hz), 3.35 (d, 1H, J = 12.7 Hz), 3.26 (m, 2H). 
13C NMR (CDCl3, 100 MHz); δ 138.0, 137.8, 128.5, 128.4, 128.3, 128.0, 127.9, 127.8, 127.7, 
127.6, 82.2, 80.1, 71.9, 71.3, 71.1, 67.5, 67.1, 62.9. HRMS calcd for C20H24O5 [M+Na]+ 
367.1521, found 367.1517. 
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2,3-Dibenzyl-4,6-dimethanesulfonyl-1-Deoxy-mannose 36. 2,3-Dibenzyl-4,6-dihydroxy-1-
Deoxy-mannose 35 (1.08 g, 3.14 mmol) was dissolved in dichloromethane (15.0 mL). 
Methanesulfonyl chloride (0.980 mL, 12.6 mmol) and triethylamine (3.00 mL, 21.5 mmol) were 
added at 0 °C. The solution was stirred at 0 °C for 30 min and then at room temperature 14 h.  
the solution was diluted with CH2Cl2 and the reaction was quenched with ice. After separating 
the phases, the organic phase was washed with water and dried on Na2SO4. The solvent was 
evaporated and the crude mixture was purified on SiO2 gel using a gradient of pure hexane to 
hexane:EtOAc 2:1. The pure product was obtained as a light brown semi solid (1.34 g, 2.68 
mmol). Yield: 85%. 1H NMR (CDCl3, 400 MHz); δ 7.38-7.24 (m, 10H), 4.84 (t, 1H, J = 9.6 Hz), 
4.69 (d, 1H, J = 12.2 Hz), 4.59 (m, 2H), 4.44 (d, 1H, J = 11.3 Hz), 4.36 (dd, 1H, J = 11.5, 5.7 
Hz), 4.14 (d, 1H, J = 12.9 Hz), 3.88 (bs, 1H), 3.68 (dd, 1H, J = 9.4, 2.8 Hz), 3.62 (m, 1H), 3.37 
(d, 1H, J = 12.9 Hz), 3.01 (s, 3H), 2.93 (s, 3H). 13C NMR (CDCl3, 100 MHz); δ 137.5, 136.7, 
128.4, 128.3, 127.9, 127.8, 127.7, 127.6, 79.1, 76.2, 71.7, 71.0, 70.9, 68.4, 66.3, 38.4, 37.3. 
HRMS calcd for C22H28O9S2 [M+Na]+ 523.1072, found 523.1087. 
 
2,3-Dibenzyl-6-bromo-4-methanesulfonyl-1-Deoxy-mannose 37. 2,3-Dibenzyl-4,6-
dimethanesulfonyl-1-Deoxy-mannose 36 (0.920 g, 1.84 mmol) was dissolved in anhydrous 
DMSO (10.0 mL). Sodium bromide (1.14 g, 11.1 mmol) and tetrabutylammonium bromide 
(0.178 g, 0.552 mmol) were added to the solution and the mixture was stirred at 60 °C for 36 h. 
DMSO was evaporated under nitrogen and the crude residue was taken up in CH2Cl2. The 
organic phase was washed with H2O, dried on Na2SO4, filtered and evaporated under vacuum. 
The crude mixture was purified on SiO2 gel using a gradient of pure hexane to hexane:EtOAc 
6:1. The pure product was obtained as a light yellow solid (0.691 g, 1.42 mmol). Yield: 78%. 
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Mp: 74-75 °C 1H NMR (CDCl3, 400 MHz); δ 7.39-7.27 (m, 10H), 4.77 (m, 1H), 4.74 (m, 2H), 
4.59 (t, 1H, J = 12.5 Hz), 4.39 (d, 1H, J = 11.3 Hz), 4.22 (dd, 1H, J = 12.9, 2.3 Hz), 3.86 (m, 
1H), 3.81 (dd, 1H, J = 10.9, 1.8 Hz), 3.63 (dd, 1H, J = 9.4, 3.2 Hz), 3.52 (m, 2H), 3.36 (d, 1H, J 
= 12.9 Hz), 2.93 (s, 3H). 13C NMR (CDCl3, 100 MHz); δ 137.5, 136.8, 128.6, 128.5, 128.3, 
127.9, 79.3, 79.0, 78.5, 71.7, 71.1, 71.0, 66.4, 38.6, 31.7. HRMS calcd for C21H25BrO6S 
[M+Na]+ 507.0453, found 507.0471. 
 
2,3-Dibenzyl-6-(N-boc-diethylaminomalonyl)-4-methanesulfonyl-1-Deoxy-mannose 38. N-
Boc-diethylaminomalonate (0.426 g, 1.55 mmol) was dissolved in anhydrous toluene (1.00 mL). 
After cooling to 0 °C, sodium hydride (57-63% in mineral oil, 65.3 mg, 1.55 mmol) was added 
and the solution was stirred for 45 min. 2,3-Dibenzyl-6-bromo-4-methanesulfonyl-1-Deoxy-
mannose 37 (0.146 g, 0.301 mmol) in 1.00 mL of anhydrous toluene and TBAI (34.4 mg, 0.093 
mmol) were added to the mixture and the solution was stirred under reflux for 14 h. The solution 
was cooled to room temperature, diluted with CH2Cl2 and quenched with ice. After separating 
the phases, the organic phase was washed twice with water and dried on Na2SO4. After filtration 
and concentration, the crude mixture was purified on SiO2 gel using a gradient of solvent of pure 
hexane to hexane:EtOAc 6:1. The pure product was obtained as a white solid (104 mg, 0.153 
mmol). Yield: 51%. Mp: 41-42 °C 1H NMR (CDCl3, 400 MHz); δ 7.37-7.25 (m, 1H), 6.03 (bs, 
1H), 4.73 (m, 1H), 4.59 (m, 3H), 4.17 (q, 4H, J = 13.6, 6.6 Hz), 3.80 (m, 2H), 3.55 (d, 1H, J = 
8.3 Hz), 3.39 (t, 1H, J = 9.9 Hz), 3.15 (d, 1H, J = 12.8 Hz), 2.93 (m, 3H), 2.54 (dd, 1H, J = 14.9, 
10.8 Hz), 1.42 (s, 9H), 1.22 (t, 3H, J = 6.7 Hz). 13C NMR (CDCl3, 100 MHz); δ (major rotomer) 
168.4, 153.9, 137.8, 128.4, 128.3, 127.9, 127.6, 81.6, 79.5, 74.7, 72.5, 71.2, 71.1, 66.3, 64.2, 
62.5, 38.9, 35.0, 28.1, 13.7. (minor rotomer) 167.8, 153.5, 137.3, 128.4, 128.3, 127.9, 127.6, 
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81.6, 79.3, 74.7, 72.4, 71.4, 70.9, 66.1, 64.2, 62.0, 38.6, 35.1, 27.8, 13.8. HRMS calcd for 
C33H45NO12S [M+Na]+ 702.2560, found 702.2571. 
 
2,3-Dibenzyl-6-(N-boc-2-amino-ethylacetate)-4-methanesulfonyl-1-Deoxy-mannose 39. 1H 
NMR (CDCl3, 400 MHz); δ 7.39-7.25 (m, 10H), 4.64 (m, 5H), 4.38 (m, 2H), 4.16 (m, 3H), 3.83 
(d, 1H, J = 15.8 Hz), 3.58 (dt, 1H, J = 9.5, 5.5, 2.8 Hz), 3.43 (t, 1H, J = 9.0 Hz), 3.27 (m, 2H), 
2.91-2.85 (m, 3H), 2.11 (m, 1H), 1.44 (s, 9H), 1.28-1.23 (m, 3H). 13C NMR (CDCl3, 100 MHz); 
δ (major isomer): 172.3, 155.6, 137.5, 136.7, 128.4, 128.3, 127.8, 79.8, 79.5, 75.7, 72.1, 71.9, 
71.1, 70.8, 66.6, 61.1, 50.6, 38.5, 33.9, 28.1, 13.9. (minor isomer): 172.1, 155.0, 137.6, 136.8, 
128.4, 128.2, 127.8, 79.8, 79.3, 75.6, 72.1, 71.9, 71.1, 70.9, 66.3, 61.1, 50.9, 38.5, 33.9, 28.1, 
13.8. Yield: 91%. HRMS calcd for C30H41NO10S [M+Na]+ 630.2349, found 630.2346. 
 
2,3-Dibenzyl-6-(2-amino-ethylacetate)-4-methanesulfonyl-1-Deoxy-mannose 40. 1H NMR 
(CDCl3, 400 MHz); δ 7.43-7.22 (m, 10H), 4.70 (m, 2H), 4.57 (m, 2H), 4.39 (d, 1H, J = 11.1 Hz), 
4.19 (m, 4H), 3.86 (s, 1H), 3.65 (m, 1H), 3.41 (m, 1H), 2.89 (s, 3H), 2.38 (m, 2H), 1.26 (m, 3H). 
Yield: 96%.  
 
(2S,3aR,6R,7S,7aS)- 2-ethyl-carboxylate-6,7-bis(benzyloxy)octahydroindole 41. 1H NMR 
(CDCl3, 400 MHz); δ 7.41-7.27 (m, 10H), 4.77 (d, 1H, J = 12.5 Hz), 4.76 (q, 2H, J = 23.6, 12.2 
Hz), 4.65 (d, 1H, J = 12.2 Hz), 4.17 (q, 2H, J = 14.2, 7.0 Hz), 4.14 (t, 1H, J = 7.9 Hz), 4.03 (d, 
1H, J = 12.6 Hz), 3.94 (bs, 1H), 3.69 (m, 2H), 3.52 (bs, 1H), 3.27 (d, 1H, J = 12.7 Hz), 2.26 (dd, 
1H, J = 13.9, 8.7 Hz), 2.09 (m, 1H), 1.29 (m, 5H). 13C NMR (CDCl3, 100 MHz); δ 175.3, 138.2, 
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138.1, 128.4, 128.3, 127.8, 127.7, 127.6, 127.5, 79.6, 73.6, 72.7, 72.3, 69.1, 67.1, 60.7, 60.6, 
58.5, 37.4, 14.1. Yield: 38%. HRMS calcd for C24H29NO5 [M+H]+ 412.2124, found 412.2133. 
 
(2R,3aR,6R,7S,7aS)- 2-ethyl-carboxylate-6,7-bis(benzyloxy)octahydroindole 42. 1H NMR 
(CDCl3, 400 MHz); δ 7.49-7.26 (m, 10H), 4.79 (q, 2H, J = 29.9, 12.4 Hz), 4.68 (q, 2H, J = 33.3, 
12.4 Hz), 4.14 (m, 2H), 4.07 (dd, 2H, J = 12.9, 1.9 Hz), 3.82 (m, 2H), 3.72 (m, 2H), 3.23 (d, 2H, 
J = 12.7 Hz), 2.27 (m, 1H), 2.08 (dd, 1H, J = 14.3, 4.5 Hz), 1.19 (t, 3H, J = 7.1 Hz). 13C NMR 
(CDCl3, 100 MHz); δ 173.3, 138.3, 138.1, 128.3, 128.2, 127.8, 127.6, 127.5, 127.4, 78.8, 73.8, 
72.2, 71.9, 69.3, 66.9, 61.7, 60.9, 59.3, 38.1, 14.0. Yield: 46%. HRMS calcd for C24H29NO5 
[M+H]+ 412.2124, found 412.2112. 
 
Ethyl-6,7-dihydroxyl-octahydropyrano[3,2-b]pyrrole-2-carboxylate (43 + 44). 1H NMR 
(CDCl3, 400 MHz); δ 4.79 (m, 2H), 4.27 (m, 5H), 3.52 (m, 2H), 2.58 (m, 1H), 2.29 (m, 1H), 1.29 
(t, 3H, J = 7.1 Hz). ). 13C NMR (CDCl3, 100 MHz); δ 171.1, 83.2, 75.2, 68.8, 66.9, 63.2, 58.0, 
52.4, 36.0, 13.7. HRMS calcd for C10H17NO5 [M+H]+ 232.1185, found 232.1181. 
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